var title_f21_22_21856="Contents: Hospital cardiovascular medicine";
var content_f21_22_21856=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?2/63/3070\">",
"       Hospital Medicine",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Hospital cardiovascular medicine",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Hospital cardiovascular medicine",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/45/16090\">",
"           ACE inhibitors in heart failure due to systolic dysfunction: Therapeutic use",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/3/13368\">",
"           Acute arterial occlusion of the lower extremities (acute limb ischemia)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/55/13175\">",
"           Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Recommendations for use",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/39/2680\">",
"           Angiotensin II receptor blockers in heart failure due to systolic dysfunction: Therapeutic use",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/57/5018\">",
"           Anticoagulant therapy in acute ST elevation myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/2/5162\">",
"           Anticoagulant therapy in non-ST elevation acute coronary syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/27/35257\">",
"           Anticoagulation prior to and after restoration of sinus rhythm in atrial fibrillation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/20/39242\">",
"           Antiplatelet agents in acute non-ST elevation acute coronary syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/49/35610\">",
"           Antiplatelet agents in acute ST elevation myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/19/31034\">",
"           Approach to the diagnosis and treatment of wide QRS complex tachycardias",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/26/28072\">",
"           Basic approach to arrhythmias due to digoxin toxicity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/35/17977\">",
"           Basic principles and technique of cardioversion and defibrillation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/53/11098\">",
"           Beta blockers in the management of acute coronary syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/28/28101\">",
"           Biomarkers of cardiac injury other than troponins and creatine kinase",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/37/28250\">",
"           Brugada syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/42/41637\">",
"           Bundle branch reentrant ventricular tachycardia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/33/40469\">",
"           Calcium channel blockers in the management of acute coronary syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/57/39831\">",
"           Calcium channel blockers in the treatment of cardiac arrhythmias",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/61/983\">",
"           Cardiac resynchronization therapy in atrial fibrillation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/56/18314\">",
"           Cardiac resynchronization therapy in heart failure: Indications",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/52/19273\">",
"           Cardiac tamponade",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/27/40378\">",
"           Carotid endarterectomy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/55/33656\">",
"           Cholesterol lowering after an acute coronary syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/53/28505\">",
"           Classification of unstable angina and non-ST elevation myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/10/30890\">",
"           Clinical features and treatment of ventricular arrhythmias during acute myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/19/25914\">",
"           Clinical manifestations and diagnosis of aortic dissection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/60/16329\">",
"           Clinical manifestations and diagnosis of cardiogenic shock in acute myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/35/39481\">",
"           Clinical manifestations, diagnosis, and evaluation of narrow QRS complex tachycardias",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/47/37625\">",
"           Clinical presentation and diagnostic evaluation of acute pericarditis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/11/4282\">",
"           Conduction abnormalities after myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/53/24408\">",
"           Control of ventricular rate in atrial fibrillation: Nonpharmacologic therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/50/12074\">",
"           Control of ventricular rate in atrial fibrillation: Pharmacologic therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/57/18328\">",
"           Control of ventricular rate in atrial flutter",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/1/29722\">",
"           Coronary arteriography and revascularization for unstable angina or non-ST elevation acute myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/59/16314\">",
"           Coronary reperfusion for acute myocardial infarction in older adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/39/25209\">",
"           Criteria for the diagnosis of acute myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/54/9064\">",
"           Diagnosis and evaluation of the sick sinus syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/3/24633\">",
"           Diagnosis and management of ischemic cardiomyopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/59/4025\">",
"           Diagnosis and treatment of pericardial effusion",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/15/34042\">",
"           Diagnostic approach to chest pain in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/0/26634\">",
"           Differential diagnosis of chest pain in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/3/42039\">",
"           Drugs that should be avoided or used with caution in patients with heart failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/12/6344\">",
"           Elective noncardiac surgery after percutaneous coronary intervention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/7/23669\">",
"           Electrocardiogram in pericarditis and pericardial effusion",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/24/11658\">",
"           Electrocardiogram in the diagnosis of myocardial ischemia and infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/53/15192\">",
"           Electrocardiographic and electrophysiologic features of type I atrial flutter",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/56/12165\">",
"           Electrocardiographic and electrophysiologic features of type II atrial flutter",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/13/9431\">",
"           Electrocardiographic diagnosis of myocardial infarction in the presence of bundle branch block or a paced rhythm",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/30/2537\">",
"           Elevated cardiac troponin concentration in the absence of an acute coronary syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/37/2650\">",
"           End of life considerations for heart failure patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/60/36810\">",
"           Estimation of cardiac risk prior to noncardiac surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/23/7544\">",
"           Evaluation of acute decompensated heart failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/13/31961\">",
"           Evaluation of patients with chest pain at low or intermediate risk for acute coronary syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/15/18682\">",
"           Evaluation of syncope in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/28/39369\">",
"           Evaluation of the patient with heart failure or cardiomyopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/30/19945\">",
"           Evaluation of the patient with suspected heart failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/24/4490\">",
"           Evaluation of the survivor of sudden cardiac arrest",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/57/22421\">",
"           Fibrinolytic (thrombolytic) agents in unstable angina and acute non-ST elevation myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/43/1721\">",
"           Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/33/44567\">",
"           Glycemic control for acute myocardial infarction in patients with and without diabetes mellitus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/44/10953\">",
"           Guideline adherence and outcomes in coronary heart disease and heart failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/47/9978\">",
"           High-output heart failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/15/6394\">",
"           Ischemic reperfusion injury of the heart",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/4/25673\">",
"           Left ventricular aneurysm and pseudoaneurysm following acute myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/23/5497\">",
"           Left ventricular thrombus after acute myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/54/25449\">",
"           Management of aortic dissection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/45/29402\">",
"           Management of cardiac risk for noncardiac surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/40/4743\">",
"           Management of refractory heart failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/11/28855\">",
"           Management of the patient with syncope",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/7/10361\">",
"           Management and outcome of thoracic aortic aneurysm",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/31/22008\">",
"           Manifestations and causes of the sick sinus syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/19/39225\">",
"           Mechanical complications of acute myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/62/12266\">",
"           Mechanisms of atrial fibrillation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/51/9018\">",
"           Medical therapy versus revascularization in the management of stable angina pectoris",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/22/19818\">",
"           Natriuretic peptide measurement in heart failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/63/24566\">",
"           Nitrates in the management of acute coronary syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/57/1944\">",
"           Noncardiogenic pulmonary edema",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/56/29578\">",
"           Noninvasive imaging and stress testing in patients with suspected acute coronary syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/22/361\">",
"           Overview of atrial fibrillation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/60/13256\">",
"           Overview of the evaluation and management of atrial flutter",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/55/890\">",
"           Overview of sudden cardiac arrest and sudden cardiac death",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/41/44697\">",
"           Overview of the acute management of ST elevation myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/20/6473\">",
"           Overview of the acute management of tachyarrhythmias",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/20/37193\">",
"           Overview of the acute management of unstable angina and non-ST elevation myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/63/38906\">",
"           Overview of the therapy of heart failure due to systolic dysfunction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/41/31384\">",
"           Paroxysmal atrial fibrillation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/31/24055\">",
"           Pericardial complications of myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/0/18440\">",
"           Perioperative heart failure in noncardiac surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/17/29975\">",
"           Perioperative myocardial infarction after noncardiac surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/9/40089\">",
"           Periprocedural bleeding in patients undergoing percutaneous coronary intervention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/48/38666\">",
"           Periprocedural complications of percutaneous coronary intervention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/51/39737\">",
"           Periprocedural myocardial infarction following percutaneous coronary intervention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/37/35418\">",
"           Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/62/42984\">",
"           Reentry and the development of cardiac arrhythmias",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/57/22426\">",
"           Restoration of sinus rhythm in atrial fibrillation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/49/18201\">",
"           Restoration of sinus rhythm in atrial flutter",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/43/5817\">",
"           Rhythm control versus rate control in atrial fibrillation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/52/35658\">",
"           Risk stratification for cardiac events after acute ST elevation myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/43/2746\">",
"           Risk stratification after unstable angina or non-ST elevation myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/42/18087\">",
"           Second degree atrioventricular block: Mobitz type I (Wenckebach block)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/62/998\">",
"           Second degree atrioventricular block: Mobitz type II",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/55/19322\">",
"           Secondary and primary prevention of sudden cardiac death in heart failure and cardiomyopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/50/3878\">",
"           Sinus bradycardia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/61/21465\">",
"           Temporary cardiac pacing",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/42/26278\">",
"           The electrocardiogram in atrial fibrillation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/54/7018\">",
"           Treatment and prognosis of diastolic heart failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/42/33446\">",
"           Treatment of acute decompensated heart failure in acute coronary syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/56/34698\">",
"           Treatment of acute decompensated heart failure: Components of therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/7/41079\">",
"           Treatment of acute decompensated heart failure: General considerations",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/20/41289\">",
"           Treatment of acute myocardial infarction in diabetes mellitus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/44/713\">",
"           Treatment of acute pericarditis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/60/15305\">",
"           Pharmacologic therapy of arrhythmias associated with the Wolff-Parkinson-White syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/44/37576\">",
"           Treatment of the sick sinus syndrome",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-9ABE0893AD-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f21_22_21856=[""].join("\n");
var outline_f21_22_21856=null;
var title_f21_22_21857="Pulm AVM CXR I";
var content_f21_22_21857=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F72468&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F72468&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Arteriovenous malformation in right lower lobe in patient who developed a stroke",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 311px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A chest radiograph shows a feeding artery and draining vein in the right lower lobe.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_22_21857=[""].join("\n");
var outline_f21_22_21857=null;
var title_f21_22_21858="Mature teratoma";
var content_f21_22_21858=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F70608&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F70608&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Opened mature cystic teratoma (dermoid cyst) of the ovary",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 304px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hair (bottom) and a mixture of tissues are evident.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Crum CP. The Female Genital Tract. In: Pathologic Basis of Disease, 6th ed, Cotran RS, Kumar V, Collins T (Eds), WB Saunders Company, Pennsylvania 1999. Copyright &copy; 1999 Elsevier.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_22_21858=[""].join("\n");
var outline_f21_22_21858=null;
var title_f21_22_21859="Ocular effects of hypertension";
var content_f21_22_21859=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Ocular effects of hypertension",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/22/21859/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/22/21859/contributors\">",
"     Norman M Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/22/21859/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/22/21859/contributors\">",
"     George L Bakris, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/22/21859/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/22/21859/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/22/21859/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of ocular abnormalities are directly or indirectly associated with hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21859/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. These include some that are a direct consequence of elevated blood pressure, including hypertensive retinopathy, choroidopathy, and optic neuropathy. With other abnormalities, hypertension is a significant risk factor, including retinal vein and artery occlusion, retinal artery emboli, and diabetic retinopathy. In addition, hypertension may accelerate nonvascular eye disease, including age-related macular degeneration and glaucoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OCULAR DISEASES DIRECTLY RELATED TO HYPERTENSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fundoscopy should be part of the physical examination on every patient with newly diagnosed hypertension, since the retina is the only part of the vasculature that can be visualized non-invasively. Pupillary dilatation with a short-acting mydriatic (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/58/8100?source=see_link\">",
"     tropicamide",
"    </a>",
"    1 percent) is almost always useful, since the mild changes are hard to quantify, even with retinal photography [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21859/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most common ocular diseases directly related to hypertension are progressively increasing retinal microvascular changes, which are subsumed under the name \"hypertensive retinopathy.\" Classically, the features are divided into four degrees and their morphological classification has been widely used [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21859/abstract/4\">",
"     4",
"    </a>",
"    ]. However, a more pathophysiological division has been proposed and seems more logical [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21859/abstract/3\">",
"     3",
"    </a>",
"    ]. This three-degree classification includes mild, moderate, and severe:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mild &mdash; Retinal arteriolar narrowing related to vasospasm, arteriolar wall thickening or opacification, and arteriovenous nicking, referred to as nipping [",
"      <a class=\"abstract\" href=\"UTD.htm?21/22/21859/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Moderate &mdash; Hemorrhages, either flame or dot-shaped, cotton-wool spots, hard exudates, and microaneurysms (",
"      <a class=\"graphic graphic_picture graphicRef67621 \" href=\"UTD.htm?13/42/13999\">",
"       picture 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Severe &mdash; Some or all of the above, plus optic disc edema (",
"      <a class=\"graphic graphic_picture graphicRef78225 graphicRef57183 \" href=\"UTD.htm?30/56/31620\">",
"       picture 2A-B",
"      </a>",
"      ). The presence of papilledema mandates rapid lowering of the blood pressure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Generalized narrowing and nicking are related to current and previous blood pressure levels; by comparison, focal narrowing, hemorrhages, and exudates are related only to current blood pressure levels [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21859/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Retinal arterial narrowing, a predictor of the future development of hypertension, is linked to non-ocular systemic vascular diseases, particularly stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21859/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Substantial evidence exists for the association with coronary heart disease, left ventricular remodeling, and kidney damage [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21859/abstract/8-11\">",
"     8-11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The presence of hypertensive retinopathy should serve as an additional stimulus to ensure adequate control of hypertension. With good control, retinopathy may regress, providing an easily obtained indicator of success [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21859/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     HYPERTENSION AS A RISK FACTOR FOR OCULAR DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertension increases the risk of a number of ocular diseases. The most common is diabetic retinopathy, which is the most common cause of blindness in developed societies. In a multi-ethnic cohort in the United States, retinopathy was found in 33 percent of diabetics over age 40, 8 percent of whom had vision-threatening retinopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21859/abstract/13\">",
"     13",
"    </a>",
"    ]. Multiple factors may be involved in the added risk of hypertension to the development and progression of diabetic retinopathy, including increased endothelial damage [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21859/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fortunately, good control of hypertension can reduce the threat of diabetic retinopathy, independent of control of hyperglycemia [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21859/abstract/15\">",
"     15",
"    </a>",
"    ]. In the UK Prospective Diabetes study, the risk of retinopathy was reduced 10 percent for each 10 mmHg lower systolic blood pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21859/abstract/15\">",
"     15",
"    </a>",
"    ]. Limited evidence supports an additional protective effect of ACE inhibitors beyond their antihypertensive effect [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21859/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other ocular diseases wherein hypertension serves as a risk factor include retinal venous and arterial occlusion, retinal emboli, retinal macroaneurysm, and anterior ischemic optic neuropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21859/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     OCULAR DISEASES WHEREIN HYPERTENSION MAY BE A RISK FACTOR",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk for two of the more common causes of vision loss, age-related macular degeneration and glaucoma, may be increased by the presence of systemic hypertension. Although cross sectional data support an association [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21859/abstract/17,18\">",
"     17,18",
"    </a>",
"    ], the evidence is not conclusive. It should be noted that systemic hypotension, especially at night from excessive antihypertension therapy, has been shown to further reduce blood flow to the optic nerve, accentuating the damage of high intraocular pressure from glaucoma [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21859/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/52/6986?source=see_link\">",
"     \"Age-related macular degeneration: Clinical presentation, etiology, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15289?source=see_link\">",
"     \"Open-angle glaucoma: Epidemiology, clinical presentation, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most common ocular diseases directly related to hypertension are progressively increasing retinal microvascular changes, which are subsumed under the name \"hypertensive retinopathy.\" The three-degree classification includes mild, moderate, and severe disease. The presence of papilledema mandates rapid lowering of the blood pressure. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Ocular diseases directly related to hypertension'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hypertension increases the risk of a number of ocular diseases, with the most common being diabetic retinopathy. Other ocular diseases wherein hypertension serves as a risk factor include retinal venous and arterial occlusion, retinal emboli, retinal macroaneurysm, and anterior ischemic optic neuropathy. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Hypertension as a risk factor for ocular disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The risk for two of the more common causes of vision loss, age-related macular degeneration and glaucoma, may be increased by the presence of systemic hypertension. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Ocular diseases wherein hypertension may be a risk factor'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21859/abstract/1\">",
"      Wong TY, Wong T, Mitchell P. The eye in hypertension. Lancet 2007; 369:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21859/abstract/2\">",
"      Gudmundsdottir H, Taarnh&oslash;j NC, Strand AH, et al. Blood pressure development and hypertensive retinopathy: 20-year follow-up of middle-aged normotensive and hypertensive men. J Hum Hypertens 2010; 24:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21859/abstract/3\">",
"      Wong TY, Mitchell P. Hypertensive retinopathy. N Engl J Med 2004; 351:2310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21859/abstract/4\">",
"      Keith NM, Wagener HP, Barker NW. Some different types of essential hypertension: their course and prognosis. Am J Med Sci 1974; 268:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21859/abstract/5\">",
"      Sharrett AR, Hubbard LD, Cooper LS, et al. Retinal arteriolar diameters and elevated blood pressure: the Atherosclerosis Risk in Communities Study. Am J Epidemiol 1999; 150:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21859/abstract/6\">",
"      Wong TY, Klein R, Sharrett AR, et al. Retinal arteriolar diameter and risk for hypertension. Ann Intern Med 2004; 140:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21859/abstract/7\">",
"      Wong TY, Klein R, Couper DJ, et al. Retinal microvascular abnormalities and incident stroke: the Atherosclerosis Risk in Communities Study. Lancet 2001; 358:1134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21859/abstract/8\">",
"      Wong TY, Klein R, Sharrett AR, et al. Retinal arteriolar narrowing and risk of coronary heart disease in men and women. The Atherosclerosis Risk in Communities Study. JAMA 2002; 287:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21859/abstract/9\">",
"      Cheung N, Bluemke DA, Klein R, et al. Retinal arteriolar narrowing and left ventricular remodeling: the multi-ethnic study of atherosclerosis. J Am Coll Cardiol 2007; 50:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21859/abstract/10\">",
"      Wong TY, Coresh J, Klein R, et al. Retinal microvascular abnormalities and renal dysfunction: the atherosclerosis risk in communities study. J Am Soc Nephrol 2004; 15:2469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21859/abstract/11\">",
"      Shantha GP, Kumar AA, Bhaskar E, et al. Hypertensive retinal changes, a screening tool to predict microalbuminuria in hypertensive patients: a cross-sectional study. Nephrol Dial Transplant 2010; 25:1839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21859/abstract/12\">",
"      Bock, KD. Regression of retinal vascular changes by antihypertensive therapy. Hypertens 1984; 6:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21859/abstract/13\">",
"      Wong TY, Klein R, Islam FM, et al. Diabetic retinopathy in a multi-ethnic cohort in the United States. Am J Ophthalmol 2006; 141:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21859/abstract/14\">",
"      Hsueh WA, Anderson PW. Hypertension, the endothelial cell, and the vascular complications of diabetes mellitus. Hypertension 1992; 20:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21859/abstract/15\">",
"      Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998; 317:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21859/abstract/16\">",
"      Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. The EUCLID Study Group. Lancet 1997; 349:1787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21859/abstract/17\">",
"      Hyman L, Schachat AP, He Q, Leske MC. Hypertension, cardiovascular disease, and age-related macular degeneration. Age-Related Macular Degeneration Risk Factors Study Group. Arch Ophthalmol 2000; 118:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21859/abstract/18\">",
"      Mitchell P, Lee AJ, Rochtchina E, Wang JJ. Open-angle glaucoma and systemic hypertension: the blue mountains eye study. J Glaucoma 2004; 13:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21859/abstract/19\">",
"      Hayreh SS, Zimmerman MB, Podhajsky P, Alward WL. Nocturnal arterial hypotension and its role in optic nerve head and ocular ischemic disorders. Am J Ophthalmol 1994; 117:603.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3859 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-C5FDE4D645-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_22_21859=[""].join("\n");
var outline_f21_22_21859=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H5\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OCULAR DISEASES DIRECTLY RELATED TO HYPERTENSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      HYPERTENSION AS A RISK FACTOR FOR OCULAR DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      OCULAR DISEASES WHEREIN HYPERTENSION MAY BE A RISK FACTOR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/3859\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3859|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/42/13999\" title=\"picture 1\">",
"      Cotton wool spots",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/27/39359\" title=\"picture 2A\">",
"      Grade IV HTN retinopathy I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/44/19136\" title=\"picture 2B\">",
"      Grade IV HTN retinopathy II",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/52/6986?source=related_link\">",
"      Age-related macular degeneration: Clinical presentation, etiology, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15289?source=related_link\">",
"      Open-angle glaucoma: Epidemiology, clinical presentation, and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_22_21860="Prednisolone and gentamicin: Patient drug information";
var content_f21_22_21860=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Prednisolone and gentamicin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/44/6852?source=see_link\">",
"     see \"Prednisolone and gentamicin: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/54/26466?source=see_link\">",
"     see \"Prednisolone and gentamicin: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F213037\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Pred-G&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10014051\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691501",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat eye infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10014050\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702787",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to prednisolone, gentamicin, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705252",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a very bad eye infection.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10014055\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10014056\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698045",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Eye irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697912",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Blurred eyesight. Use care when driving or doing other tasks that call for clear eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697926",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bright lights may bother you. Wear sunglasses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10014058\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10014053\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705561",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Suspension:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694913",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For the eye only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shake well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695783",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take out contact lenses before using this drug. Lenses may be put back in 15 minutes after this drug is given. Do not put contacts back in if your eyes are irritated or infected.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not touch the container tip to the eye, lid, or other skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696124",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tilt your head back and drop drug into the eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694401",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       After use, keep your eyes closed. Put pressure on the inside corner of the eye. Do this for 1 to 2 minutes. This keeps the drug in your eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Space each eye drug by 5 minutes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705468",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Ointment:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694913",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For the eye only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695513",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Place drug inside the lower lid. Close the eye for 1 to 2 minutes. Roll eyeball around.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695617",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Space each eye drug by 10 minutes.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10014054\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10014059\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10014060\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10991 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-210.101.131.232-54E23519EC-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_22_21860=[""].join("\n");
var outline_f21_22_21860=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213037\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014051\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014050\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014055\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014056\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014058\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014053\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014054\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014059\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014060\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?6/44/6852?source=related_link\">",
"      Prednisolone and gentamicin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/54/26466?source=related_link\">",
"      Prednisolone and gentamicin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_22_21861="Filgrastim: Patient drug information";
var content_f21_22_21861=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Filgrastim: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/13/23767?source=see_link\">",
"     see \"Filgrastim: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?43/27/44470?source=see_link\">",
"     see \"Filgrastim: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F171203\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Neupogen&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F171204\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Neupogen&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10012242\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691773",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat cancer patients who have had bone marrow problems caused by chemo.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691396",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to raise the number of stem cells.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691943",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat low white blood cell counts.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat myelodysplasia.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10012241\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702124",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to filgrastim or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701364",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a latex allergy, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705177",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not get this drug on the same day that you are getting chemo or radiation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10012246\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697341",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have sickle cell disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698458",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. The dose of this drug may be changed depending on the results. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10012247\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697916",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bone pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10012249\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699048",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad shoulder pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10012244\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696001",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into the fatty part of the skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696360",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Your doctor may teach you how to give the shot.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694561",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Before giving the shot, bring it to room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw syringe away after use. Do not use more than one time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696118",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away needles in a needle/sharp disposal box and take the box back to your doctor when it is full.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10012245\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10012250\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699391",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a refrigerator. Do not freeze.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699161",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not shake.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10012251\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12472 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-58.240.98.179-704953041C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_22_21861=[""].join("\n");
var outline_f21_22_21861=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171203\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171204\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012242\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012241\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012246\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012247\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012249\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012244\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012245\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012250\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012251\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?23/13/23767?source=related_link\">",
"      Filgrastim: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?43/27/44470?source=related_link\">",
"      Filgrastim: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_22_21862="Seborrheic dermatitis peds PI";
var content_f21_22_21862=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F82990&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F82990&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Seborrheic dermatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 315px; height: 498px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) In babies, seborrheic dermatitis is commonly called \"cradle cap\" when it happens on the scalp.",
"    <br>",
"     (B) Seborrheic dermatitis can affect the scalp, face, ears, neck, and diaper area.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Reproduced with permission from: Kenneth Greer, MD.",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_22_21862=[""].join("\n");
var outline_f21_22_21862=null;
var title_f21_22_21863="RT portal paraaortic nodes";
var content_f21_22_21863=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F59921&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F59921&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Extended field radiation therapy (EFRT) for cervical or endometrial cancer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 407px; height: 424px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Extended field anteroposterior (AP) radiation portal covering the para-aortic nodes.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kristin Bradley, MD and Derek McHaffie, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_22_21863=[""].join("\n");
var outline_f21_22_21863=null;
var title_f21_22_21864="Focal atrial tachycardia";
var content_f21_22_21864=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Focal atrial tachycardia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/22/21864/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/22/21864/contributors\">",
"     Peter Kistler, MBBS, FRACP, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/22/21864/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/22/21864/contributors\">",
"     Samuel L&eacute;vy, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/22/21864/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/22/21864/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/22/21864/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 29, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrial tachycardia (AT) is a regular atrial rhythm at a constant rate of &gt;100 beats per min originating outside of the sinus node (",
"    <a class=\"graphic graphic_waveform graphicRef74611 \" href=\"UTD.htm?42/4/43079\">",
"     waveform 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21864/abstract/1\">",
"     1",
"    </a>",
"    ]. Focal ATs arise from a single site within the left or right atrium, in contrast to macroreentrant atrial arrhythmias (eg, atrial flutter) and atrial fibrillation, which involve multiple sites or larger circuits.",
"   </p>",
"   <p>",
"    In the past, focal ATs were considered to be due predominantly to enhanced automaticity. Thus, they were often referred to as automatic ATs. However, the more inclusive term focal AT is preferred, as this encompasses automatic, triggered, and microreentrant etiologies that cannot be distinguished easily on the surface electrocardiogram.",
"   </p>",
"   <p>",
"    Focal ATs are usually paroxysmal and self-limited, although in some patients, focal AT may be present nearly continuously (ie, incessant AT). Incessant AT is important as it may be associated with left ventricular dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21864/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27097?source=see_link&amp;anchor=H11#H11\">",
"     \"Tachycardia-mediated cardiomyopathy\", section on 'Atrial tachycardia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The characteristics and management of the common, repetitive forms of focal AT are discussed here. Macroreentrant atrial arrhythmias (eg, atrial flutter), atrial fibrillation, and other forms of supraventricular tachycardia are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/60/13256?source=see_link\">",
"     \"Overview of the evaluation and management of atrial flutter\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/22/361?source=see_link\">",
"     \"Overview of atrial fibrillation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39481?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and evaluation of narrow QRS complex tachycardias\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BACKGROUND",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Definition",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2001, the Joint Expert Group from the Working Group of Arrhythmias of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology (now called the Heart Rhythm Society) classified regular ATs according to electrophysiologic mechanisms and anatomy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21864/abstract/1\">",
"     1",
"    </a>",
"    ]. The Joint Expert Group defined focal AT as \"being characterized by atrial activation starting rhythmically at a small area (focus) from where it spreads centrifugally.\" This definition indicates that the arrhythmia arises from an area that is smaller than would be required for classical macroreentry, which conventionally is considered to be a circuit greater than 2 cm in diameter.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Incidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Repetitive focal AT is relatively rare, accounting for between 5 and 15 percent of arrhythmias in adults undergoing study for paroxysmal supraventricular tachycardia [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21864/abstract/3\">",
"     3",
"    </a>",
"    ]. Men and women seem to be equally affected.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     MECHANISMS AND ETIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Electrophysiologic mechanisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The focal activity responsible for AT can be produced by three distinct electrophysiologic mechanisms [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21864/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Enhanced automaticity &mdash; Enhanced automaticity refers to an acceleration of a normal automatic pacemaker by an increase in the slope of phase four depolarization (",
"      <a class=\"graphic graphic_figure graphicRef64133 \" href=\"UTD.htm?26/24/27023\">",
"       figure 1",
"      </a>",
"      ), shortening of the refractory period, a decrease in the threshold for excitation, or some combination of these mechanisms. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/5/42070?source=see_link\">",
"       \"Enhanced cardiac automaticity\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Triggered activity &mdash; Triggered activity is the result of electrophysiologic phenomena called afterdepolarizations. Afterdepolarizations are focal electrical events that result in repeat depolarization of a single cell or small area prior to full repolarization. Early afterdepolarizations occur during the plateau phase of the action potential, while delayed afterdepolarizations occur during phase four.",
"     </li>",
"     <li>",
"      Microreentry &mdash; Microreentry requires a small circuit in which conduction is sufficiently slow that the tissue can recover its excitability and be re-excited by the time the wave of depolarization returns. Such slow conduction may be due to a variety of mechanisms, including a rise in the maximum diastolic potential, changes in threshold, alterations in the activation and inactivation of channels responsible for depolarization or repolarization, and poor cell-cell coupling due to a decrease in transmission through gap junctions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The hypothesis that cellular uncoupling is required for the development of focal atrial tachycardias is supported by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Low-amplitude fractionated electrograms are commonly found in the focal areas in which these atrial arrhythmias arise [",
"      <a class=\"abstract\" href=\"UTD.htm?21/22/21864/abstract/6,7\">",
"       6,7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Focal arrhythmogenesis often occurs in areas having discontinuities in atrial structure [",
"      <a class=\"abstract\" href=\"UTD.htm?21/22/21864/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Sites of origin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Focal ATs do not occur randomly throughout the atria, but rather cluster at predefined anatomic locations [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21864/abstract/8\">",
"     8",
"    </a>",
"    ]. These locations are characterized by alterations in myocardial fiber orientation or sites of automatic tissue. In a series of 186 patients with clinically documented paroxysmal or incessant AT, 63 percent of ATs arose in the right atrium (RA) and 37 percent in the left atrium (LA) (",
"    <a class=\"graphic graphic_figure graphicRef62431 \" href=\"UTD.htm?24/46/25317\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21864/abstract/9\">",
"     9",
"    </a>",
"    ]. The distribution of sites of origin among the right atrial tachycardias was:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Tricuspid annulus (35 percent) (",
"      <a class=\"graphic graphic_waveform graphicRef74611 \" href=\"UTD.htm?42/4/43079\">",
"       waveform 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Crista terminalis (34 percent) (",
"      <a class=\"graphic graphic_waveform graphicRef50523 \" href=\"UTD.htm?20/2/20519\">",
"       waveform 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Coronary sinus ostium (17 percent)",
"     </li>",
"     <li>",
"      Perinodal tissues(9 percent)",
"     </li>",
"     <li>",
"      RA appendage (4 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Left atrial tachycardias were predominantly located around the pulmonary veins (67 percent) (",
"    <a class=\"graphic graphic_waveform graphicRef57390 \" href=\"UTD.htm?29/42/30374\">",
"     waveform 3",
"    </a>",
"    ). Less common sites of origin include the mitral annulus (17 percent), coronary sinus body (6 percent), left intraatrial septum (6 percent), and the LA appendage (4 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21864/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Associated conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Focal AT may occur in patients with organic heart disease in response to atrial stretch due to elevated atrial pressure in conditions such as hypertension and cardiomyopathy. In addition to chronic heart disease, AT can also be associated with acute events such as a myocardial infarction, pulmonary decompensation, infection, excessive alcohol ingestion, hypokalemia, hypoxia, stimulants, cocaine ingestion, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21864/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. AT can occur in the absence of heart disease and in such settings, it has a benign prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21864/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17173656\">",
"    <span class=\"h3\">",
"     Incessant AT resulting in cardiomyopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term &ldquo;incessant\" is applied to an AT when the AT is present for at least 90 percent of the time a patient is monitored [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21864/abstract/15\">",
"     15",
"    </a>",
"    ]. Incessant AT is often found in otherwise normal young individuals, including children, although it may occur in patients with organic heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21864/abstract/16-19\">",
"     16-19",
"    </a>",
"    ]. The rate tends to be faster during the day than at night, and it may increase with exercise or pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21864/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Incessant focal AT may be responsible for tachycardia-mediated cardiomyopathy, which refers to left ventricular (LV) chamber dilatation and systolic dysfunction in a patient with persistent tachyarrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21864/abstract/18,22,23\">",
"     18,22,23",
"    </a>",
"    ]. Focal ATs originating in the atrial appendages and pulmonary veins are more frequently associated with cardiomyopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21864/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27097?source=see_link\">",
"     \"Tachycardia-mediated cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1542581\">",
"    <span class=\"h3\">",
"     Post-atrial fibrillation ablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of atrial tachycardia appears to be higher among patients who have undergone catheter ablation for atrial fibrillation (AF) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21864/abstract/25\">",
"     25",
"    </a>",
"    ]. Catheter ablation of persistent AF commonly involves an extensive biatrial ablation strategy that combines linear ablation and the targeting of complex fractionated activity beyond pulmonary vein isolation. This form of substrate modification has been associated with an improvement in the drug-free achievement of sinus rhythm, but may also create an electrophysiologic milieu for micro reentry [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21864/abstract/25\">",
"     25",
"    </a>",
"    ]. The occurrence of AT in this setting is related to AF duration and extent of ablation. These ATs are often incessant, associated with rapid ventricular rates, and respond poorly to pharmacologic measures. Although seen as a positive sign in the longer-term restoration of sinus rhythm, postablation AT poses specific challenges often requiring repeat catheter ablation procedures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/62/40938?source=see_link&amp;anchor=H20#H20\">",
"     \"Radiofrequency catheter ablation to prevent recurrent atrial fibrillation\", section on 'Efficacy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21082008\">",
"    <span class=\"h3\">",
"     Digitalis toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients taking digitalis, toxicity should be suspected if a new AT develops, particularly if 2:1 or higher grade AV block is present. Digitalis should be discontinued in this case, and anti-digitalis antibodies should be considered if hemodynamic compromise is present or other dangerous arrhythmias accompany the tachycardia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/13/25817?source=see_link\">",
"     \"Digitalis (cardiac glycoside) poisoning\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20806678\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with focal AT report palpitations associated with their episodes of tachycardia. Palpitations can manifest in different ways. The abrupt onset of a rapid fluttering sensation in the chest or neck is most consistent with a tachyarrhythmia such as focal AT. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/11/20665?source=see_link\">",
"     \"Overview of palpitations in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with focal AT can rarely present with syncope, particularly when the ventricular heart rate exceeds 150",
"    <span class=\"nowrap\">",
"     beats/minute.",
"    </span>",
"    Syncope, however, is more frequently seen with a ventricular tachyarrhythmia such as ventricular tachycardia than with focal AT. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/9/5272?source=see_link&amp;anchor=H5#H5\">",
"     \"Pathogenesis and etiology of syncope\", section on 'Cardiac arrhythmias'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with other underlying cardiac comorbidities (eg, heart failure, angina) can present with symptoms associated with worsening of their underlying disease (eg, dyspnea, chest pain).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15492827\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of focal AT is based primarily on electrocardiographic (ECG) findings demonstrating an atrial arrhythmia of &gt;100 beats per minute originating from outside the sinus node. The tachycardia is generally sudden in onset and offset and frequently demonstrates a change in P wave morphology. Focal AT is suggested by bursts of atrial activity with an isoelectric interval between P waves with confirmation of &ldquo;focal&rdquo; as opposed to macroreentry dependent on the findings at EP study. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Electrophysiologic studies'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Electrocardiographic features",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     P waves",
"    </span>",
"    &nbsp;&mdash;&nbsp;The atrial rate during focal AT is generally between 130 and 250 beats per minute. Infants, children and young adults often have faster rates.",
"   </p>",
"   <p>",
"    The P wave morphology can appear normal or abnormal, depending upon the site of origin of the tachycardia [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21864/abstract/26\">",
"     26",
"    </a>",
"    ]. If the focus is from the superior portion of the crista terminalis, the P wave may be similar in appearance to the sinus P wave. Usually, there is a subtle difference in P waves from sinus rhythm to AT, so comparison to an ECG with known sinus P waves is recommended whenever possible. ECG leads V1 and lead II are the most useful in assessing P wave morphology.",
"   </p>",
"   <p>",
"    Observation over several minutes with multiple ECGs is invaluable in distinguishing focal AT from sinus tachycardia. Although focal ATs are regular, the rate may accelerate or \"warm up\" in the first few beats of the tachycardia and decelerate in the last few beats. An abrupt onset or termination (eg, over three to four beats) favors a focal AT. Sinus tachycardia requires 30 seconds to several minutes to speed up or slow down.",
"   </p>",
"   <p>",
"    In occasional patients, intracardiac atrial depolarizations can be recorded during electrophysiologic study, yet no P waves appear on the surface ECG. Thus, the ECG alone suggests atrioventricular (AV) junctional tachycardia [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21864/abstract/27\">",
"     27",
"    </a>",
"    ]. This may occur if the atrial and ventricular complexes are closely associated such that the P wave is buried in the QRS complex. Reentrant AV junctional tachycardias can also simulate atrial tachycardia by presenting with inverted P waves shortly before the QRS complex; however, this occurs in less than 10 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21864/abstract/10,26,28\">",
"     10,26,28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Atrioventricular relationship",
"    </span>",
"    &nbsp;&mdash;&nbsp;In focal AT, atrioventricular (AV) conduction is usually 1:1. The PR interval is often in the normal range, producing a long R-P interval, which can help to distinguish focal AT from other forms of supraventricular tachycardia (SVT). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39481?source=see_link&amp;anchor=H20#H20\">",
"     \"Clinical manifestations, diagnosis, and evaluation of narrow QRS complex tachycardias\", section on 'RP relationship'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mobitz type 1 and 2 conduction may also be seen depending on the rate of the atrial tachycardia and the conducting properties of the AV node. The appearance of &ldquo;grouped beating&rdquo; as seen in Mobitz type 1 conduction (Wenckebach) favors focal atrial tachycardia as the responsible mechanism for SVT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     QRS morphology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The QRS morphology is usually the same as in sinus rhythm, although aberrant conduction may occur at higher ventricular rates.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H189482685\">",
"    <span class=\"h2\">",
"     Localization of AT focus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Algorithms which attempt to prediction the origin of the atrial tachycardia focus have been proposed [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21864/abstract/9,29\">",
"     9,29",
"    </a>",
"    ]. A series of 126 patients undergoing electrophysiology study for focal atrial tachycardia led to the development of an algorithm that was able to predict the arrhythmogenic focus in 93 percent (",
"    <a class=\"graphic graphic_algorithm graphicRef53718 \" href=\"UTD.htm?23/27/23998\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21864/abstract/9\">",
"     9",
"    </a>",
"    ]. This algorithm is most useful for predicting the site of AT origin to guide mapping and ablation at the time of electrophysiology study.",
"   </p>",
"   <p>",
"    The algorithm begins with an evaluation of the P wave in lead V1 [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21864/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      If the P wave in V1 is negative or biphasic with an initially",
"      <span class=\"nowrap\">",
"       positive/terminally",
"      </span>",
"      negative deflection, the AT focus is likely in the right atrium (",
"      <a class=\"graphic graphic_waveform graphicRef74611 \" href=\"UTD.htm?42/4/43079\">",
"       waveform 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_waveform graphicRef50523 \" href=\"UTD.htm?20/2/20519\">",
"       waveform 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      If the P wave in V1 is positive or biphasic with an initially",
"      <span class=\"nowrap\">",
"       negative/terminally",
"      </span>",
"      positive deflection, the AT focus is likely in the left atrium (",
"      <a class=\"graphic graphic_waveform graphicRef57390 \" href=\"UTD.htm?29/42/30374\">",
"       waveform 3",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    With close inspection of the P wave in other leads, likely sites of origin could be predicted, including those in the coronary sinus, crista terminalis, left atrial appendage, right atrial appendage, interatrial septum, or pulmonary veins.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Electrophysiologic studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The electrophysiologic evaluation of ATs is complex and the characteristics of the arrhythmia depend upon the mechanism [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21864/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. The studies are best performed initially under light sedation as automatic ATs may be more difficult to induce under deeper sedation or general anesthesia. Other ATs are inducible by programmed extrastimulation, and less sensitive to the effects of anesthesia. The findings on electrophysiologic study vary depending upon the mechanism of AT:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Automatic ATs cannot be initiated, entrained, or terminated by electrophysiologic stimulation. They may be initiated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/31/23029?source=see_link\">",
"       isoproterenol",
"      </a>",
"      or adrenaline.",
"     </li>",
"     <li>",
"      Microreentrant ATs can be initiated, terminated, and entrained by programmed stimulation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The ability to identify the focus responsible for AT has improved with the development of three-dimensional mapping systems.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of focal AT is divided into acute treatment and chronic suppressive, or prophylactic, therapy. There are few data to guide treatment strategies. Our approach is consistent with that presented in the 2003 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart",
"    <span class=\"nowrap\">",
"     Association/European",
"    </span>",
"    Society of Cardiology",
"    <span class=\"nowrap\">",
"     (ACC/AHA/ESC)",
"    </span>",
"    guidelines for the management of supraventricular arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21864/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Acute treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The acute management of a patient with an AT is guided by the ventricular rate, symptoms, and the hemodynamic stability of the patient. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39481?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical manifestations, diagnosis, and evaluation of narrow QRS complex tachycardias\", section on 'Assessing the patient for hemodynamic stability'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/20/6473?source=see_link&amp;anchor=H13#H13\">",
"     \"Overview of the acute management of tachyarrhythmias\", section on 'Atrial tachycardia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There have been no randomized trials to assess the efficacy of the acute pharmacologic management of AT. For the acute management of patients with AT with a rapid ventricular response, we suggest the following approach, which is based upon small case series and retrospective studies, but is in general agreement with the 2003",
"    <span class=\"nowrap\">",
"     ACC/AHA/ESC",
"    </span>",
"    guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21864/abstract/30\">",
"     30",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Efforts should be made to identify and treat any precipitating factors (see",
"      <a class=\"local\" href=\"#H8\">",
"       'Associated conditions'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H21082008\">",
"       'Digitalis toxicity'",
"      </a>",
"      above). In particular:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In patients who present with hypokalemia, potassium should be repleted.",
"     </li>",
"     <li>",
"      In patients on digitalis where toxicity is suspected, digitalis should be discontinued and administration of anti-digitalis antibodies should be considered if hemodynamic compromise or other life-threatening arrhythmias (ie, ventricular tachycardia) are present.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Efforts can be made to terminate focal AT by having the patient perform vagal maneuvers or by administering intravenous adenosine. However, vagal maneuvers and adenosine are generally less effective for termination of AT than for other supraventricular tachycardias.",
"     </li>",
"     <li>",
"      Intravenous beta blockers or nondihydropyridine calcium channel blockers (ie,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"       diltiazem",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      ) may be given to the hemodynamically stable patient. These drugs slow the ventricular response and may terminate the arrhythmia. In patients with a borderline blood pressure, cautious use of these medications, initially at low doses (eg, diltiazem at 20 mg IV), may paradoxically improve blood pressure due to improved cardiac output at lower heart rates.",
"     </li>",
"     <li>",
"      In patients who are intolerant of, or are likely to be intolerant of, beta blockers and nondihydropyridine calcium channel blockers, we suggest intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      , which can provide acute rate control, may terminate the arrhythmia, and results in less hypotension than beta blockers,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"       diltiazem",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      . In appropriately selected patients, class Ic (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"       flecainide",
"      </a>",
"      ), or class III (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"       sotalol",
"      </a>",
"      ) antiarrhythmic drugs can also be used. However, because of the unique risk profiles of each of these agents, decisions regarding the use of antiarrhythmic drugs, other than amiodarone, should be made with the assistance of a cardiologist experienced in arrhythmia management. In particular class 1c drugs are contraindicated in the setting of structural heart disease.",
"     </li>",
"     <li>",
"      For patients with hemodynamically unstable AT with a rapid ventricular response who do not respond to medical therapy and do not have a reversible precipitating cause, we suggest an attempt at electrical cardioversion.",
"      <br/>",
"      <br/>",
"      However, ATs may be particularly resistant to cardioversion for two reasons. First, many ATs are caused by enhanced automaticity, and electrical cardioversion is ineffective for such arrhythmias. Secondly, ATs are often precipitated by significant underlying illnesses that both limit the efficacy of cardioversion and increase the likelihood of early arrhythmia recurrence. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Electrophysiologic mechanisms'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Associated conditions'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Hemodynamically unstable patients with persistent AT despite treatment with rate-controlling medications and efforts at electrical cardioversion should have an attempt at chemical cardioversion using",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4348457\">",
"    <span class=\"h2\">",
"     Chronic or maintenance therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic therapy of repetitive focal AT is designed to prevent arrhythmia recurrence and to control the ventricular rate if the arrhythmia recurs. Patients with relatively rare and brief arrhythmias and few or no symptoms do not require chronic therapy.",
"   </p>",
"   <p>",
"    The published literature addressing chronic suppressive treatment of AT includes only observational studies of small numbers of patients. Some of these studies included patients with atrial fibrillation and atrial flutter, which have different mechanisms and may respond differently to therapy. With these limitations in mind, we suggest the following approach for chronic treatment of patients with frequent or symptomatic AT, which is in general agreement with the 2003",
"    <span class=\"nowrap\">",
"     ACC/AHA/ESC",
"    </span>",
"    guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21864/abstract/30\">",
"     30",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest initial therapy with oral beta blockers or nondihydropyridine calcium channel blockers (ie,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"       diltiazem",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      ). Patients who do not respond to one of these agents may have successful suppression with another. Therefore, we suggest switching from one drug to another before considering class I or III antiarrhythmic drugs or catheter ablation.",
"     </li>",
"     <li>",
"      In patients with recurrent symptomatic AT despite therapy with beta blockers,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"       diltiazem",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      , we suggest catheter ablation. The threshold for considering catheter ablation is lower for younger patients and in patients with tachycardia-mediated cardiomyopathy. (See",
"      <a class=\"local\" href=\"#H17173656\">",
"       'Incessant AT resulting in cardiomyopathy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/41/33431?source=see_link\">",
"       \"Catheter ablation of atrial tachycardia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      More aggressive antiarrhythmic drugs may be considered for patients who fail beta blockers,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"       diltiazem",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      who do not want or are not good candidates for ablation therapy. In patients with significant comorbidities and structural heart disease,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      is frequently the preferred agent. As with acute therapy of ATs however, other class Ic (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"       flecainide",
"      </a>",
"      ), or class III (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"       sotalol",
"      </a>",
"      ) antiarrhythmic drugs can be used in appropriately selected patients. However, because of the unique risk profiles of each of these agents, decisions regarding the use of antiarrhythmic drugs, other than amiodarone, should be made with the assistance of a cardiologist experienced in arrhythmia management.",
"     </li>",
"     <li>",
"      Patients with recurrent symptomatic AT in whom all other therapeutic options have been unsuccessful (including catheter ablation) may also be considered for pacemaker implantation followed by AV nodal ablation. This typically provides symptomatic relief although generally leaves the patient pacemaker dependent. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/53/24408?source=see_link&amp;anchor=H5#H5\">",
"       \"Control of ventricular rate in atrial fibrillation: Nonpharmacologic therapy\", section on 'AV nodal ablation'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9439996\">",
"    <span class=\"h2\">",
"     Treatment of incessant AT",
"    </span>",
"    &nbsp;&mdash;&nbsp;As described above, patients with incessant AT may present with a cardiomyopathy. Even patients with normal left ventricular systolic function on initial presentation are at risk of developing a cardiomyopathy following extended periods of tachycardia. This LV systolic dysfunction typically reverses weeks to months following the restoration of sinus rhythm. As such, aggressive efforts should be made to restore normal sinus rhythm in an attempt to prevent or reverse LV systolic dysfunction. (See",
"    <a class=\"local\" href=\"#H17173656\">",
"     'Incessant AT resulting in cardiomyopathy'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27097?source=see_link\">",
"     \"Tachycardia-mediated cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While there have been occasional reports of the successful treatment of incessant AT using beta blockers and Class IC antiarrhythmic drugs (ie,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"     flecainide",
"    </a>",
"    ), pharmacologic therapy is generally",
"    <strong>",
"     ineffective",
"    </strong>",
"    in incessant AT [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21864/abstract/31-37\">",
"     31-37",
"    </a>",
"    ]. For this reason, if medical therapy with rate-controlling medications and antiarrhythmic drugs is unsuccessful, patients with AT and concomitant LV systolic dysfunction should undergo catheter ablation (",
"    <a class=\"graphic graphic_waveform graphicRef50523 \" href=\"UTD.htm?20/2/20519\">",
"     waveform 2",
"    </a>",
"    ). Success rates vary according to the site of AT origin, with successful ablation more likely for AT originating in the right atrium [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21864/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. Only 10 to 15 percent of patients will have recurrence of AT following catheter ablation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/41/33431?source=see_link\">",
"     \"Catheter ablation of atrial tachycardia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1509844\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Atrial tachycardia (AT) is a regular atrial rhythm at a constant rate of &gt;100 beats per minute, usually paroxysmal and self-limited, which originates outside of the sinus node. Focal AT accounts for between 5 and 15 percent of paroxysmal supraventricular tachycardia in adults. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Background'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mechanistically, AT can result from enhanced automaticity, triggered activity, or microreentry. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Electrophysiologic mechanisms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The majority of ATs originate in the right atrium along the tricuspid annulus or the crista terminalis. Left atrial AT predominantly originates near the pulmonary veins. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Sites of origin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most patients with focal AT report palpitations associated with their episodes of tachycardia. Rarely, patients may present with syncope or exacerbation of an underlying cardiac condition (eg, angina). (See",
"      <a class=\"local\" href=\"#H20806678\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The P wave morphology can appear normal or abnormal, depending upon the site of origin of the tachycardia. Usually, there is a subtle difference in P waves from sinus rhythm to AT, so comparison to an ECG with known sinus P waves is advised, whenever possible. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Electrocardiographic features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The acute treatment of patients with AT depends upon the presence of symptoms and the patient&rsquo;s hemodynamic status:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For an asymptomatic hemodynamically stable patient with AT, we suggest initial observation rather than acute treatment with a beta blocker or nondihydropyridine calcium channel blocker (ie,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"       diltiazem",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Acute treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For a hemodynamically stable patient with symptomatic AT, we suggest acute treatment with an oral or intravenous beta blocker or nondihydropyridine calcium channel blocker (ie,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"       diltiazem",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Such treatment may slow the ventricular response",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      terminate the arrhythmia. Intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      is an acceptable alternative that may be preferred in a patient with borderline hypotension. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Acute treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who are hemodynamically unstable are not candidates for medical therapy with intravenous beta blocker or nondihydropyridine calcium channel blocker because these treatments are likely to exacerbate hypotension. For such patients, we suggest an attempt at electrical cardioversion (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Hemodynamically unstable patients with persistent AT despite treatment with rate-controlling medications and efforts at electrical cardioversion should have an attempted chemical cardioversion using intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      .(See",
"      <a class=\"local\" href=\"#H16\">",
"       'Acute treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic therapy of repetitive focal AT is designed to prevent arrhythmia recurrence and to control the ventricular rate if the arrhythmia recurs.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Patients with relatively rare or brief AT episodes with few or no symptoms can receive treatment as needed for acute episodes of AT but do not require chronic suppressive therapy. (See",
"      <a class=\"local\" href=\"#H4348457\">",
"       'Chronic or maintenance therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with frequent, symptomatic AT, we suggest acute management followed by chronic maintenance therapy with an oral beta blocker or nondihydropyridine calcium channel blocker (ie,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"       diltiazem",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4348457\">",
"       'Chronic or maintenance therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with frequent, symptomatic AT who have failed initial medical therapy should be seen in consultation by a cardiologist who specializes in arrhythmias for potential anti-arrhythmic medication or catheter ablation. (See",
"      <a class=\"local\" href=\"#H4348457\">",
"       'Chronic or maintenance therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with incessant AT with preserved left ventricular function and few or no symptoms, an initial trial of rate-controlling medications or antiarrhythmic medications may be reasonable. The efficacy of this approach should be reassessed within one to two weeks and, if unsuccessful, the patient should be referred for catheter ablation. (See",
"      <a class=\"local\" href=\"#H9439996\">",
"       'Treatment of incessant AT'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with cardiomyopathy felt to be related to incessant AT, we recommend aggressive attempts to restore a normal ventricular heart rate (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). This can be accomplished in most patients by catheter ablation of the AT focus. However, if catheter ablation of the AT focus is unsuccessful, pacemaker implantation followed by AV nodal ablation typically provides symptomatic relief. (See",
"      <a class=\"local\" href=\"#H9439996\">",
"       'Treatment of incessant AT'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21864/abstract/1\">",
"      Saoudi N, Cos&iacute;o F, Waldo A, et al. A classification of atrial flutter and regular atrial tachycardia according to electrophysiological mechanisms and anatomical bases; a Statement from a Joint Expert Group from The Working Group of Arrhythmias of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Eur Heart J 2001; 22:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21864/abstract/2\">",
"      Medi C, Kalman JM, Haqqani H, et al. Tachycardia-mediated cardiomyopathy secondary to focal atrial tachycardia: long-term outcome after catheter ablation. J Am Coll Cardiol 2009; 53:1791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21864/abstract/3\">",
"      Chen SA, Chiang CE, Yang CJ, et al. Sustained atrial tachycardia in adult patients. Electrophysiological characteristics, pharmacological response, possible mechanisms, and effects of radiofrequency ablation. Circulation 1994; 90:1262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21864/abstract/4\">",
"      Roberts-Thomson KC, Kistler PM, Kalman JM. Atrial tachycardia: mechanisms, diagnosis, and management. Curr Probl Cardiol 2005; 30:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21864/abstract/5\">",
"      Roberts-Thomson KC, Kistler PM, Kalman JM. Focal atrial tachycardia I: clinical features, diagnosis, mechanisms, and anatomic location. Pacing Clin Electrophysiol 2006; 29:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21864/abstract/6\">",
"      Higa S, Tai CT, Lin YJ, et al. Focal atrial tachycardia: new insight from noncontact mapping and catheter ablation. Circulation 2004; 109:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21864/abstract/7\">",
"      De Groot NM, Schalij MJ. Fragmented, long-duration, low-amplitude electrograms characterize the origin of focal atrial tachycardia. J Cardiovasc Electrophysiol 2006; 17:1086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21864/abstract/8\">",
"      Kistler PM, Sanders P, Hussin A, et al. Focal atrial tachycardia arising from the mitral annulus: electrocardiographic and electrophysiologic characterization. J Am Coll Cardiol 2003; 41:2212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21864/abstract/9\">",
"      Kistler PM, Roberts-Thomson KC, Haqqani HM, et al. P-wave morphology in focal atrial tachycardia: development of an algorithm to predict the anatomic site of origin. J Am Coll Cardiol 2006; 48:1010.",
"     </a>",
"    </li>",
"    <li>",
"     Josephson, ME. Clinical Cardiac Electrophysiology: Techniques and Interpretations, 2nd, Lea &amp; Febiger, Philadelphia 1993.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21864/abstract/11\">",
"      Josephson ME. Paroxysmal supraventricular tachycardia: an electrophysiologic approach. Am J Cardiol 1978; 41:1123.",
"     </a>",
"    </li>",
"    <li>",
"     Akhtar, M. Supraventricular tachycardias. Electrophysiologic mechanisms, diagnosis and pharmacologic therapy. In: Tachycardias: Mechanisms, Diagnosis, Treatment, Josephson, ME, Wellens, H (Eds), Lea &amp; Febiger, Philadelphia 1984. p.137.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21864/abstract/13\">",
"      Levine HD, Smith C Jr. Repetitive paroxysmal tachycardia in adults. Cardiology 1970; 55:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21864/abstract/14\">",
"      Parkinson J, Papp C. Repetitive paroxysmal tachycardia. Br Heart J 1942; 10:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21864/abstract/15\">",
"      Sung RJ. Incessant supraventricular tachycardia. Pacing Clin Electrophysiol 1983; 6:1306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21864/abstract/16\">",
"      Gillette PC, Smith RT, Garson A Jr, et al. Chronic supraventricular tachycardia. A curable cause of congestive cardiomyopathy. JAMA 1985; 253:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21864/abstract/17\">",
"      Gillette PC, Wampler DG, Garson A Jr, et al. Treatment of atrial automatic tachycardia by ablation procedures. J Am Coll Cardiol 1985; 6:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21864/abstract/18\">",
"      Packer DL, Bardy GH, Worley SJ, et al. Tachycardia-induced cardiomyopathy: a reversible form of left ventricular dysfunction. Am J Cardiol 1986; 57:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21864/abstract/19\">",
"      Bertil Olsson S, Blomstr&ouml;m P, Sabel KG, William-Olsson G. Incessant ectopic atrial tachycardia: successful surgical treatment with regression of dilated cardiomyopathy picture. Am J Cardiol 1984; 53:1465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21864/abstract/20\">",
"      Scheinman MM, Basu D, Hollenberg M. Electrophysiologic studies in patients with persistent atrial tachycardia. Circulation 1974; 50:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21864/abstract/21\">",
"      Doig JC, McComb JM, Reid DS. Incessant atrial tachycardia accelerated by pregnancy. Br Heart J 1992; 67:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21864/abstract/22\">",
"      Chen SA, Tai CT, Chiang CE, et al. Focal atrial tachycardia: reanalysis of the clinical and electrophysiologic characteristics and prediction of successful radiofrequency ablation. J Cardiovasc Electrophysiol 1998; 9:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21864/abstract/23\">",
"      Koike K, Hesslein PS, Finlay CD, et al. Atrial automatic tachycardia in children. Am J Cardiol 1988; 61:1127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21864/abstract/24\">",
"      Kistler PM, Sanders P, Fynn SP, et al. Electrophysiological and electrocardiographic characteristics of focal atrial tachycardia originating from the pulmonary veins: acute and long-term outcomes of radiofrequency ablation. Circulation 2003; 108:1968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21864/abstract/25\">",
"      O'Neill MD, Wright M, Knecht S, et al. Long-term follow-up of persistent atrial fibrillation ablation using termination as a procedural endpoint. Eur Heart J 2009; 30:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21864/abstract/26\">",
"      MacLean WA, Karp RB, Kouchoukos NT, et al. P waves during ectopic atrial rhythms in man: a study utilizing atrial pacing with fixed electrodes. Circulation 1975; 52:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21864/abstract/27\">",
"      Zipes DP, Gaum WE, Genetos BC, et al. Atrial tachycardia without P waves masquerading as an A-V junctional tachycardia. Circulation 1977; 55:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21864/abstract/28\">",
"      B&auml;r FW, Brugada P, Dassen WR, Wellens HJ. Differential diagnosis of tachycardia with narrow QRS complex (shorter than 0.12 second). Am J Cardiol 1984; 54:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21864/abstract/29\">",
"      Qian ZY, Hou XF, Xu DJ, et al. An algorithm to predict the site of origin of focal atrial tachycardia. Pacing Clin Electrophysiol 2011; 34:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21864/abstract/30\">",
"      Blomstr&ouml;m-Lundqvist C, Scheinman MM, Aliot EM, et al. ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Supraventricular Arrhythmias). Circulation 2003; 108:1871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21864/abstract/31\">",
"      Gillette PC, Garson A Jr. Electrophysiologic and pharmacologic characteristics of automatic ectopic atrial tachycardia. Circulation 1977; 56:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21864/abstract/32\">",
"      Iwai S, Markowitz SM, Stein KM, et al. Response to adenosine differentiates focal from macroreentrant atrial tachycardia: validation using three-dimensional electroanatomic mapping. Circulation 2002; 106:2793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21864/abstract/33\">",
"      Keane JF, Plauth WH, Nadas AS. Chronic ectopic tachycardia of infancy and childhood. Am Heart J 1972; 84:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21864/abstract/34\">",
"      Yoshimura H, Ishikawa T, Kuji N, et al. Two cases of dilated cardiomyopathy associated with incessant supraventricular tachycardia who showed a favorable response to beta-blockade. Heart Vessels Suppl 1990; 5:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21864/abstract/35\">",
"      Pool PE, Quart BD. Treatment of ectopic atrial arrhythmias and premature atrial complexes in adults with encainide. Am J Cardiol 1988; 62:60L.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21864/abstract/36\">",
"      Berns E, Rinkenberger RL, Jeang MK, et al. Efficacy and safety of flecainide acetate for atrial tachycardia or fibrillation. Am J Cardiol 1987; 59:1337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21864/abstract/37\">",
"      Brugada P, Abdollah H, Wellens HJ. Suppression of incessant supraventricular tachycardia by intravenous and oral encainide. J Am Coll Cardiol 1984; 4:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21864/abstract/38\">",
"      Anguera I, Brugada J, Roba M, et al. Outcomes after radiofrequency catheter ablation of atrial tachycardia. Am J Cardiol 2001; 87:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21864/abstract/39\">",
"      Scheinman MM, Huang S. The 1998 NASPE prospective catheter ablation registry. Pacing Clin Electrophysiol 2000; 23:1020.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 900 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-115.25.216.6-84049B631E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_22_21864=[""].join("\n");
var outline_f21_22_21864=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1509844\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BACKGROUND",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Definition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Incidence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      MECHANISMS AND ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Electrophysiologic mechanisms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Sites of origin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Associated conditions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17173656\">",
"      - Incessant AT resulting in cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1542581\">",
"      - Post-atrial fibrillation ablation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21082008\">",
"      - Digitalis toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20806678\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15492827\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Electrocardiographic features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - P waves",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Atrioventricular relationship",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - QRS morphology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H189482685\">",
"      Localization of AT focus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Electrophysiologic studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Acute treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4348457\">",
"      Chronic or maintenance therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9439996\">",
"      Treatment of incessant AT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1509844\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/900\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/900|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?23/27/23998\" title=\"algorithm 1\">",
"      Atrial tachycardia algorithm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/900|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/24/27023\" title=\"figure 1\">",
"      Action potential and ECG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/46/25317\" title=\"figure 2\">",
"      Atrial tachycardia foci",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/900|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?42/4/43079\" title=\"waveform 1\">",
"      Atrial tachycardia ECG 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?20/2/20519\" title=\"waveform 2\">",
"      Atrial tachycardia ECG 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?29/42/30374\" title=\"waveform 3\">",
"      Atrial tachycardia ECG 3",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/41/33431?source=related_link\">",
"      Catheter ablation of atrial tachycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39481?source=related_link\">",
"      Clinical manifestations, diagnosis, and evaluation of narrow QRS complex tachycardias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/53/24408?source=related_link\">",
"      Control of ventricular rate in atrial fibrillation: Nonpharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/13/25817?source=related_link\">",
"      Digitalis (cardiac glycoside) poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/5/42070?source=related_link\">",
"      Enhanced cardiac automaticity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/22/361?source=related_link\">",
"      Overview of atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/11/20665?source=related_link\">",
"      Overview of palpitations in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/20/6473?source=related_link\">",
"      Overview of the acute management of tachyarrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/60/13256?source=related_link\">",
"      Overview of the evaluation and management of atrial flutter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/9/5272?source=related_link\">",
"      Pathogenesis and etiology of syncope",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/62/40938?source=related_link\">",
"      Radiofrequency catheter ablation to prevent recurrent atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27097?source=related_link\">",
"      Tachycardia-mediated cardiomyopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_22_21865="Acquired hypothyroidism in childhood and adolescence";
var content_f21_22_21865=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Acquired hypothyroidism in childhood and adolescence",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/22/21865/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/22/21865/contributors\">",
"     Stephen LaFranchi, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/22/21865/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/22/21865/contributors\">",
"     Douglas S Ross, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/22/21865/contributors\">",
"     Mitchell Geffner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/22/21865/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/22/21865/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/22/21865/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 4, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypothyroidism is the most common disturbance of thyroid function in children, and is most often caused by chronic autoimmune thyroiditis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21865/abstract/1\">",
"     1",
"    </a>",
"    ]. As in adults, acquired hypothyroidism can be caused by both thyroid disease (primary hypothyroidism) and hypothalamic-pituitary disease (central hypothyroidism); furthermore, primary hypothyroidism may be either subclinical (high serum thyrotropin [TSH] and normal serum free thyroxine [T4] concentrations) or overt (high serum TSH and low serum free T4 concentrations). Whatever its cause, hypothyroidism in children can have deleterious effects on growth, pubertal development and school performance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common physical finding at presentation is a goiter. In one series from Israel, a noticeable goiter was present in 39.5 percent of children with autoimmune thyroiditis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21865/abstract/2\">",
"     2",
"    </a>",
"    ]. The most common manifestation of hypothyroidism in children is declining growth velocity, often resulting in short stature. The growth delay tends to be insidious in onset, and may be present for several years before other symptoms occur, if they occur at all [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21865/abstract/3\">",
"     3",
"    </a>",
"    ]. Thus, any child with declining growth velocity should be evaluated for hypothyroidism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/60/18376?source=see_link\">",
"     \"Diagnostic approach to short stature\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another common problem is altered school performance. Performance often declines, but it improves in some children, perhaps because they are less active and, therefore, less easily distracted and better able to concentrate. One reason for delay in diagnosis is that parents see the latter changes as positive.",
"   </p>",
"   <p>",
"    Other common symptoms are sluggishness, lethargy, cold intolerance, constipation, dry skin, brittle hair, facial puffiness, and muscle aches and pains. If the cause is hypothalamic or pituitary disease, the child may have headaches, visual symptoms, or manifestations of other pituitary hormone deficiencies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/10/14503?source=see_link\">",
"     \"Clinical manifestations of hypothyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Abnormalities on physical examination include short stature, apparent overweight (more fluid retention than obesity), puffy facies with a dull, placid expression, bradycardia, pseudohypertrophy of the muscles, and delayed deep tendon reflexes. The thyroid gland may be normal in size, not palpable, or diffusely enlarged.",
"   </p>",
"   <p>",
"    Pubertal development is delayed in most adolescent hypothyroid children. However, some children have sexual precocity, characterized by breast development in girls and macro-orchidism (enlarged testes) in boys, and slightly increased (for age) serum gonadotropin concentrations. A few patients have hyperprolactinemia and rarely galactorrhea. Growth hormone secretion may be normal or decreased, and serum insulin-like growth factor I (IGF-I) levels are usually decreased [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21865/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Primary hypothyroidism may be associated with enlargement of the sella turcica, resulting from secondary hyperplasia of thyrotroph cells [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21865/abstract/5\">",
"     5",
"    </a>",
"    ]. The enlargement may be discovered when cranial imaging is performed for evaluation of short stature. Although pituitary enlargement may be rather pronounced, with the upper convexity of the gland even abutting inferiorly on the optic chiasm, it rarely causes symptoms or signs, unlike a pituitary tumor or craniopharyngioma, and is reversible with T4 therapy. Thus, primary hypothyroidism must be excluded in any child with an enlarged sella turcica.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The causes of hypothyroidism in children are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef55456 \" href=\"UTD.htm?38/42/39595\">",
"     table 1",
"    </a>",
"    ). They are similar to those in adults, but iatrogenic hypothyroidism is relatively less common. Most can be identified from the history and physical examination. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/47/42744?source=see_link\">",
"     \"Disorders that cause hypothyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Chronic autoimmune thyroiditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common cause of hypothyroidism in children is chronic autoimmune (Hashimoto's) thyroiditis, resulting in either thyroid atrophy or goiter. It is more common in girls than boys and in whites than blacks. Among all children with this disorder, euthyroid goiter is more common than hypothyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21865/abstract/2,6,7\">",
"     2,6,7",
"    </a>",
"    ]. The changes in the thyroid gland may not be detectable on physical examination. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/45/24280?source=see_link&amp;anchor=H12#H12\">",
"     \"Congenital and acquired goiter in children\", section on 'Chronic autoimmune (Hashimoto's) thyroiditis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the National Health and Nutrition Examination Survey (NHANES III) from 1988 to 1994, 6.3 percent of adolescents (12 to 19 years of age) had positive anti-thyroglobulin antibodies (Tg Ab) and 4.8 percent had positive anti-thyroid peroxidase antibodies (TPO Ab) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21865/abstract/8\">",
"     8",
"    </a>",
"    ]. The likelihood of detecting Tg Ab and TPO Ab was two times greater in female versus male adolescents. The incidence of antithyroid antibodies was highest in Hispanic-American adolescents and lowest in black non-Hispanic adolescents; non-Hispanic whites had an incidence between these two groups. Approximately 2 percent of surveyed adolescents had a serum TSH &gt;4.5",
"    <span class=\"nowrap\">",
"     mU/L,",
"    </span>",
"    a value indicating hypothyroidism.",
"   </p>",
"   <p>",
"    The natural history of euthyroid autoimmune thyroiditis was illustrated in a report of 160 children (mean age 9.1 years) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21865/abstract/9\">",
"     9",
"    </a>",
"    ]. Among 105 children with elevated thyroid antibodies and normal TSH followed for five years, 65 percent remained euthyroid, 10 percent developed minor elevation in serum TSH concentrations, and 26 percent developed serum TSH levels twofold above the upper limit of normal. Of 55 children with elevated thyroid antibodies and minor elevation in serum TSH concentrations, 29 percent developed a normal serum TSH, 29 percent were unchanged, and 42 percent developed serum TSH levels two-fold above the upper limit of normal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Different mechanisms can be responsible for thyroid atrophy or goiter formation in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21865/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/11/27833?source=see_link\">",
"     \"Pathogenesis of Hashimoto's thyroiditis (chronic autoimmune thyroiditis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Atrophic thyroiditis is primarily the result of cell-mediated cytotoxicity leading to follicular cell apoptosis; complement-dependent antibody-mediated cytotoxicity may contribute to thyroid damage. TSH receptor blocking antibodies result in loss of thyroid morphological integrity, which may be reversible.",
"     </li>",
"     <li>",
"      Goitrous thyroiditis may be induced by one of three mechanisms: lymphocytic and plasma cell infiltration (and lymphoid germinal centers), the production of antibodies that stimulate thyroid growth, or excess TSH secretion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Associations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with some chromosomal disorders or other autoimmune disorders are at increased risk for chronic autoimmune thyroiditis and, to a lesser extent, hypothyroidism. These include Down syndrome (trisomy 21), Turner syndrome, type 1 (autoimmune) diabetes mellitus, celiac disease, and possibly Klinefelter syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21865/abstract/11-16\">",
"     11-16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Down syndrome &mdash; In one report of children with Down syndrome, 28 percent had positive serum thyroid antibody concentrations (mostly TPO Ab), 14 percent had subclinical hypothyroidism, 7 percent overt hypothyroidism, and 5 percent hyperthyroidism [",
"      <a class=\"abstract\" href=\"UTD.htm?21/22/21865/abstract/11\">",
"       11",
"      </a>",
"      ]. In another cross-sectional study of 70 children, 24 percent were hypothyroid; the percentage increased with age in those with positive serum antithyroid antibody concentrations [",
"      <a class=\"abstract\" href=\"UTD.htm?21/22/21865/abstract/17\">",
"       17",
"      </a>",
"      ]. In a longitudinal series, the cumulative incidence of hypothyroidism up to age 25 years was 35 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?21/22/21865/abstract/18\">",
"       18",
"      </a>",
"      ]. Because of the high rate of congenital hypothyroidism, a randomized trial was performed to determine the effects of universal treatment of all Down syndrome neonates with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/43/41656?source=see_link\">",
"       levothyroxine",
"      </a>",
"      . Treatment reduced delays in motor development and possibly mental development and was associated with greater gains in length and weight [",
"      <a class=\"abstract\" href=\"UTD.htm?21/22/21865/abstract/19\">",
"       19",
"      </a>",
"      ]. Until these results are confirmed in other randomized clinical trials, however, routine treatment of all Down syndrome neonates should NOT be considered standard of care.",
"     </li>",
"     <li>",
"      Turner syndrome &mdash; In a study of girls with Turner syndrome, 41 percent had high serum antithyroid antibody concentrations (again predominantly TPO Ab), 18 percent had a goiter, and 8 percent had subclinical or overt hypothyroidism [",
"      <a class=\"abstract\" href=\"UTD.htm?21/22/21865/abstract/12\">",
"       12",
"      </a>",
"      ]. In another series of 75 girls and women with Turner syndrome, the frequency of chronic autoimmune thyroiditis increased from 15 percent in the first decade of life to 30 percent in the third decade [",
"      <a class=\"abstract\" href=\"UTD.htm?21/22/21865/abstract/13\">",
"       13",
"      </a>",
"      ]. A study from Sweden confirmed that hypothyroidism becomes more common over time [",
"      <a class=\"abstract\" href=\"UTD.htm?21/22/21865/abstract/20\">",
"       20",
"      </a>",
"      ]. At the beginning of the study, 23 of 91 adult women (mean age 37.7 &plusmn;11 years) with Turner syndrome had hypothyroidism [",
"      <a class=\"abstract\" href=\"UTD.htm?21/22/21865/abstract/20\">",
"       20",
"      </a>",
"      ]. At the end of a five-year follow-up, an additional 11 had developed hypothyroidism, resulting in an annual incidence of 3.2 percent. In one study, there was a higher prevalence of autoimmune hypothyroidism in those with an isochromosome X karyotype as compared with those with a 45 XO karyotype [",
"      <a class=\"abstract\" href=\"UTD.htm?21/22/21865/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Klinefelter syndrome &ndash; There is limited information on the risk of thyroid disease; one study reported hypothyroidism in one of eight boys with Klinefelter syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?21/22/21865/abstract/15\">",
"       15",
"      </a>",
"      ]. However, another study found a general shift toward lower values in serum free T4 concentrations but no compensatory increase in serum TSH, changes more consistent with central hypothyroidism [",
"      <a class=\"abstract\" href=\"UTD.htm?21/22/21865/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Type 1 diabetes mellitus &mdash; Similar findings have been noted among children with type 1 diabetes mellitus. Approximately 20 percent have high serum antithyroid antibody concentrations, and 5 percent have abnormalities in thyroid function, usually subclinical hypothyroidism [",
"      <a class=\"abstract\" href=\"UTD.htm?21/22/21865/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Celiac disease &ndash; In a study of 135 children with celiac disease, 31 (23 percent) had positive antithyroid antibodies [",
"      <a class=\"abstract\" href=\"UTD.htm?21/22/21865/abstract/23\">",
"       23",
"      </a>",
"      ]. During long-term follow up, 26 percent of the patients with positive antibodies developed subclinical hypothyroidism, while 76 percent remained euthyroid. Another study examined the development of celiac disease in 302 children with autoimmune thyroid disease, in whom 4.6 percent had positive tissue transglutaminase antibodies, and half of whom had confirmed celiac disease on biopsy [",
"      <a class=\"abstract\" href=\"UTD.htm?21/22/21865/abstract/24\">",
"       24",
"      </a>",
"      ]. Excluding children with Down syndrome and type 1 diabetes mellitus, the incidence of celiac disease fell to 1.3 percent, similar to the general population. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/3/37946?source=see_link&amp;anchor=H29#H29\">",
"       \"Clinical manifestations and diagnosis of celiac disease in children\", section on 'Autoimmune thyroiditis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Thus, children with Down, Turner, or Klinefelter syndrome, type 1 diabetes, or celiac disease should be screened annually for hypothyroidism by measuring serum TSH. Thyroid screening starts when the syndrome or disease is diagnosed. In the case of Down syndrome this is typically in infancy. Children discovered to have autoimmune thyroiditis by screening present at an earlier stage of the disease, and so have fewer clinical symptoms and signs of hypothyroidism [",
"      <a class=\"abstract\" href=\"UTD.htm?21/22/21865/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Autoimmune polyglandular syndrome &mdash; A few children with chronic autoimmune thyroiditis have or later develop other autoimmune endocrinopathies, and, therefore, have an autoimmune polyglandular syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?21/22/21865/abstract/26\">",
"       26",
"      </a>",
"      ]. Chronic autoimmune thyroiditis occurs in about 10 percent of children with type I autoimmune polyglandular syndrome (APECED or Whitaker syndrome); the more common manifestations of this syndrome are hypoparathyroidism, adrenal insufficiency, and mucocutaneous candidiasis. Chronic autoimmune thyroiditis also occurs in about 70 percent of children with type II autoimmune polyglandular syndrome (Schmidt syndrome), which has as its other major manifestations adrenal insufficiency and autoimmune diabetes. In one study, autoimmune gastritis with antibodies to gastric parietal cells was found in 30 percent of children with autoimmune thyroiditis [",
"      <a class=\"abstract\" href=\"UTD.htm?21/22/21865/abstract/27\">",
"       27",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/0/40969?source=see_link&amp;anchor=H2#H2\">",
"       \"Causes of primary adrenal insufficiency (Addison's disease)\", section on 'Autoimmune adrenalitis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      IPEX syndrome &mdash; Autoimmune thyroiditis may present in infancy as part of the rare x-linked disorder characterized by autoimmune endocrinopathy, enteropathy, and eczema. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/15/25850?source=see_link\">",
"       \"IPEX: Immune dysregulation, polyendocrinopathy, enteropathy, X-linked\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Obesity &mdash; Moderate elevation of TSH concentration occurs in 10 to 23 percent of obese children, associated with normal or slightly elevated T4 and T3 values [",
"      <a class=\"abstract\" href=\"UTD.htm?21/22/21865/abstract/28\">",
"       28",
"      </a>",
"      ]. The elevated TSH levels in obesity seem a consequence rather than a cause of obesity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pericardial and pleural effusions may occur in children with severe hypothyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21865/abstract/29\">",
"     29",
"    </a>",
"    ]. These effusions resolve with thyroid hormone treatment. Hypothyroidism should be considered in any child with unexplained pericardial or pleural effusions.",
"   </p>",
"   <p>",
"    Rarely, an encephalopathy may occur in children or adults with autoimmune thyroiditis. This disorder has been termed Hashimoto's encephalopathy, and is thought to be immune-mediated but unrelated to thyroid dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21865/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/47/33527?source=see_link\">",
"     \"Hashimoto's encephalopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Painless thyroiditis or subacute granulomatous thyroiditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypothyroidism also occurs transiently during recovery from painless thyroiditis or subacute granulomatous thyroiditis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/51/43830?source=see_link\">",
"     \"Overview of thyroiditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Iodine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common cause of hypothyroidism worldwide is iodine deficiency (endemic goiter). Although it is rare in North America because of fortification of salt, it has been reported in immigrants [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21865/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hypothyroidism that is reversible can occur as a result of iodine excess (eg, after ingestion of health foods or iodine-rich drugs). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/47/42744?source=see_link&amp;anchor=H12#H12\">",
"     \"Disorders that cause hypothyroidism\", section on 'Iodine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Antithyroid drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypothyroidism also can occur in patients with hyperthyroidism treated with antithyroid drugs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/51/25400?source=see_link\">",
"     \"Treatment and prognosis of Graves' disease in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Thyroid injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thyroid injury and, therefore, hypothyroidism may be caused by external radiation therapy or infiltrative diseases of the thyroid (eg, histiocytosis X and cystinosis).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Craniospinal irradiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 40 percent of children with tumors of the head and neck region (eg, Hodgkin lymphoma) who are treated with radiation (5000 rads [50 Gy]) develop hypothyroidism during prolonged follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21865/abstract/32\">",
"     32",
"    </a>",
"    ]; the risk is probably life-long. Among children with brain tumors or leukemia who receive craniospinal radiation, a substantial proportion develops primary hypothyroidism or overt central hypothyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21865/abstract/33\">",
"     33",
"    </a>",
"    ]. In a study of 208 children treated successfully for cancer, 114 (55 percent) of whom had brain or head and neck tumors, 33 had primary hypothyroidism, and 62 had central hypothyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21865/abstract/34\">",
"     34",
"    </a>",
"    ]. Many of the latter were identified on the basis of a subnormal serum TSH response to thyrotropin-releasing hormone or absence of the nocturnal surge in TSH secretion. Thyroid ultrasonography will show reduced thyroid volume in irradiated patients who develop hypothyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21865/abstract/35\">",
"     35",
"    </a>",
"    ]. Chemotherapy may increase the risk of hypothyroidism.",
"   </p>",
"   <p>",
"    Follow-up of 13 to 17 year old adolescents exposed to nuclear fallout from the Chernobyl accident showed a higher prevalence of TPO Abs (6.4 versus 2.4 percent in controls), but thyroid function remained normal [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21865/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Transient suppression of the metabolic activity of the thyroid tissue may protect it from injury induced by external radiation. In a small uncontrolled study, children undergoing craniospinal irradiation for medulloblastoma or primitive neuroectodermal tumor were treated with L-thyroxine throughout the radiation treatment at doses designed to suppress thyroid activity [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21865/abstract/37\">",
"     37",
"    </a>",
"    ]. Children in whom the metabolic activity of the thyroid was suppressed during the period of external radiation (as measured by TSH levels of &lt;0.3",
"    <span class=\"nowrap\">",
"     mU/L)",
"    </span>",
"    were less likely to develop long-term hypothyroidism as compared to those in whom thyroid suppression was not achieved. Randomized trials of this approach will be required to fully examine whether concurrent administration of L-thyroxine reduces the risk for radiation-induced hypothyroidism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Hypothyroidism after treatment for Graves' disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypothyroidism also occurs after radioiodine treatment for Graves' hyperthyroidism in children as it does in adults. It develops in approximately 10 to 20 percent in the first year after therapy and in about 3 percent per year thereafter [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21865/abstract/38\">",
"     38",
"    </a>",
"    ]. With newer recommendations to treat children with higher doses of radioiodine, hypothyroidism develops by six months after therapy in essentially all treated patients [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21865/abstract/39\">",
"     39",
"    </a>",
"    ]. Similarly, hypothyroidism often occurs after subtotal thyroidectomy in children with Graves' hyperthyroidism and invariably after thyroidectomy for thyroid cancer.",
"   </p>",
"   <p>",
"    Some children diagnosed with Graves&rsquo; disease who are treated with antithyroid drugs have relatively rapid resolution of their hyperthyroidism, typically within six months of diagnosis. After discontinuation of antithyroid drug treatment, they remain hypothyroid. In hindsight, such children are recognized to have Hashitoxicosis rather than Graves&rsquo; disease [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21865/abstract/40\">",
"     40",
"    </a>",
"    ]. Other children with Graves&rsquo; disease who are treated with antithyroid drugs may achieve a true remission, remaining euthyroid after discontinuation of antithyroid drugs. About 10 percent of such children later become hypothyroid, caused by chronic autoimmune thyroiditis, either with destruction of the thyroid or due to production of a TSH receptor blocking antibody [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21865/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Late-onset congenital hypothyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Late-onset congenital hypothyroidism that develops during childhood may appear to be acquired hypothyroidism. This may occur with some forms of thyroid dysgenesis, such as an ectopic gland, or with inborn errors of thyroid hormone synthesis (dyshormonogenesis). Children with high TSH and normal free T4 during neonatal screening are more likely to have subclinical hypothyroidism during early childhood [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21865/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/39/2682?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical features and detection of congenital hypothyroidism\", section on 'Etiology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/37/1626?source=see_link\">",
"     \"Reduced sensitivity to thyroid hormone\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Williams syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subclinical hypothyroidism is common among young patients with Williams syndrome (caused by a deletion of genes in the 7q11.23 region, including elastin). In a report of 92 patients with Williams syndrome, 32 percent had subclinical hypothyroidism; none had thyroid autoantibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21865/abstract/43\">",
"     43",
"    </a>",
"    ]. In most cases, thyroid function improves with age. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/10/5287?source=see_link\">",
"     \"Williams-Beuren syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/14/34025?source=see_link&amp;anchor=H12329278#H12329278\">",
"     \"Microdeletion syndromes (chromosomes 1 to 11)\", section on '7q11.23 deletion syndrome (Williams syndrome)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Hepatitis C infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a report of 36 children with chronic hepatitis C infection acquired from their mother, 11.1 percent had subclinical hypothyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21865/abstract/44\">",
"     44",
"    </a>",
"    ]. This did not appear to be autoimmune thyroiditis because antithyroid antibodies were negative.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Hemangiomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypothyroidism can occur in young children with large hemangiomas of the liver [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21865/abstract/45\">",
"     45",
"    </a>",
"    ]. The tumors contain very high levels of type 3 deiodinase activity, which catalyzes deiodination of T4 to reverse triiodothyronine (rT3) and triiodothyronine (T3) to diiodothyronine (T2), resulting in low serum T4 and T3 concentrations. Thyroid secretion is increased, but not sufficiently to compensate for the large increase in T4 and T3 degradation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Thyroid hormone resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with generalized thyroid hormone resistance may have some clinical manifestations of hypothyroidism if they cannot sufficiently increase their serum thyroid hormone concentrations to overcome the nuclear receptor defect. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/8/16518?source=see_link\">",
"     \"Resistance to thyrotropin and thyrotropin-releasing hormone\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Central hypothyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any hypothalamic or pituitary disease can cause central hypothyroidism. In children, it is most likely to be late-onset of a congenital defect, such as septo-optic dysplasia, or to be caused by pituitary tumors, the most common of which is craniopharyngioma. The effect of pituitary tumors may either be direct or as a result of therapy. Other causes include histiocytosis X and other infiltrative disorders, other brain tumors, trauma, and radiotherapy. Isolated TSH deficiency is less common and likely the result of a TSH &szlig; subunit gene mutation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/6/18536?source=see_link\">",
"     \"Central hypothyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children suspected to have hypothyroidism should have measurements of serum TSH and free T4 (or serum total T4 with some assessment of serum binding proteins). The normal range for serum total T4 concentrations (and serum free T4 values) is slightly higher in children than in adults (",
"    <a class=\"graphic graphic_table graphicRef60095 \" href=\"UTD.htm?27/22/28012\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21865/abstract/46,47\">",
"     46,47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children with primary hypothyroidism have high serum TSH concentrations and low serum free T4 values. Questions exist regarding the upper limit of normal for serum TSH concentration. TSH levels have diurnal variation, and one series suggests that TSH values measured at 8 AM are more sensitive for the diagnosis of mild primary hypothyroidism as compared with measurements at 4 PM [",
"      <a class=\"abstract\" href=\"UTD.htm?21/22/21865/abstract/48\">",
"       48",
"      </a>",
"      ]. However, normal ranges that are specific for time of day have not been established. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3608?source=see_link\">",
"       \"Laboratory assessment of thyroid function\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In both children and adults with mild elevations of serum TSH (up to 7.5",
"      <span class=\"nowrap\">",
"       mU/L),",
"      </span>",
"      TSH levels are normal in up to 70 percent of patients when the test is repeated [",
"      <a class=\"abstract\" href=\"UTD.htm?21/22/21865/abstract/49\">",
"       49",
"      </a>",
"      ]. Thus, treatment decisions in such patients should be made only after repeat testing.",
"     </li>",
"     <li>",
"      Children with \"subclinical hypothyroidism\" have an elevated TSH and a normal free T4 level. There is some controversy about whether or not to treat children with subclinical hypothyroidism. In one study non-autoimmune subclinical hypothyroidism was due to mutations in the TSH receptor gene in 29 percent of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?21/22/21865/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Most children with central hypothyroidism have normal or low serum TSH concentrations and low serum free T4 values. However, a few have slightly high serum TSH concentrations because they secrete immunoreactive but biologically inactive TSH [",
"      <a class=\"abstract\" href=\"UTD.htm?21/22/21865/abstract/51\">",
"       51",
"      </a>",
"      ]. The study noted above [",
"      <a class=\"abstract\" href=\"UTD.htm?21/22/21865/abstract/48\">",
"       48",
"      </a>",
"      ] suggests that central hypothyroidism in children is characterized by a low ratio of the TSH values taken at 8 AM and 4 PM (8AM:4PM ratio &lt;1.3 in central hypothyroidism; normal 8AM:4PM ratio &gt;1.5), when serum free T4 is in the lower third of the normal range. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3608?source=see_link\">",
"       \"Laboratory assessment of thyroid function\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/6/18536?source=see_link\">",
"       \"Central hypothyroidism\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Chronic autoimmune thyroiditis can be confirmed as the cause of hypothyroidism by measuring antithyroid antibodies, best done by measuring TPO Ab. Approximately 85 to 90 percent of children with chronic autoimmune thyroiditis have high serum TPO Ab concentrations, while 30 to 50 percent have positive Tg Ab levels [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21865/abstract/52\">",
"     52",
"    </a>",
"    ]. In one study, 8 (9.2 percent) of 83 children with autoimmune thyroiditis had positive TSH receptor blocking antibodies; all had associated overt hypothyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21865/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pendrin, an apical protein on thyroid follicular cells, is another antigen in autoimmune thyroid disease. Pendrin antibodies were found in 81 percent of patients with autoimmune thyroid disease compared with 9 percent of controls [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21865/abstract/54\">",
"     54",
"    </a>",
"    ]. Measurement of pendrin antibodies is not yet commercially available.",
"   </p>",
"   <p>",
"    Other studies, such as thyroid ultrasonography or radionuclide scanning, are rarely indicated in children with primary hypothyroidism. In a study of 105 children with antibody positive Hashimoto's thyroiditis, only one-third showed typical ultrasound changes (scattered hypo- and hyperechogenicity) at diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21865/abstract/55\">",
"     55",
"    </a>",
"    ]. During 7 to 14 month follow-ups, more than half of the remaining children developed typical ultrasound changes. Children with central hypothyroidism should undergo cranial imaging with contrast, preferably magnetic resonance imaging, and tests for other pituitary hormone deficiencies. If the patient has a markedly asymmetric goiter or a prominent nodule, or a smaller nodule that enlarges during follow-up, fine-needle aspiration biopsy is indicated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/28/41413?source=see_link\">",
"     \"Diagnosis of hypopituitarism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/41/23191?source=see_link\">",
"     \"Thyroid nodules and cancer in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnostic studies that should be performed in children suspected of having a late-onset form of congenital hypothyroidism are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/39/2682?source=see_link\">",
"     \"Clinical features and detection of congenital hypothyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Skeletal maturation is delayed, and therefore bone age, like height age, is less than chronologic age [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21865/abstract/56\">",
"     56",
"    </a>",
"    ]. Indeed, because bone age increases so little after the onset of hypothyroidism, it may indicate the age of onset.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     TREATMENT AND PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/43/41656?source=see_link\">",
"     Levothyroxine",
"    </a>",
"    (T4) is the treatment of choice in children with hypothyroidism. The goals of treatment are to restore normal growth and development, including pubertal development. There is some controversy about the need to treat children with mild subclinical hypothyroidism, characterized by TSH elevations between 6 and 10",
"    <span class=\"nowrap\">",
"     mU/L.",
"    </span>",
"    There is general agreement to treat children with subclinical hypothyroidism and TSH levels &gt;10",
"    <span class=\"nowrap\">",
"     mU/L,",
"    </span>",
"    to prevent any subtle effects on growth and development. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     T4 dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children clear T4 more rapidly than adults; as a result, the daily replacement dose on a weight basis is higher:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age 1 to 3 years &mdash; 4 to 6",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      body weight",
"     </li>",
"     <li>",
"      Age 3 to 10 years &mdash; 3 to 5",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"     </li>",
"     <li>",
"      Age 10 to 16 years &mdash; 2 to 4",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Alternatively, the replacement dose can be calculated as a function of body surface area, in which case the dose at any age is approximately 100",
"    <span class=\"nowrap\">",
"     mcg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day.",
"    </span>",
"    Body surface area can be determined from height and weight using a calculator (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?4/27/4529?source=see_link\">",
"     calculator 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In children with primary hypothyroidism, the recommended target range for TSH is in the lower half of the reference range (optimally 0.5 to 2.0",
"    <span class=\"nowrap\">",
"     mU/L)",
"    </span>",
"    and for T4 or free T4 is in the upper half of the reference range [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21865/abstract/57\">",
"     57",
"    </a>",
"    ]. The optimal T4 range is between 9 and 13",
"    <span class=\"nowrap\">",
"     ug/dL",
"    </span>",
"    (116 to 167",
"    <span class=\"nowrap\">",
"     nmol/L).",
"    </span>",
"    Because the normal free T4 reference range varies according to the assay method, clinicians need to determine the range for their specific laboratory. As an example, if the normal free T4 reference range is 0.6 to 1.8",
"    <span class=\"nowrap\">",
"     ng/dL",
"    </span>",
"    (8 to 23",
"    <span class=\"nowrap\">",
"     pmol/L),",
"    </span>",
"    the corresponding optimal free T4 range would be between 1.2 and 1.8",
"    <span class=\"nowrap\">",
"     ng/dL",
"    </span>",
"    (15 to 23",
"    <span class=\"nowrap\">",
"     pmol/L).",
"    </span>",
"   </p>",
"   <p>",
"    In children with central hypothyroidism, only measurement of serum free T4 or T4 is useful for dosage monitoring. The target serum free T4 or T4 in these children should be the same as in children with primary hypothyroidism.",
"   </p>",
"   <p>",
"    Adult height may be diminished among children treated just before or during puberty as compared with children treated earlier [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21865/abstract/58\">",
"     58",
"    </a>",
"    ]. Although hypothyroidism may cause weight gain, this is typically attributable to fluid retention rather than adiposity. Treatment does not lead to substantial changes in weight or body mass index for most children [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21865/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For most children, therapy should be initiated with a dose in the middle of the appropriate range for age. However, in those with long-standing hypothyroidism, a somewhat lower dose should be given to avoid overly rapid acceleration of skeletal maturation and loss of adult height. In one study of children presenting prior to puberty with severe hypothyroidism, the height deficit after treatment ranged from 8 to 14 cm at the end of puberty [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21865/abstract/56\">",
"     56",
"    </a>",
"    ]. Children with more chronic (or severe) hypothyroidism also are at higher risk of poorer school achievement and hyperactivity during treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21865/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with longstanding hypothyroidism are at risk for developing pseudotumor cerebri shortly after initiation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/43/41656?source=see_link\">",
"     levothyroxine",
"    </a>",
"    treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21865/abstract/61\">",
"     61",
"    </a>",
"    ]. Children with persistent headaches or vision changes should contact their physician.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Consequences of overtreatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prolonged overtreatment with T4 should be avoided. The potential consequences of overtreatment vary with age: infants with open cranial sutures may develop craniosynostosis, and older children may develop adverse behavior changes and lower school performance [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21865/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both hypothyroidism and overtreatment can affect bone mineral density [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21865/abstract/62\">",
"     62",
"    </a>",
"    ]. On the other hand, at least one study found no difference in bone density at diagnosis or after long-term T4 therapy in adolescent girls with subclinical hypothyroidism compared with normal girls [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21865/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Course",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypothyroidism caused by chronic autoimmune thyroiditis is not invariably permanent; some children treated for several years have persistently normal thyroid function after T4 treatment is discontinued [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21865/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. One study, for example, evaluated 18 children with subclinical hypothyroidism; after approximately four years, 10 still had subclinical hypothyroidism, seven were euthyroid, and one had overt hypothyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21865/abstract/65\">",
"     65",
"    </a>",
"    ]. In another study from Taiwan, 11 of 22 patients with Hashimoto's thyroiditis (goiter and positive thyroid auto-antibodies) and who had signs of hypothyroidism and thyroid dysfunction (subclinical or overt) became euthyroid after a mean follow-up period of 6.4 &plusmn; 3.9 years [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21865/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Once T4 therapy is started, it probably is best to continue treatment until growth and pubertal development are complete. At that time, the question of permanency of hypothyroidism can be addressed by discontinuing T4 and measuring serum TSH one month later.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acquired hypothyroidism is the most common abnormality of thyroid function in children and is most often caused by chronic autoimmune thyroiditis. In the United States, 6 percent of adolescents have positive antithyroid antibodies and 2 percent have an elevated serum TSH. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Chronic autoimmune thyroiditis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Many children with acquired hypothyroidism, particularly those with subclinical hypothyroidism, will be asymptomatic. In those with overt disease, clinical features include declining growth velocity, short stature,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      the presence of a goiter. Adolescents may also have signs of pubertal delay. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with symptoms or findings on physical examination compatible with hypothyroidism should be evaluated with measurements of serum free T4 and TSH concentrations, and the results should be compared to age-specific normal values (",
"      <a class=\"graphic graphic_table graphicRef60095 \" href=\"UTD.htm?27/22/28012\">",
"       table 2",
"      </a>",
"      ). If another etiology is not obvious, testing for anti-thyroglobulin antibodies (Tg Ab) and anti-thyroid peroxidase antibodies (TPO Ab) should be performed. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      T4 is the treatment of choice in children with hypothyroidism. The goals of treatment are to restore normal growth and development. If subclinical hypothyroidism is detected and confirmed by repeat testing, we suggest T4 treatment (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ) to prevent any untoward effects on growth and development. Once growth and pubertal development are complete, thyroid hormone treatment can be discontinued and thyroid function re-evaluated. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Treatment and prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients and families should be aware that treatment may sometimes cause temporary behavior symptoms, poorer school achievement, and may not restore full growth potential in children with long-standing hypothyroidism and marked delay in skeletal maturation. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Treatment and prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21865/abstract/1\">",
"      Rallison ML, Dobyns BM, Keating FR, et al. Occurrence and natural history of chronic lymphocytic thyroiditis in childhood. J Pediatr 1975; 86:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21865/abstract/2\">",
"      de Vries L, Bulvik S, Phillip M. Chronic autoimmune thyroiditis in children and adolescents: at presentation and during long-term follow-up. Arch Dis Child 2009; 94:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21865/abstract/3\">",
"      Ozer G, Y&uuml;ksel B, Kozano��lu M, et al. Growth and development of 280 hypothyroidic patients at diagnosis. Acta Paediatr Jpn 1995; 37:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21865/abstract/4\">",
"      Purandare A, Co Ng L, Godil M, et al. Effect of hypothyroidism and its treatment on the IGF system in infants and children. J Pediatr Endocrinol Metab 2003; 16:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21865/abstract/5\">",
"      Atchison JA, Lee PA, Albright AL. Reversible suprasellar pituitary mass secondary to hypothyroidism. JAMA 1989; 262:3175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21865/abstract/6\">",
"      Rallison ML, Dobyns BM, Meikle AW, et al. Natural history of thyroid abnormalities: prevalence, incidence, and regression of thyroid diseases in adolescents and young adults. Am J Med 1991; 91:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21865/abstract/7\">",
"      Demirbilek H, Kandemir N, Gonc EN, et al. Hashimoto's thyroiditis in children and adolescents: a retrospective study on clinical, epidemiological and laboratory properties of the disease. J Pediatr Endocrinol Metab 2007; 20:1199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21865/abstract/8\">",
"      Hollowell JG, Staehling NW, Flanders WD, et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 2002; 87:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21865/abstract/9\">",
"      Radetti G, Gottardi E, Bona G, et al. The natural history of euthyroid Hashimoto's thyroiditis in children. J Pediatr 2006; 149:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21865/abstract/10\">",
"      Matsuura N, Konishi J, Yuri K, et al. Comparison of atrophic and goitrous auto-immune thyroiditis in children: clinical, laboratory and TSH-receptor antibody studies. Eur J Pediatr 1990; 149:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21865/abstract/11\">",
"      Pueschel SM, Pezzullo JC. Thyroid dysfunction in Down syndrome. Am J Dis Child 1985; 139:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21865/abstract/12\">",
"      Gru&ntilde;eiro de Papendieck L, Iorcansky S, Coco R, et al. High incidence of thyroid disturbances in 49 children with Turner syndrome. J Pediatr 1987; 111:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21865/abstract/13\">",
"      Chiovato L, Larizza D, Bendinelli G, et al. Autoimmune hypothyroidism and hyperthyroidism in patients with Turner's syndrome. Eur J Endocrinol 1996; 134:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21865/abstract/14\">",
"      Kondo T. Klinefelter syndrome associated with juvenile hypothyroidism due to chronic thyroiditis. Eur J Pediatr 1993; 152:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21865/abstract/15\">",
"      Mazen I, El-Ruby M, El-Bassyouni HT. Variable associations of Klinefelter syndrome in children. J Pediatr Endocrinol Metab 2010; 23:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21865/abstract/16\">",
"      Bj&oslash;rn AM, Bojesen A, Gravholt CH, Laurberg P. Hypothyroidism secondary to hypothalamic-pituitary dysfunction may be part of the phenotype in klinefelter syndrome: a case-control study. J Clin Endocrinol Metab 2009; 94:2478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21865/abstract/17\">",
"      Ivarsson SA, Ericsson UB, Gustafsson J, et al. The impact of thyroid autoimmunity in children and adolescents with Down syndrome. Acta Paediatr 1997; 86:1065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21865/abstract/18\">",
"      Karlsson B, Gustafsson J, Hedov G, et al. Thyroid dysfunction in Down's syndrome: relation to age and thyroid autoimmunity. Arch Dis Child 1998; 79:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21865/abstract/19\">",
"      van Trotsenburg AS, Vulsma T, van Rozenburg-Marres SL, et al. The effect of thyroxine treatment started in the neonatal period on development and growth of two-year-old Down syndrome children: a randomized clinical trial. J Clin Endocrinol Metab 2005; 90:3304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21865/abstract/20\">",
"      El-Mansoury M, Bryman I, Berntorp K, et al. Hypothyroidism is common in turner syndrome: results of a five-year follow-up. J Clin Endocrinol Metab 2005; 90:2131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21865/abstract/21\">",
"      Elsheikh M, Wass JA, Conway GS. Autoimmune thyroid syndrome in women with Turner's syndrome--the association with karyotype. Clin Endocrinol (Oxf) 2001; 55:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21865/abstract/22\">",
"      Riley WJ, Maclaren NK, Lezotte DC, et al. Thyroid autoimmunity in insulin-dependent diabetes mellitus: the case for routine screening. J Pediatr 1981; 99:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21865/abstract/23\">",
"      Cassio A, Ricci G, Baronio F, et al. Long-term clinical significance of thyroid autoimmunity in children with celiac disease. J Pediatr 2010; 156:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21865/abstract/24\">",
"      Sattar N, Lazare F, Kacer M, et al. Celiac disease in children, adolescents, and young adults with autoimmune thyroid disease. J Pediatr 2011; 158:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21865/abstract/25\">",
"      DeBoer MD, LaFranchi S. Differential presentation for children with autoimmune thyroiditis discovered because of symptom development or screening. J Pediatr Endocrinol Metab 2008; 21:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21865/abstract/26\">",
"      Neufeld M, Maclaren N, Blizzard R. Autoimmune polyglandular syndromes. Pediatr Ann 1980; 9:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21865/abstract/27\">",
"      Segni M, Borrelli O, Pucarelli I, et al. Early manifestations of gastric autoimmunity in patients with juvenile autoimmune thyroid diseases. J Clin Endocrinol Metab 2004; 89:4944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21865/abstract/28\">",
"      Reinehr T. Thyroid function in the nutritionally obese child and adolescent. Curr Opin Pediatr 2011; 23:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21865/abstract/29\">",
"      Martinez-Soto T, Deal C, Stephure D, et al. Pericardial effusion in severe hypothyroidism in children. J Pediatr Endocrinol Metab 2010; 23:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21865/abstract/30\">",
"      Alink J, de Vries TW. Unexplained seizures, confusion or hallucinations: think Hashimoto encephalopathy. Acta Paediatr 2008; 97:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21865/abstract/31\">",
"      Pacaud D, Van Vliet G, Delvin E, et al. A Third World endocrine disease in a 6-year-old North American boy. J Clin Endocrinol Metab 1995; 80:2574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21865/abstract/32\">",
"      Samaan NA, Schultz PN, Yang KP, et al. Endocrine complications after radiotherapy for tumors of the head and neck. J Lab Clin Med 1987; 109:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21865/abstract/33\">",
"      Ogilvy-Stuart AL, Shalet SM, Gattamaneni HR. Thyroid function after treatment of brain tumors in children. J Pediatr 1991; 119:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21865/abstract/34\">",
"      Rose SR, Lustig RH, Pitukcheewanont P, et al. Diagnosis of hidden central hypothyroidism in survivors of childhood cancer. J Clin Endocrinol Metab 1999; 84:4472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21865/abstract/35\">",
"      Bonato C, Severino RF, Elnecave RH. Reduced thyroid volume and hypothyroidism in survivors of childhood cancer treated with radiotherapy. J Pediatr Endocrinol Metab 2008; 21:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21865/abstract/36\">",
"      Agate L, Mariotti S, Elisei R, et al. Thyroid autoantibodies and thyroid function in subjects exposed to Chernobyl fallout during childhood: evidence for a transient radiation-induced elevation of serum thyroid antibodies without an increase in thyroid autoimmune disease. J Clin Endocrinol Metab 2008; 93:2729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21865/abstract/37\">",
"      Massimino M, Gandola L, Collini P, et al. Thyroid-stimulating hormone suppression for protection against hypothyroidism due to craniospinal irradiation for childhood medulloblastoma/primitive neuroectodermal tumor. Int J Radiat Oncol Biol Phys 2007; 69:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21865/abstract/38\">",
"      Safa AM, Schumacher OP, Rodriguez-Antunez A. Long-term follow-up results in children and adolescents treated with radioactive iodine (131I) for hyperthyroidism. N Engl J Med 1975; 292:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21865/abstract/39\">",
"      Nebesio TD, Siddiqui AR, Pescovitz OH, Eugster EA. Time course to hypothyroidism after fixed-dose radioablation therapy of Graves' disease in children. J Pediatr 2002; 141:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21865/abstract/40\">",
"      Nabhan ZM, Kreher NC, Eugster EA. Hashitoxicosis in children: clinical features and natural history. J Pediatr 2005; 146:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21865/abstract/41\">",
"      Tamai H, Kasagi K, Takaichi Y, et al. Development of spontaneous hypothyroidism in patients with Graves' disease treated with antithyroidal drugs: clinical, immunological, and histological findings in 26 patients. J Clin Endocrinol Metab 1989; 69:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21865/abstract/42\">",
"      Calaciura F, Motta RM, Miscio G, et al. Subclinical hypothyroidism in early childhood: a frequent outcome of transient neonatal hyperthyrotropinemia. J Clin Endocrinol Metab 2002; 87:3209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21865/abstract/43\">",
"      Cambiaso P, Orazi C, Digilio MC, et al. Thyroid morphology and subclinical hypothyroidism in children and adolescents with Williams syndrome. J Pediatr 2007; 150:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21865/abstract/44\">",
"      Indolfi G, Stagi S, Bartolini E, et al. Thyroid function and anti-thyroid autoantibodies in untreated children with vertically acquired chronic hepatitis C virus infection. Clin Endocrinol (Oxf) 2008; 68:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21865/abstract/45\">",
"      Huang SA, Tu HM, Harney JW, et al. Severe hypothyroidism caused by type 3 iodothyronine deiodinase in infantile hemangiomas. N Engl J Med 2000; 343:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21865/abstract/46\">",
"      Nelson JC, Clark SJ, Borut DL, et al. Age-related changes in serum free thyroxine during childhood and adolescence. J Pediatr 1993; 123:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21865/abstract/47\">",
"      Elmlinger MW, K&uuml;hnel W, Lambrecht HG, Ranke MB. Reference intervals from birth to adulthood for serum thyroxine (T4), triiodothyronine (T3), free T3, free T4, thyroxine binding globulin (TBG) and thyrotropin (TSH). Clin Chem Lab Med 2001; 39:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21865/abstract/48\">",
"      Rose SR. Improved diagnosis of mild hypothyroidism using time-of-day normal ranges for thyrotropin. J Pediatr 2010; 157:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21865/abstract/49\">",
"      Lazar L, Frumkin RB, Battat E, et al. Natural history of thyroid function tests over 5 years in a large pediatric cohort. J Clin Endocrinol Metab 2009; 94:1678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21865/abstract/50\">",
"      Nicoletti A, Bal M, De Marco G, et al. Thyrotropin-stimulating hormone receptor gene analysis in pediatric patients with non-autoimmune subclinical hypothyroidism. J Clin Endocrinol Metab 2009; 94:4187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21865/abstract/51\">",
"      Persani L, Ferretti E, Borgato S, et al. Circulating thyrotropin bioactivity in sporadic central hypothyroidism. J Clin Endocrinol Metab 2000; 85:3631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21865/abstract/52\">",
"      Zois C, Stavrou I, Svarna E, et al. Natural course of autoimmune thyroiditis after elimination of iodine deficiency in northwestern Greece. Thyroid 2006; 16:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21865/abstract/53\">",
"      Feingold SB, Smith J, Houtz J, et al. Prevalence and functional significance of thyrotropin receptor blocking antibodies in children and adolescents with chronic lymphocytic thyroiditis. J Clin Endocrinol Metab 2009; 94:4742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21865/abstract/54\">",
"      Yoshida A, Hisatome I, Taniguchi S, et al. Pendrin is a novel autoantigen recognized by patients with autoimmune thyroid diseases. J Clin Endocrinol Metab 2009; 94:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21865/abstract/55\">",
"      Vlachopapadopoulou E, Thomas D, Karachaliou F, et al. Evolution of sonographic appearance of the thyroid gland in children with Hashimoto's thyroiditis. J Pediatr Endocrinol Metab 2009; 22:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21865/abstract/56\">",
"      Rivkees SA, Bode HH, Crawford JD. Long-term growth in juvenile acquired hypothyroidism: the failure to achieve normal adult stature. N Engl J Med 1988; 318:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21865/abstract/57\">",
"      Baloch Z, Carayon P, Conte-Devolx B, et al. Laboratory medicine practice guidelines. Laboratory support for the diagnosis and monitoring of thyroid disease. Thyroid 2003; 13:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21865/abstract/58\">",
"      Chiesa A, Gru&ntilde;eiro de Papendieck L, Keselman A, et al. Final height in long-term primary hypothyroid children. J Pediatr Endocrinol Metab 1998; 11:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21865/abstract/59\">",
"      Lomenick JP, El-Sayyid M, Smith WJ. Effect of levo-thyroxine treatment on weight and body mass index in children with acquired hypothyroidism. J Pediatr 2008; 152:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21865/abstract/60\">",
"      Rovet JF, Daneman D, Bailey JD. Psychologic and psychoeducational consequences of thyroxine therapy for juvenile acquired hypothyroidism. J Pediatr 1993; 122:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21865/abstract/61\">",
"      Van Dop C, Conte FA, Koch TK, et al. Pseudotumor cerebri associated with initiation of levothyroxine therapy for juvenile hypothyroidism. N Engl J Med 1983; 308:1076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21865/abstract/62\">",
"      Vestergaard P, Mosekilde L. Fractures in patients with hyperthyroidism and hypothyroidism: a nationwide follow-up study in 16,249 patients. Thyroid 2002; 12:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21865/abstract/63\">",
"      Saggese G, Bertelloni S, Baroncelli GI, et al. Bone mineral density in adolescent females treated with L-thyroxine: a longitudinal study. Eur J Pediatr 1996; 155:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21865/abstract/64\">",
"      Sklar CA, Qazi R, David R. Juvenile autoimmune thyroiditis. Hormonal status at presentation and after long-term follow-up. Am J Dis Child 1986; 140:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21865/abstract/65\">",
"      Moore DC. Natural course of 'subclinical' hypothyroidism in childhood and adolescence. Arch Pediatr Adolesc Med 1996; 150:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21865/abstract/66\">",
"      Wang SY, Tung YC, Tsai WY, et al. Long-term outcome of hormonal status in Taiwanese children with Hashimoto's thyroiditis. Eur J Pediatr 2006; 165:481.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5838 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.25.216.6-A93D27A9D4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_22_21865=[""].join("\n");
var outline_f21_22_21865=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Chronic autoimmune thyroiditis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Associations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Painless thyroiditis or subacute granulomatous thyroiditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Iodine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Antithyroid drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Thyroid injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Craniospinal irradiation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Hypothyroidism after treatment for Graves' disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Late-onset congenital hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Williams syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Hepatitis C infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Hemangiomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Thyroid hormone resistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Central hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      TREATMENT AND PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      T4 dose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Consequences of overtreatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Course",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5838\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5838|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/42/39595\" title=\"table 1\">",
"      Hypothyroidism in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/22/28012\" title=\"table 2\">",
"      Pediatric range TFTs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?4/27/4529?source=related_link\" title=\"calculator 1\">",
"      Calculator: Body Surface Area (Mosteller, square root method)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/0/40969?source=related_link\">",
"      Causes of primary adrenal insufficiency (Addison's disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/6/18536?source=related_link\">",
"      Central hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/39/2682?source=related_link\">",
"      Clinical features and detection of congenital hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/3/37946?source=related_link\">",
"      Clinical manifestations and diagnosis of celiac disease in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/10/14503?source=related_link\">",
"      Clinical manifestations of hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/45/24280?source=related_link\">",
"      Congenital and acquired goiter in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/28/41413?source=related_link\">",
"      Diagnosis of hypopituitarism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/60/18376?source=related_link\">",
"      Diagnostic approach to short stature",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/47/42744?source=related_link\">",
"      Disorders that cause hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/47/33527?source=related_link\">",
"      Hashimoto's encephalopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/15/25850?source=related_link\">",
"      IPEX: Immune dysregulation, polyendocrinopathy, enteropathy, X-linked",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3608?source=related_link\">",
"      Laboratory assessment of thyroid function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/14/34025?source=related_link\">",
"      Microdeletion syndromes (chromosomes 1 to 11)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/51/43830?source=related_link\">",
"      Overview of thyroiditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/11/27833?source=related_link\">",
"      Pathogenesis of Hashimoto's thyroiditis (chronic autoimmune thyroiditis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/37/1626?source=related_link\">",
"      Reduced sensitivity to thyroid hormone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/8/16518?source=related_link\">",
"      Resistance to thyrotropin and thyrotropin-releasing hormone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/41/23191?source=related_link\">",
"      Thyroid nodules and cancer in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/51/25400?source=related_link\">",
"      Treatment and prognosis of Graves' disease in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/10/5287?source=related_link\">",
"      Williams-Beuren syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_22_21866="Treatment of von Willebrand disease";
var content_f21_22_21866=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of von Willebrand disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/22/21866/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/22/21866/contributors\">",
"     Margaret E Rick, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/22/21866/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/22/21866/contributors\">",
"     Lawrence LK Leung, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/22/21866/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/22/21866/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/22/21866/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Von Willebrand disease (VWD) is the most common of the inherited bleeding disorders, with a prevalence of approximately 1 percent when random laboratory screening is performed [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/1\">",
"     1",
"    </a>",
"    ]. Symptomatic VWD seen at hemostasis centers is less common, with a prevalence of about 0.01 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/2\">",
"     2",
"    </a>",
"    ]. VWD is characterized by mutations that lead to an impairment in the synthesis or action of von Willebrand factor (VWF). There are also acquired forms of VWD that are caused by several different pathophysiologic mechanisms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/8/44169?source=see_link\">",
"     \"Classification and pathophysiology of von Willebrand disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Von Willebrand factor (VWF) plays an important role in primary hemostasis by binding to both platelets and endothelial components, forming an adhesive bridge between platelets and vascular subendothelial structures and between adjacent platelets at sites of endothelial injury. It also contributes to fibrin clot formation by acting as a carrier protein for factor VIII, which has a greatly shortened half-life unless it is bound to VWF. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/41/17049?source=see_link\">",
"     \"Biology and normal function of von Willebrand factor\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although VWD is common, only a fraction of patients come to medical attention because of bleeding symptoms and are diagnosed as having VWD. This low incidence of bleeding is due to the mild nature of the disease in many patients and to the lack of bleeding challenges",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    lack of recognition of minor excessive bleeding (eg, heavy menstrual bleeding) in others. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24794?source=see_link\">",
"     \"Clinical presentation and diagnosis of von Willebrand disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The treatment of VWD will be reviewed here. Concise reviews of the treatment of VWD have been published [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/3-8\">",
"     3-8",
"    </a>",
"    ]. Discussion of the pathophysiology, classification, clinical presentation, and diagnosis of VWD, as well as the function of VWF, can be found elsewhere in the program.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inherited von Willebrand disease has been classified into three types &mdash; 1, 2 (four subtypes), and 3 (",
"    <a class=\"graphic graphic_table graphicRef71525 \" href=\"UTD.htm?5/14/5356\">",
"     table 1",
"    </a>",
"    ). Although discussed in detail elsewhere, it is useful to briefly review the characteristics of the different types because they may affect the choice of therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/8/44169?source=see_link\">",
"     \"Classification and pathophysiology of von Willebrand disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Type 1",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type 1, an autosomal dominant disease, is the most common, accounting for approximately 70 percent of patients. It reflects a",
"    <strong>",
"     quantitative",
"    </strong>",
"    deficiency of VWF. The clinical presentation varies from mild to moderately severe, as determined by bleeding symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Type 2",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type 2, which is usually an autosomal dominant disease, accounts for 25 to 30 percent of cases. It is characterized by several",
"    <strong>",
"     qualitative",
"    </strong>",
"    abnormalities of VWF. Four subtypes have been identified: 2A, 2B, 2M, and 2N.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Type 2A accounts for 10 to 15 percent of cases of VWD. The mutations are associated with a decrease in the hemostatically active high and intermediate molecular weight multimers of VWF. Some mutations cause a defect in the intracellular assembly and transport of normal VWF multimers (group 1), while others affect a normal cleavage site in VWF and cause increased susceptibility to proteolysis by the VWF cleaving protease (ADAMTS13) after secretion (group 2). Affected patients usually present with moderate to moderately severe bleeding.",
"     </li>",
"     <li>",
"      Type 2B VWD accounts for approximately 5 percent of cases of VWD. The abnormal VWF binds more readily to its platelet receptor, platelet glycoprotein (GP)Ib; the increase in binding of larger VWF multimers results in their loss from the circulation and, in some patients, thrombocytopenia. Affected patients generally present with moderate to moderately severe bleeding.",
"     </li>",
"     <li>",
"      Type 2M is an uncommon disorder characterized by reduced binding of VWF to GPIb. All multimers of VWF are present but are not fully functional. Affected patients typically have significant bleeding symptoms.",
"     </li>",
"     <li>",
"      Type 2N is an uncommon disorder inherited in an autosomal recessive manner, in which the mutations occur within the binding site for factor VIII and cause decreased binding to factor VIII, which is then catabolized more quickly. As a result, factor VIII levels are usually 5 to 15 percent of normal, while the platelet-related functions of VWF are intact. The net effect is that patients present with the type of bleeding associated with factor VIII deficiency such as soft tissue, joint, and urinary bleeding and bleeding after invasive procedures, rather than the moderate to severe mucocutaneous bleeding seen in the other forms of VWD (",
"      <a class=\"graphic graphic_table graphicRef77834 \" href=\"UTD.htm?2/43/2748\">",
"       table 2",
"      </a>",
"      ). This disorder can be confused with hemophilia A; it should be suspected in females who present with isolated factor VIII deficiency (with normal levels of VWF activity and antigen) and in families where an autosomal inheritance pattern is suggested, rather than an X-linked pattern as seen in hemophilia A.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Type 3",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type 3 VWD, an autosomal recessive disorder, leads to severe disease with extremely reduced or undetectable levels of VWF. These patients present with severe bleeding involving both the skin and mucous membrane surfaces (due to decreased VWF) and soft tissues and joints (due to the low concentration of factor VIII) (",
"    <a class=\"graphic graphic_table graphicRef77834 \" href=\"UTD.htm?2/43/2748\">",
"     table 2",
"    </a>",
"    ). They may initially be diagnosed as having hemophilia A before the results of VWF testing are available. Replacement therapy with VWF is usually required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     GENERAL CONSIDERATIONS OF THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Decisions about therapy begin with an accurate and complete diagnosis of VWD. In addition, the patient's past history of bleeding with various challenges, response to treatment, general medical condition, and current medications need to be taken into account. The patient should be specifically questioned about use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    -containing medications or nonsteroidal antiinflammatory drugs that are commonly available over-the-counter and aggravate bleeding. If the patient is taking an antiplatelet drug and bleeding is serious and not controlled by therapy for VWD, consideration must be given to correction of the platelet defect, usually by platelet transfusion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/6/20586?source=see_link\">",
"     \"Clinical and laboratory aspects of platelet transfusion therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is no laboratory test for VWF that correlates well with bleeding symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/9\">",
"     9",
"    </a>",
"    ]. As a result, there are no absolute guidelines about the best parameter(s) to follow when treating the patient. In addition to clinical monitoring, many experts follow the ristocetin cofactor and factor VIII levels [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/10\">",
"     10",
"    </a>",
"    ]; the latter is often the only result available in a timely fashion for clinical decision-making. It is generally felt that it is not necessary to completely normalize the bleeding time in order to achieve adequate hemostasis in patients with VWD [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     INHERITED VWD",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are five classes of medications for the treatment of VWD:",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    ; replacement therapy with VWF-containing concentrates; antifibrinolytic drugs; topical therapy with thrombin or fibrin sealant; and estrogen therapy in some settings in women (",
"    <a class=\"graphic graphic_table graphicRef75956 \" href=\"UTD.htm?13/59/14268\">",
"     table 3",
"    </a>",
"    ). There is also a role for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/42/30373?source=see_link\">",
"     recombinant human factor VIIa",
"    </a>",
"    in the treatment of patients with severe (type 3) VWD who develop inhibitors to replacement VWF (see",
"    <a class=\"local\" href=\"#H16\">",
"     'Recombinant Factor VIIa'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Desmopressin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     Desmopressin",
"    </a>",
"    (dDAVP), first shown in 1977 to increase VWF and factor VIII levels [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/12\">",
"     12",
"    </a>",
"    ], is a synthetic analog of antidiuretic hormone which retains antidiuretic activity but lacks vasopressor activity. It promotes the release of VWF from endothelial cell storage sites; this response is indirect, since it cannot be reproduced by direct exposure of endothelial cells to dDAVP [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/13\">",
"     13",
"    </a>",
"    ]. Desmopressin may also have other actions, such as enhanced hemostasis in patients with platelet function defects. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/9/29850?source=see_link&amp;anchor=H36#H36\">",
"     \"Congenital and acquired disorders of platelet function\", section on 'Desmopressin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     Desmopressin",
"    </a>",
"    can be administered intravenously, by subcutaneous injection, or by intranasal spray. When given intravenously for prophylaxis before invasive procedures or for acute bleeding episodes, a dose of 0.3",
"    <span class=\"nowrap\">",
"     micrograms/kg",
"    </span>",
"    (maximum 20 micrograms) is diluted in 50 mL of normal saline and infused over 20 to 30 minutes; the same dose is given with subcutaneous therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/14\">",
"     14",
"    </a>",
"    ]. A three- to fivefold increase in baseline levels of VWF and factor VIII levels is expected at approximately 30 to 60 minutes after the infusion, with the response persisting for 6 to 12 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/15\">",
"     15",
"    </a>",
"    ]. The half-life of the released VWF will correspond to the particular half-life of the patient's own VWF [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. A repeat dose may be given at 8 to 12 hours. Subsequent doses are often switched to once daily doses for one to three or more days [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]; tachyphylaxis and hyponatremia can occur with prolonged dosing (see below).",
"   </p>",
"   <p>",
"    Intranasal administration has become a favored choice for many patients who have less serious bleeding not requiring a hospital visit or who need treatment prior to a planned minor invasive procedure, since therapy can be performed at home in a timely manner. As an example, intranasal therapy at the onset of menses has been used by women with VWD to control excessive menstrual bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. Benefits also have been noted for epistaxis or bleeding related to minor surgery or tooth extraction. The usual dose is 150 micrograms for children weighing less than 50 kg and 300 micrograms for larger children and adults [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/14\">",
"     14",
"    </a>",
"    ]. In adults, the VWF levels achieved with 300 micrograms of intranasal spray are approximately equivalent to that seen with an intravenous dose of 0.2",
"    <span class=\"nowrap\">",
"     micrograms/kg",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Side effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    include vasodilatation that causes facial flushing, headache (which can often be controlled by decreasing the rate of infusion), nausea, and occasional tingling [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/24\">",
"     24",
"    </a>",
"    ]. Both hypotension and hypertension have been reported, but are not common and are usually mild. Thrombosis has occurred following desmopressin administration [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/25\">",
"     25",
"    </a>",
"    ], but it is uncertain whether the medication is causal [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/26\">",
"     26",
"    </a>",
"    ]. Common sense dictates caution with the use of dDAVP in patients with known coronary or cerebral arterial vascular disease.",
"   </p>",
"   <p>",
"    Tachyphylaxis occurs after repeated administration and, because of the persistent antidiuretic activity, water retention leading to serious hyponatremia, seizures, and even death can occur [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/24,27,28\">",
"     24,27,28",
"    </a>",
"    ]. While nonsteroidal antiinflammatory agents (NSAIDs) should not generally be used in patients with VWD or other bleeding disorders, their inadvertent use by patients receiving dDAVP may aggravate hyponatremia; accordingly, NSAIDs should be used with caution in patients receiving dDAVP for any indication [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/29\">",
"     29",
"    </a>",
"    ]. Doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    are usually limited to once daily after the first day for a total of three days, water intake is restricted, and serum sodium levels are assessed. Adverse events requiring medical intervention are rare [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Responses according to VWD type",
"    </span>",
"    &nbsp;&mdash;&nbsp;As will be discussed below, the utility of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    varies with the type of VWD [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/14,30-33\">",
"     14,30-33",
"    </a>",
"    ]. Because of this variability in response, and in the absence of firm data from clinical trials, a \"test\" infusion should be given",
"    <strong>",
"     in advance",
"    </strong>",
"    of a planned procedure while the patient is at baseline, in order to assess both the VWF and factor VIII responses [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/34\">",
"     34",
"    </a>",
"    ]. Once an adequate response is documented, desmopressin can be used for subsequent bleeding episodes or invasive procedures without further therapeutic trials.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Type 1",
"      </strong>",
"      &mdash;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"       Desmopressin",
"      </a>",
"      is effective in almost all patients with mild or moderate type 1 disease, including those due to accelerated clearance of VWF [",
"      <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/35\">",
"       35",
"      </a>",
"      ]. In comparison, a high proportion of those with severe bleeding symptoms and marked prolongation of the bleeding time do not respond sufficiently to desmopressin [",
"      <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/14,32\">",
"       14,32",
"      </a>",
"      ]. Desmopressin is also ineffective in the rare patients with type 1 disease who have normal or decreased levels of plasma VWF accompanied by absent stores of VWF in platelets (\"platelet-low\" VWD) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/14,36\">",
"       14,36",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      As an example, in a study of 77 patients with type 1 VWD, complete, partial, or non-response to desmopressin was seen in 83, 13, and 4 percent of patients, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/33\">",
"       33",
"      </a>",
"      ]. Most partial and nonresponders had mutations of VWF in the A1-A3 domains, and others who had good initial increases but short-lived responses had mutations in the D'-D3 domain. This reinforces the need for performing a \"test\" infusion in any patient with clinically significant type 1 VWD in order to plan its future use.",
"      <br/>",
"      <br/>",
"      Although platelet VWF levels can be measured, a therapeutic trial of dDAVP is the best method to determine the effectiveness of dDAVP in all VWD patients. It has been suggested that platelet VWF can substitute in part for plasma VWF to promote platelet adhesion, an effect absent in some patients [",
"      <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Type 2A",
"      </strong>",
"      &mdash; The administration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"       desmopressin",
"      </a>",
"      to patients with type 2A disease increases factor VIII levels, but has a variable effect on the VWF level, the amount of high and intermediate molecular weight multimers,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      the bleeding time [",
"      <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/14,32\">",
"       14,32",
"      </a>",
"      ]. Patients who do respond with a reduction in the bleeding time may belong to group 2, which is characterized by normal VWF secretion but increased susceptibility to proteolysis by the VWF cleaving protease (ADAMTS13) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/14,38,39\">",
"       14,38,39",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      In one study, for example, desmopressin produced an increase in the higher molecular weight VWF multimers that persisted for at least four hours; these were detectable only when blood was collected in the presence of protease inhibitors, as opposed to citrate alone [",
"      <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Type 2B",
"      </strong>",
"      &mdash; Patients with type 2B often have thrombocytopenia due, as mentioned above, to increased binding of the abnormal VWF to platelet GPIb, a problem that can worsen after treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"       desmopressin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/40\">",
"       40",
"      </a>",
"      ]. It is presumed that increasing the level of abnormal 2B VWF causes more binding to platelets, resulting in microaggregate formation and sequestration or clearance of platelets. Despite these concerns, some type 2B patients have benefited from desmopressin [",
"      <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/41-43\">",
"       41-43",
"      </a>",
"      ] without either marked thrombocytopenia or thrombotic complications [",
"      <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/42\">",
"       42",
"      </a>",
"      ]. The reduction in platelet count is transient, usually normalizing within two hours [",
"      <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/44\">",
"       44",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Desmopressin should be considered in type 2B disease only if response to this agent has been documented after a trial infusion has been conducted. Patients who are markedly thrombocytopenic may also benefit from platelet transfusion in addition to therapeutic measures that increase the level of normal VWF.",
"      <br/>",
"      <br/>",
"      A similar phenotype to type 2B VWD occurs in patients with pseudo- or \"platelet type\" VWD who have a gain-of-function mutation in platelet GPIb, resulting in increased binding of their normal VWF [",
"      <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/45-47\">",
"       45-47",
"      </a>",
"      ]. Treatment for this disorder includes transfusion of normal platelets and increasing VWF levels to between 50 and 100 percent with VWF concentrate if platelet transfusions do not control the clinical bleeding [",
"      <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Type 2M",
"      </strong>",
"      &mdash; Although data are limited,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"       desmopressin",
"      </a>",
"      may produce a good response in some patients with type 2M VWD [",
"      <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/14,32,33,49\">",
"       14,32,33,49",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Type 2N",
"      </strong>",
"      &mdash; Patients with type 2N have normal VWF platelet function but impaired binding to factor VIII, leading to low factor VIII levels. These patients may benefit from",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"       desmopressin",
"      </a>",
"      , despite the shorter than normal half-life of the released factor VIII [",
"      <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/17,32,50\">",
"       17,32,50",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      In one study, for example, a desmopressin infusion resulted in a 2.3-fold increase of VWF and a variable rise (9.5 &plusmn; 7.7 -fold) in factor VIII; the factor VIII response was more transient than the VWF response, with a disappearance half-time of approximately three hours [",
"      <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Type 3",
"      </strong>",
"      &mdash;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"       Desmopressin",
"      </a>",
"      does not increase VWF levels in patients with type 3 VWD, probably due to a lack of VWF in the storage sites [",
"      <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/14\">",
"       14",
"      </a>",
"      ]. It is therefore not recommended for use in patients with type 3 VWD.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Replacement therapy with VWF",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18189762\">",
"    <span class=\"h3\">",
"     Short-term replacement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with type 3 VWD and those with more severe type 2A, 2B, and 2M disease often require replacement therapy with VWF. Replacement therapy is also indicated in some patients with type 1 VWD who have a more severe decrease of VWF, particularly in more serious bleeding situations when other measures have failed, or in those who may need more prolonged treatment (eg, post-surgery). VWF replacement therapy is most often used for short term prophylaxis for a planned procedure or following trauma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18189769\">",
"    <span class=\"h3\">",
"     Prophylaxis with VWF",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although VWF has not been generally given as long-term prophylaxis (ie, over many months as carried out for hemophilia A), the following observations are pertinent:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A cohort of 35 patients given continuous replacement therapy has been followed for a median of 11 years in Sweden with a reduction in bleeding having been reported [",
"      <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A second cohort of 32 patients given long-term prophylaxis has been reported [",
"      <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An international group is being organized to administer long-term replacement VWF to severely affected patients in a prophylactic manner; this study will follow several parameters including dose schedules, the frequency of bleeding episodes, frequency of hospitalizations, quality of life issues, and adverse effects [",
"      <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Preparations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several products are available that contain VWF in high concentration, including \"intermediate purity\"",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/12/198?source=see_link\">",
"     factor VIII concentrates",
"    </a>",
"    (which also contain VWF), more highly purified VWF concentrates, cryoprecipitate, and a recombinant VWF product that is still in development [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/54\">",
"     54",
"    </a>",
"    ]. Unless there are special considerations, such as a single related donor [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/55\">",
"     55",
"    </a>",
"    ] or no other recourse in a life-threatening setting, cryoprecipitate is not recommended because of the risk of viral transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/54\">",
"     54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/33/9752?source=see_link&amp;anchor=H14#H14\">",
"     \"Clinical use of plasma components\", section on 'Cryoprecipitate'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The intermediate purity",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/12/198?source=see_link\">",
"     factor VIII concentrates",
"    </a>",
"    and higher purity VWF concentrates are pasteurized or treated with solvent detergent methods to reduce the risk of transmission of viruses, such as hepatitis viruses and HIV. The manufacturing process must allow for preservation of the larger (as well as the smaller) VWF multimers, since the larger multimers are the most hemostatically active. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/39/11895?source=see_link&amp;anchor=H7#H7\">",
"     \"Preparation of blood components\", section on 'Blood components'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Three of the intermediate purity",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/12/198?source=see_link\">",
"       factor VIII concentrates",
"      </a>",
"      (Humate P&reg;, Alphanate&reg;, and Solvent",
"      <span class=\"nowrap\">",
"       Detergent/Heat",
"      </span>",
"      Treated, Wilate) are approved for use in the United States. They are labeled with ristocetin cofactor activity units, and studies of their efficacy in patients with VWD have been published [",
"      <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/56-60\">",
"       56-60",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Koate DVI&reg; is another product licensed for use in hemophilia A that also contains VWF. This product is not labeled for VWF activity units and since it contains different ratios of VWF and factor VIII, it is not interchangeable with Humate P&reg; or Alphanate&reg; or Wilate. Another concentrate, 8Y, is manufactured in the United Kingdom and approved for use there [",
"      <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/61\">",
"       61",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A very high purity VWF concentrate, LFB-von Willebrand factor, is produced in France and contains a much higher ratio of VWF activity to factor VIII (approximately 10:1); this concentrate is available in several European countries [",
"      <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/62,63\">",
"       62,63",
"      </a>",
"      ]. However, since many patients with VWD also have low levels of factor VIII, it is necessary to replace factor VIII using a recombinant factor VIII product when treatment is first started with LFB-von Willebrand factor if the patient's factor VIII is less than 20 percent. Subsequent doses of high purity VWF usually do not require additional factor VIII, because the production and half-life of factor VIII are generally prolonged sufficiently in the presence of the transfused VWF [",
"      <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/62,64\">",
"       62,64",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Recombinant human VWF, which contains a full spectrum of multimers as well as adequate levels of VWF activity and antigen, has been produced in CHO cells. When tested in dogs with VWD, there is good recovery of VWF with the expected hemostatic effects [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/65\">",
"     65",
"    </a>",
"    ]. The recombinant product appears to be resistant to proteolytic digestion after infusion in this animal model [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/66\">",
"     66",
"    </a>",
"    ]. Recombinant human VWF is not currently available for use in humans.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Summary for replacement VWF",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recommendations for replacement doses of VWF are empirical, since no laboratory tests adequately predict the hemostatic effects. The dose given is also dependent upon the site and the degree of bleeding (",
"    <a class=\"graphic graphic_table graphicRef75956 \" href=\"UTD.htm?13/59/14268\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In general, the goal is to maintain the activity of factor VIII and of VWF (generally measured as ristocetin cofactor) between 50 to 100 percent for 3 to 14 days for more serious bleeding or major surgery. The infusion of 20 to 40 international",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    of ristocetin cofactor activity as labeled on these concentrates raises the plasma concentration to 50 to 100 percent, or by approximately 0.7",
"    <span class=\"nowrap\">",
"     units/mL",
"    </span>",
"    (70 percent), and is administered every 12 to 24 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/67,68\">",
"     67,68",
"    </a>",
"    ]. A &ldquo;loading&rdquo; dose of 40 to 60 international",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    is often given at the beginning of the treatment period to insure reaching the desired level at the onset of treatment.",
"   </p>",
"   <p>",
"    Patients with severe VWD (usually type 3) who have mucous membrane bleeding, particularly gastrointestinal bleeding, may require higher replacement doses of VWF (80 to 100 percent). If bleeding is not controlled by VWF replacement therapy, these patients may benefit from the addition of platelet transfusions [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/69\">",
"     69",
"    </a>",
"    ]. Also, platelet transfusions, in addition to VWF replacement, may decrease bleeding in those patients with type 2B VWD who have moderately severe thrombocytopenia.",
"   </p>",
"   <p>",
"    There appears to be a small risk of venous thromboembolism when intermediate purity",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/12/198?source=see_link\">",
"     factor VIII concentrates",
"    </a>",
"    are used in high doses as replacement therapy during perioperative periods or for gastrointestinal bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/70,71\">",
"     70,71",
"    </a>",
"    ]. In some of these cases a high factor VIII level (&gt;200 percent) has been documented, which may have contributed to the thrombosis. Accordingly, it has been recommended that factor VIII concentrations be followed on a daily basis to avoid levels in excess of 200 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/4,71\">",
"     4,71",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=see_link&amp;anchor=H18#H18\">",
"     \"Overview of the causes of venous thrombosis\", section on 'Factor VIII'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Replacement VWF is usually given by intravenous infusion over less than 20 minutes at 8 to 12 hour intervals, at a dose of 20 to 40 international",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    to keep VWF levels above 50 percent or to control clinical bleeding (",
"    <a class=\"graphic graphic_table graphicRef75956 \" href=\"UTD.htm?13/59/14268\">",
"     table 3",
"    </a>",
"    ). However, studies indicate that continuous infusion of VWF may reduce the clearance of the infused product, thereby lowering the total dose that is consumed by 20 to 50 percent and lowering the ultimate cost [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/72,73\">",
"     72,73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to measuring ristocetin cofactor activity, physicians may consider utilizing the platelet function analyzer (PFA-100) to follow VWF activity after replacement therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/74\">",
"     74",
"    </a>",
"    ]. While the PFA can be used to follow some patients after treatment, it does not appear to be accurate for monitoring replacement therapy in patients with type 3 VWD [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/74,75\">",
"     74,75",
"    </a>",
"    ]. This limitation is thought to reflect dependence of the instrument's assessment method on platelet VWF; the latter is very low or absent in patients with type 3 VWD, even after plasma replacement therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/59/23482?source=see_link&amp;anchor=H17#H17\">",
"     \"Platelet function testing\", section on 'The platelet function analyzer'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/9/29850?source=see_link&amp;anchor=H12#H12\">",
"     \"Congenital and acquired disorders of platelet function\", section on 'Platelet Function Analyzer (PFA-100)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Antifibrinolytic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epsilon",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/38/30311?source=see_link\">",
"     aminocaproic acid",
"    </a>",
"    (EACA) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/58/14248?source=see_link\">",
"     tranexamic acid",
"    </a>",
"    have been used to prevent dissolution of the hemostatic plug that is formed, particularly in mucous membrane areas with naturally high fibrinolytic activity (eg, to decrease bleeding with dental procedures or in patients with menorrhagia [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/22\">",
"     22",
"    </a>",
"    ]). These drugs can be used as the sole therapy in cases of mild bleeding or as an adjunct to other medications, such as the combined use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    and an antifibrinolytic agent in the management of children with type I VWD undergoing adenotonsillar procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These two antifibrinolytic agents can be given orally or intravenously. When given orally, they must be given three or four times over a 24-hour period due to their short half-lives, and the dose must be adjusted in patients with renal insufficiency. EACA is usually given four times daily in a dose of 25 to 50",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/58/14248?source=see_link\">",
"     tranexamic acid",
"    </a>",
"    is given three times daily in a dose of 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV (",
"    <a class=\"graphic graphic_table graphicRef75956 \" href=\"UTD.htm?13/59/14268\">",
"     table 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/4\">",
"     4",
"    </a>",
"    ]. When administered for dental procedures, minor epistaxis, or other similar procedures, the agents are given for periods varying from three to seven days [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/15,18,19,67\">",
"     15,18,19,67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prolonged use of either antifibrinolytic agent carries a risk of thrombosis in patients who have an underlying hypercoagulable state. These agents are contraindicated in the presence of gross hematuria, since unlysed clots may lead to ureteral obstruction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Topical agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical agents are most often used for nasal or oral bleeding. With this approach, supports such as Gelfoam or Surgicel are soaked in",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/42/40612?source=see_link\">",
"     topical thrombin",
"    </a>",
"    and applied to local areas of bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/31\">",
"     31",
"    </a>",
"    ]. It is recommended that human thrombin be used for this purpose. If human thrombin is not available, bovine thrombin can be used, although large exposures to topical bovine thrombin carry a risk of antibody formation against the bovine factor V that is present in some thrombin preparations. This has been associated with bleeding, since these antibodies can crossreact with human factor V [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/76\">",
"     76",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/36/4682?source=see_link&amp;anchor=H13#H13\">",
"     \"Clinical use of coagulation tests\", section on 'Thrombin time'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Micronized collagen (Avitene), which is available in strips for packing, and fibrin sealant (using human thrombin) are other topical agents that can be used [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25094?source=see_link&amp;anchor=H6#H6\">",
"     \"Fibrin sealant\", section on 'Source of thrombin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Estrogen",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of estrogen therapy in patients with VWD was suggested by the incidental observation that three women with type 1 VWD had significantly less bleeding and improved hemostasis when they took estrogen either for oral contraception or prevention of menopausal symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/77\">",
"     77",
"    </a>",
"    ]. Estrogen acts at least in part by increasing the synthesis of VWF [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/78\">",
"     78",
"    </a>",
"    ]. However, data regarding the side effects related to long-term replacement therapy with estrogen require a full discussion of risks and benefits with the patient before such treatment is given [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/79\">",
"     79",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=see_link\">",
"     \"Postmenopausal hormone therapy: Benefits and risks\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Recombinant Factor VIIa",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several authors have reported on the successful use of recombinant factor VIIa in the treatment of patients with type 3 VWD who developed alloantibodies to VWF after receiving replacement therapy with VWF [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/80,81\">",
"     80,81",
"    </a>",
"    ]. Factor VIIa bypasses the need for factor VIII in the intrinsic coagulation pathway, and binds to activated platelets and initiates the extrinsic clotting cascade with subsequent formation of thrombin and fibrin [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/82-84\">",
"     82-84",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/13/31962?source=see_link&amp;anchor=H3#H3\">",
"     \"Therapeutic uses of recombinant coagulation factor VIIa\", section on 'Mechanism of action'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Whether factor VIIa provides a \"bypass\" for the platelet-related functions of VWF is not clear, but clinical hemostasis has been achieved in these severe VWD patients who lack plasma and platelet VWF. Because of the increased risk of thrombosis when using this agent, factor VIIa should be used with caution in patients with risk factors for coronary artery disease [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/85\">",
"     85",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/13/31962?source=see_link&amp;anchor=H26#H26\">",
"     \"Therapeutic uses of recombinant coagulation factor VIIa\", section on 'Thromboembolic events'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     TREATMENT OF ACQUIRED VWD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acquired VWD is associated with a number of different disease states and is caused by several different pathophysiologic mechanisms [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/86-89\">",
"     86-89",
"    </a>",
"    ]. These include antibody formation, proteolysis, binding to tumor cells with increased clearance, and decreased synthesis as in hypothyroidism. Acquired VWD is most frequently described in patients with lymphoproliferative and autoimmune diseases (systemic lupus erythematosus), some of whom have demonstrable antibodies to VWF. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/8/44169?source=see_link&amp;anchor=H13#H13\">",
"     \"Classification and pathophysiology of von Willebrand disease\", section on 'Acquired von Willebrand disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment of acquired VWD depends in part upon the pathogenetic mechanism [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/90\">",
"     90",
"    </a>",
"    ]. It may involve empiric trials to select the best treatment regimen (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    , VWF replacement therapy, or intravenous immune globulin [IVIG]) as well as treatment of the underlying disease, if possible [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/86,87,91-93\">",
"     86,87,91-93",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Control of thrombocytosis using cytoreduction or plateletpheresis may alleviate a bleeding diathesis due to acquired VWD in patients with myeloproliferative neoplasms and high platelet counts. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/28/32202?source=see_link&amp;anchor=H9#H9\">",
"       \"Prognosis and treatment of essential thrombocythemia\", section on 'Treatment overview'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Aortic valve replacement might be considered in a patient with severe aortic stenosis and severe bleeding due to acquired VWD. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21706?source=see_link&amp;anchor=H27#H27\">",
"       \"Clinical features and evaluation of aortic stenosis in adults\", section on 'Bleeding tendency'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Specific treatments for bleeding episodes in patients with acquired VWD include the following [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/94\">",
"     94",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"       Desmopressin",
"      </a>",
"      &mdash; A trial of desmopressin is usually recommended, with monitoring of factor VIII and VWF levels at baseline, one, two, and four hours to assess the response [",
"      <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/91\">",
"       91",
"      </a>",
"      ]. Desmopressin is less likely to be effective in patients with circulating inhibitors (autoantibodies) of VWF. As an example, in one study desmopressin was effective in four of eight patients with a circulating inhibitor to VWF, versus 15 of 16 patients without inhibitors [",
"      <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/95\">",
"       95",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      VWF replacement &mdash; If",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"       desmopressin",
"      </a>",
"      is ineffective, the patient should receive a trial of VWF replacement therapy with an intermediate purity factor VIII product containing VWF or a higher purity VWF concentrate if available (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Preparations'",
"      </a>",
"      above.). Factor VIII and VWF levels should be measured before and at intervals over the next 12 hours to assess the half-life of the infused factor. Patients with circulating inhibitors may require very large doses of VWF (50 to 100",
"      <span class=\"nowrap\">",
"       U/kg),",
"      </span>",
"      and the dose requirements may change if the factor is needed over several days or weeks.",
"     </li>",
"     <li>",
"      IVIG &mdash; High-dose IVIG (1",
"      <span class=\"nowrap\">",
"       g/kg",
"      </span>",
"      per day for two days) has been used in patients with acquired VWD associated with autoimmune disease or a monoclonal gammopathy. It acts at least in part by increasing the half-life of circulating VWF [",
"      <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/96\">",
"       96",
"      </a>",
"      ]. IVIG has a longer duration of action than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"       desmopressin",
"      </a>",
"      or VWF replacement [",
"      <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/91\">",
"       91",
"      </a>",
"      ] and may be successful in patients who do not respond to desmopressin [",
"      <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/95,97,98\">",
"       95,97,98",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Recombinant factor VIIa &mdash; In two patients with bleeding, acquired VWD, and monoclonal gammopathy, in whom treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"       desmopressin",
"      </a>",
"      , VWF, and IVIG were unsuccessful, treatment with recombinant factor VIIa arrested the bleeding in one [",
"      <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/99\">",
"       99",
"      </a>",
"      ] and allowed elective surgery to be safely performed in the other [",
"      <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/100\">",
"       100",
"      </a>",
"      ]. This agent has also been successfully employed in patients with acquired VWD due to the presence of alloantibodies [",
"      <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/101\">",
"       101",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Recombinant Factor VIIa'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other treatments that are much less often used include plasmapheresis, extracorporeal immunoadsorption, and immunosuppressive medications for the underlying disease (eg, corticosteroids or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    for systemic lupus erythematosus) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/97\">",
"     97",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     TREATMENT OF EXCESSIVE MENSTRUAL BLEEDING",
"    </span>",
"    &nbsp;&mdash;&nbsp;In women with VWD who have excessive menstrual bleeding who do not desire pregnancy, the use of combined oral contraceptives is beneficial [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/102\">",
"     102",
"    </a>",
"    ]. A second choice in these patients is the levonorgestrel-releasing intrauterine system [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/103\">",
"     103",
"    </a>",
"    ]. Endometrial ablation has also been used and has been shown to reduce menstrual blood loss, and although the procedure was initially thought to be less successful in patients with VWD compared with patients with other causes of menorrhagia, further studies have shown that the treatment is effective and comparable to the use of the levonorgestrel-releasing intrauterine system [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/104-106\">",
"     104-106",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When pregnancy is desired, antifibrinolytics",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    replacement therapy can be used. Some women also benefit from dDAVP given with the onset of menstrual bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/20-22\">",
"     20-22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     TREATMENT IN PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Levels of VWF rise in normal individuals and in most patients with VWD during the second and third trimesters of pregnancy to two to three times baseline. Consequently, many patients with VWD reach normal levels of both VWF and factor VIII at term. However, the qualitative abnormalities in type 2 VWD will persist and thrombocytopenia in type 2B VWD may worsen [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/107,108\">",
"     107,108",
"    </a>",
"    ]. Although treatment is not needed during pregnancy in the majority of women with VWD, many require treatment during delivery and during the following one to three weeks thereafter. It is recommended that levels of VWF and factor VIII be maintained at 50",
"    <span class=\"nowrap\">",
"     IU/dL",
"    </span>",
"    or higher during delivery and for at least three to five days after delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/6,7,109\">",
"     6,7,109",
"    </a>",
"    ]. Procedures such as amniocentesis, chorionic villus sampling, and regional anesthesia are generally safe if these levels are maintained and the coagulation screen is otherwise normal [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/109\">",
"     109",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Plasma levels of factor VIII and VWF fall quickly after delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/110\">",
"     110",
"    </a>",
"    ] and excessive bleeding may occur at this time [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/111\">",
"     111",
"    </a>",
"    ]. The average time of onset for postpartum hemorrhage in women with VWD is from 11 to 23 days post delivery. Thus,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    or VWF replacement therapy may be required during or shortly after delivery, and for the first two to four weeks thereafter. Since desmopressin has a theoretical possibility of initiating uterine contractions, it is not generally used prior to delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/107,111\">",
"     107,111",
"    </a>",
"    ]. However, limited data indicate that dDAVP has been used \"without mishap\" in 31 pregnant women for prophylaxis before invasive procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An anesthesia consultation should be obtained prior to the onset of labor to discuss options for regional anesthesia or analgesia. Regional anesthesia may be considered when VWF and factor VIII levels are maintained at about 50",
"    <span class=\"nowrap\">",
"     IU/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/112\">",
"     112",
"    </a>",
"    ]. Knowledge of the woman's type of VWD, activity of factor VIII and VWF, current and prior responses to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    , and past bleeding episodes is useful for guiding peripartum therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/4,113\">",
"     4,113",
"    </a>",
"    ]. In one review of 84 pregnancies in 31 women with VWD, miscarriage and primary or secondary postpartum hemorrhage each occurred in approximately 20 percent of pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/112\">",
"     112",
"    </a>",
"    ]. The majority of hemorrhages were in women with factor VIII levels less than 50",
"    <span class=\"nowrap\">",
"     IU/dL",
"    </span>",
"    who did not receive prophylaxis.",
"   </p>",
"   <p>",
"    Low factor VIII appears to be the most important determinant of increased bleeding during delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/107\">",
"     107",
"    </a>",
"    ]. It is generally recommended that factor VIII levels be at or above 50 percent for a cesarean section [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/114\">",
"     114",
"    </a>",
"    ]. Cesarean delivery should be reserved for the usual obstetrical indications; fetal intraventricular hemorrhage due to maternal or fetal VWD is rare [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/115\">",
"     115",
"    </a>",
"    ]. Elective surgical procedures on the newborn (eg, circumcision) should be delayed until the infant's VWD and factor VIII status have been determined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?38/32/39425?source=see_link\">",
"       \"Patient information: von Willebrand disease (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?5/55/6002?source=see_link\">",
"       \"Patient information: von Willebrand disease (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     General concerns",
"    </span>",
"    &nbsp;&mdash;&nbsp;Decisions about therapy begin with an accurate and complete diagnosis of VWD (ie, VWD, type 1,2, or 3, with subgrouping as relevant). Ideally, this should be known or verified before any treatment is given. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Classification'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/8/44169?source=see_link&amp;anchor=H4#H4\">",
"     \"Classification and pathophysiology of von Willebrand disease\", section on 'Mutations in von Willebrand disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The patient's past history of bleeding with various challenges (eg, menses, surgery, pregnancy), response to treatment, general medical condition, and current medications need to be taken into account, especially the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , antiplatelet agents, and nonsteroidal antiinflammatory drugs. Medical illnesses associated with potential alterations in hemostasis or thrombosis should also be reviewed (eg, uremia, ischemic vascular disease). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24794?source=see_link\">",
"     \"Clinical presentation and diagnosis of von Willebrand disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The recommendations given below follow those put forth by the National Heart, Lung and Blood Institute [",
"    <a class=\"abstract\" href=\"UTD.htm?21/22/21866/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Treatment of bleeding in a specific patient with VWD depends on the following variables:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Nature and severity of the type of VWD present",
"     </li>",
"     <li>",
"      Location and severity of the bleeding episode or challenge",
"     </li>",
"     <li>",
"      Response to the treatment of prior bleeding episodes",
"     </li>",
"     <li>",
"      Other medications and illnesses affecting hemostasis",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Trial of DDAVP",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend that a trial of DDAVP be carried out in all type 1 patients, most type 2 patients, but not in type 3 patients at the time of diagnosis or when the patient is not bleeding, in order to assess response prior to its actual need (",
"    <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"     Grade 1C",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    An effective response to DDAVP at approximately 30 to 60 minutes after the infusion is a VWF activity level of at least 30",
"    <span class=\"nowrap\">",
"     IU/dL;",
"    </span>",
"    levels of at least 50",
"    <span class=\"nowrap\">",
"     IU/dL",
"    </span>",
"    are optimal. Once an adequate response is documented, DDAVP can be used for subsequent bleeding episodes or invasive procedures without further therapeutic trials. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Desmopressin'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Minor bleeding and minor surgery",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest the use of IV or intranasal DDAVP as initial treatment of minor bleeding or at the time of minor surgery in patients who have shown a prior response to this agent (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). VWF ristocetin cofactor activity levels should reach at least 30",
"      <span class=\"nowrap\">",
"       IU/dL;",
"      </span>",
"      50",
"      <span class=\"nowrap\">",
"       IU/dL",
"      </span>",
"      is optimal. DDAVP may be used at approximately 12-hour intervals for 2 to 4 doses. Water intake should be decreased to avoid hyponatremia. (",
"      <a class=\"graphic graphic_table graphicRef75956 \" href=\"UTD.htm?13/59/14268\">",
"       table 3",
"      </a>",
"      ), (see",
"      <a class=\"local\" href=\"#H8\">",
"       'Desmopressin'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Bleeding should be followed clinically, and as needed with laboratory monitoring if the expected clinical response is not seen. If the patient continues to have bleeding, we suggest the use of VWF concentrate (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Replacement therapy with VWF'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest the use of antifibrinolytic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      topical therapies to supplement the treatments outlined above (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (",
"      <a class=\"graphic graphic_table graphicRef75956 \" href=\"UTD.htm?13/59/14268\">",
"       table 3",
"      </a>",
"      ), (see",
"      <a class=\"local\" href=\"#H13\">",
"       'Antifibrinolytic therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Topical agents'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Major bleeding and major surgery",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For episodes of major bleeding or major surgical procedures, we recommend that patients be hospitalized at a location where expertise in management of VWD and laboratory monitoring of VWF levels are available (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      We suggest the use of VWF concentrate over DDAVP in order to reach a target level of approximately 100",
"      <span class=\"nowrap\">",
"       IU/dL",
"      </span>",
"      of VWF ristocetin cofactor activity (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). This usually requires an initial dose of 40 to 60 international",
"      <span class=\"nowrap\">",
"       units/kg;",
"      </span>",
"      repeated doses of 20 to 40 international",
"      <span class=\"nowrap\">",
"       units/kg",
"      </span>",
"      should be given approximately every 12 hours to maintain a level between 50 to 100",
"      <span class=\"nowrap\">",
"       IU/dL",
"      </span>",
"      of VWF ristocetin cofactor activity. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Replacement therapy with VWF'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that the above levels of VWF ristocetin cofactor activity be maintained for 7 to 14 days or more as needed (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). When potential sites of bleeding are visible or easily detected, treatment duration may be reduced if bleeding is controlled.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Acquired VWD",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest that patients with acquired VWD who have bleeding or who need surgery receive a trial of DDAVP; levels of VWF activity should be monitored for possible rapid clearance (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      In patients who do not respond adequately to DDAVP, we suggest the use of VWF concentrates in patients with active bleeding or prior to surgery (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      If the patient does not respond to DDAVP, and especially in patients who have documented antibody-mediated acquired VWD, we suggest a trial of high-dose IVIG (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Treatment of acquired VWD'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of the underlying disease should be undertaken if feasible",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Pregnancy and childbirth",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The obstetrician and a hematologist with expertise in the management of VWD should jointly evaluate the patient before or as early in the pregnancy as possible and monitor her throughout the pregnancy and delivery. For delivery, the patient should be hospitalized in a center where VWF and factor VIII levels can be monitored. Caesarean section should be carried out only for the usual obstetrical reasons. Excessive bleeding may occur up to 21 or more days following delivery and should be treated with DDAVP or VWF concentrates as appropriate to the bleeding episode (see",
"      <a class=\"local\" href=\"#H19\">",
"       'Treatment in pregnancy'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      We suggest that VWF ristocetin cofactor activity and factor VIII levels of at least 50",
"      <span class=\"nowrap\">",
"       IU/dL",
"      </span>",
"      be achieved before delivery and maintained for three to five days afterward (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For patients who do not have this degree and length of response on their own or following the use of DDAVP, we suggest the use of VWF concentrates (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      In patients who are known to adequately respond to DDAVP, we suggest that DDAVP be given after the beginning of labor and as close to the time of delivery as can be estimated (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Subsequent doses may be given as suggested above (see",
"      <a class=\"local\" href=\"#H25\">",
"       'Minor bleeding and minor surgery'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      We suggest that regional anesthesia can be considered if VWF and factor VIII levels can be maintained above 50",
"      <span class=\"nowrap\">",
"       IU/dL",
"      </span>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/1\">",
"      Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand's disease. Blood 1987; 69:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/2\">",
"      Sadler JE, Mannucci PM, Berntorp E, et al. Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost 2000; 84:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/3\">",
"      Mannucci PM. How I treat patients with von Willebrand disease. Blood 2001; 97:1915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/4\">",
"      Mannucci PM. Treatment of von Willebrand's Disease. N Engl J Med 2004; 351:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/5\">",
"      Pasi KJ, Collins PW, Keeling DM, et al. Management of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' Organization. Haemophilia 2004; 10:218.",
"     </a>",
"    </li>",
"    <li>",
"     The National Heart, Lung, and Blood Institute. The Evaluation and Management of Von Willebrand Disease, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda 2007. Available at www.nhlbi.nih.gov/guidelines/vwd.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/7\">",
"      Nichols WL, Hultin MB, James AH, et al. von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia 2008; 14:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/8\">",
"      Rodeghiero F, Castaman G, Tosetto A. How I treat von Willebrand disease. Blood 2009; 114:1158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/9\">",
"      Ratnoff OD, Saito H. Letter: Bleeding in von Willebrand's disease. N Engl J Med 1974; 290:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/10\">",
"      Lusher JM. Clinical guidelines for treating von Willebrand disease patients who are not candidates for DDAVP--a survey of European physicians. Haemophilia 1998; 4 Suppl 3:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/11\">",
"      Federici AB, Mannucci PM. Optimizing therapy with factor VIII/von Willebrand factor concentrates in von Willebrand disease. Haemophilia 1998; 4 Suppl 3:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/12\">",
"      Mannucci PM, Ruggeri ZM, Pareti FI, Capitanio A. 1-Deamino-8-d-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrands' diseases. Lancet 1977; 1:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/13\">",
"      Moffat EH, Giddings JC, Bloom AL. The effect of desamino-D-arginine vasopressin (DDAVP) and naloxone infusions on factor VIII and possible endothelial cell (EC) related activities. Br J Haematol 1984; 57:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/14\">",
"      Sutor AH. DDAVP is not a panacea for children with bleeding disorders. Br J Haematol 2000; 108:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/15\">",
"      Aledort LM. Treatment of von Willebrand's disease. Mayo Clin Proc 1991; 66:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/16\">",
"      Michiels JJ, van de Velde A, van Vliet HH, et al. Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: diagnostic and therapeutic implications. Semin Thromb Hemost 2002; 28:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/17\">",
"      Mazurier C, Gaucher C, Jorieux S, Goudemand M. Biological effect of desmopressin in eight patients with type 2N ('Normandy') von Willebrand disease. Collaborative Group. Br J Haematol 1994; 88:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/18\">",
"      Jim&eacute;nez-Yuste V, Prim MP, De Diego JI, et al. Otolaryngologic surgery in children with von Willebrand disease. Arch Otolaryngol Head Neck Surg 2002; 128:1365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/19\">",
"      Witmer CM, Elden L, Butler RB, et al. Incidence of bleeding complications in pediatric patients with type 1 von Willebrand disease undergoing adenotonsillar procedures. J Pediatr 2009; 155:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/20\">",
"      Lethagen S, Ragnarson Tennvall G. Self-treatment with desmopressin intranasal spray in patients with bleeding disorders: effect on bleeding symptoms and socioeconomic factors. Ann Hematol 1993; 66:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/21\">",
"      Amesse LS, Pfaff-Amesse T, Leonardi R, et al. Oral contraceptives and DDAVP nasal spray: patterns of use in managing vWD-associated menorrhagia: a single-institution study. J Pediatr Hematol Oncol 2005; 27:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/22\">",
"      Kouides PA, Byams VR, Philipp CS, et al. Multisite management study of menorrhagia with abnormal laboratory haemostasis: a prospective crossover study of intranasal desmopressin and oral tranexamic acid. Br J Haematol 2009; 145:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/23\">",
"      Lethagen S, Harris AS, Sj&ouml;rin E, Nilsson IM. Intranasal and intravenous administration of desmopressin: effect on F VIII/vWF, pharmacokinetics and reproducibility. Thromb Haemost 1987; 58:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/24\">",
"      Dunn AL, Powers JR, Ribeiro MJ, et al. Adverse events during use of intranasal desmopressin acetate for haemophilia A and von Willebrand disease: a case report and review of 40 patients. Haemophilia 2000; 6:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/25\">",
"      Byrnes JJ, Larcada A, Moake JL. Thrombosis following desmopressin for uremic bleeding. Am J Hematol 1988; 28:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/26\">",
"      Mannucci PM, Lusher JM. Desmopressin and thrombosis. Lancet 1989; 2:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/27\">",
"      Mannucci PM, Bettega D, Cattaneo M. Patterns of development of tachyphylaxis in patients with haemophilia and von Willebrand disease after repeated doses of desmopressin (DDAVP). Br J Haematol 1992; 82:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/28\">",
"      Shepherd LL, Hutchinson RJ, Worden EK, et al. Hyponatremia and seizures after intravenous administration of desmopressin acetate for surgical hemostasis. J Pediatr 1989; 114:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/29\">",
"      Gomez Garc&iacute;a EB, Ruitenberg A, Madretsma GS, Hintzen RQ. Hyponatraemic coma induced by desmopressin and ibuprofen in a woman with von Willebrand's disease. Haemophilia 2003; 9:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/30\">",
"      Mannucci PM. Treatment of von Willebrand disease. Haemophilia 1998; 4:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/31\">",
"      Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada. CMAJ 1995; 153:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/32\">",
"      Federici AB, Mazurier C, Berntorp E, et al. Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: results of a multicenter European study. Blood 2004; 103:2032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/33\">",
"      Castaman G, Lethagen S, Federici AB, et al. Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD. Blood 2008; 111:3531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/34\">",
"      Federici AB, Berntorp E, Lee CA, et al. A standard trial infusion with desmopressin is always required before factor VIII/von Willebrand factor concentrates in severe type 1 and 2 von Willebrand disease: Results of a multicenter European study (abstract). Thromb Haemost 1999; (Suppl):795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/35\">",
"      Castaman G, Tosetto A, Federici AB, Rodeghiero F. Bleeding tendency and efficacy of anti-haemorrhagic treatments in patients with type 1 von Willebrand disease and increased von Willebrand factor clearance. Thromb Haemost 2011; 105:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/36\">",
"      Mannucci PM, Lombardi R, Bader R, et al. Heterogeneity of type I von Willebrand disease: evidence for a subgroup with an abnormal von Willebrand factor. Blood 1985; 66:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/37\">",
"      Fressinaud E, Federici AB, Castaman G, et al. The role of platelet von Willebrand factor in platelet adhesion and thrombus formation: a study of 34 patients with various subtypes of type I von Willebrand disease. Br J Haematol 1994; 86:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/38\">",
"      Gralnick HR, Williams SB, McKeown LP, et al. DDAVP in type IIa von Willebrand's disease. Blood 1986; 67:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/39\">",
"      Batlle J, Lopez Fernandez MF, Campos M, et al. The heterogeneity of type IIA von Willebrand's disease: studies with protease inhibitors. Blood 1986; 68:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/40\">",
"      Holmberg L, Nilsson IM, Borge L, et al. Platelet aggregation induced by 1-desamino-8-D-arginine vasopressin (DDAVP) in Type IIB von Willebrand's disease. N Engl J Med 1983; 309:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/41\">",
"      McKeown LP, Connaghan G, Wilson O, et al. 1-Desamino-8-arginine-vasopressin corrects the hemostatic defects in type 2B von Willebrand's disease. Am J Hematol 1996; 51:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/42\">",
"      Casonato A, Steffan A, Pontara E, et al. Post-DDAVP thrombocytopenia in type 2B von Willebrand disease is not associated with platelet consumption: failure to demonstrate glycocalicin increase or platelet activation. Thromb Haemost 1999; 81:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/43\">",
"      Mauz-K&ouml;rholz C, Budde U, Kruck H, et al. Management of severe chronic thrombocytopenia in von Willebrand's disease type 2B. Arch Dis Child 1998; 78:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/44\">",
"      Casonato A, Pontara E, Dannhaeuser D, et al. Re-evaluation of the therapeutic efficacy of DDAVP in type IIB von Willebrand's disease. Blood Coagul Fibrinolysis 1994; 5:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/45\">",
"      Weiss HJ, Meyer D, Rabinowitz R, et al. Pseudo-von Willebrand's disease. An intrinsic platelet defect with aggregation by unmodified human factor VIII/von Willebrand factor and enhanced adsorption of its high-molecular-weight multimers. N Engl J Med 1982; 306:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/46\">",
"      Miller JL, Castella A. Platelet-type von Willebrand's disease: characterization of a new bleeding disorder. Blood 1982; 60:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/47\">",
"      Othman M, Notley C, Lavender FL, et al. Identification and functional characterization of a novel 27-bp deletion in the macroglycopeptide-coding region of the GPIBA gene resulting in platelet-type von Willebrand disease. Blood 2005; 105:4330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/48\">",
"      Miller JL. Platelet-type von Willebrand disease. Thromb Haemost 1996; 75:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/49\">",
"      Mauz-K&ouml;rholz C, Budde U, K&ouml;rholz D, G&ouml;bel U. DDAVP treatment in a child with von Willebrand disease type 2M. Eur J Pediatr 1999; 158 Suppl 3:S174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/50\">",
"      Nishino M, Nishino S, Sugimoto M, et al. Changes in factor VIII binding capacity of von Willebrand factor and factor VIII coagulant activity in two patients with type 2N von Willebrand disease after hemostatic treatment and during pregnancy. Int J Hematol 1996; 64:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/51\">",
"      Berntorp E, Petrini P. Long-term prophylaxis in von Willebrand disease. Blood Coagul Fibrinolysis 2005; 16 Suppl 1:S23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/52\">",
"      Halimeh S, Kr&uuml;mpel A, Rott H, et al. Long-term secondary prophylaxis in children, adolescents and young adults with von Willebrand disease. Results of a cohort study. Thromb Haemost 2011; 105:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/53\">",
"      Berntorp E, de Moerloose P, Ljung RC. The role of prophylaxis in bleeding disorders. Haemophilia 2010; 16 Suppl 5:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/54\">",
"      Chang AC, Rick ME, Ross Pierce L, Weinstein MJ. Summary of a workshop on potency and dosage of von Willebrand factor concentrates. Haemophilia 1998; 4 Suppl 3:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/55\">",
"      Pomper GJ, Rick ME, Epstein JS, et al. Management of severe VWD with cryoprecipitate collected by repeated apheresis of a single dedicated donor. Transfusion 2003; 43:1514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/56\">",
"      Lillicrap D, Poon MC, Walker I, et al. Efficacy and safety of the factor VIII/von Willebrand factor concentrate, haemate-P/humate-P: ristocetin cofactor unit dosing in patients with von Willebrand disease. Thromb Haemost 2002; 87:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/57\">",
"      Rivard GE, Aledort L, Alphanate Surgical Investigators. Efficacy of factor VIII/von Willebrand factor concentrate Alphanate in preventing excessive bleeding during surgery in subjects with von Willebrand disease. Haemophilia 2008; 14:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/58\">",
"      Mannucci PM, Chediak J, Hanna W, et al. Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: a prospective, multicenter study. Blood 2002; 99:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/59\">",
"      Berntorp E, Windyga J, European Wilate Study Group. Treatment and prevention of acute bleedings in von Willebrand disease--efficacy and safety of Wilate, a new generation von Willebrand factor/factor VIII concentrate. Haemophilia 2009; 15:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/60\">",
"      Windyga J, von Depka-Prondzinski M, European Wilate&reg; Study Group. Efficacy and safety of a new generation von Willebrand factor/factor VIII concentrate (Wilate&reg;) in the management of perioperative haemostasis in von Willebrand disease patients undergoing surgery. Thromb Haemost 2011; 105:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/61\">",
"      Pasi KJ, Williams MD, Enayat MS, Hill FG. Clinical and laboratory evaluation of the treatment of von Willebrand's disease patients with heat-treated factor VIII concentrate (BPL 8Y). Br J Haematol 1990; 75:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/62\">",
"      Goudemand J, Negrier C, Ounnoughene N, Sultan Y. Clinical management of patients with von Willebrand's disease with a VHP vWF concentrate: the French experience. Haemophilia 1998; 4 Suppl 3:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/63\">",
"      Mazurier C. In vitro evaluation of the haemostatic value of the LFB-von Willebrand factor concentrate. Haemophilia 1998; 4 Suppl 3:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/64\">",
"      Menache D. Pharmacokinetics of von Willebrand factor and factor VIII coagulant activity in patients with von Willebrand disease type 3 and type 2. Haemophilia 1998; 4 Suppl 3:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/65\">",
"      Turecek PL, Gritsch H, Pichler L, et al. In vivo characterization of recombinant von Willebrand factor in dogs with von Willebrand disease. Blood 1997; 90:3555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/66\">",
"      Schwarz HP, Dorner F, Mitterer A, et al. Evaluation of recombinant von Willebrand factor in a canine model of von Willebrand disease. Haemophilia 1998; 4 Suppl 3:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/67\">",
"      Scott JP, Montgomery RR. Therapy of von Willebrand disease. Semin Thromb Hemost 1993; 19:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/68\">",
"      Mannucci PM. Treatment of von Willebrand's disease. J Intern Med Suppl 1997; 740:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/69\">",
"      Castillo R, Escolar G, Monteagudo J, et al. Hemostasis in patients with severe von Willebrand disease improves after normal platelet transfusion and normalizes with further correction of the plasma defect. Transfusion 1997; 37:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/70\">",
"      Makris M, Colvin B, Gupta V, et al. Venous thrombosis following the use of intermediate purity FVIII concentrate to treat patients with von Willebrand's disease. Thromb Haemost 2002; 88:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/71\">",
"      Mannucci PM. Venous thromboembolism in von Willebrand disease. Thromb Haemost 2002; 88:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/72\">",
"      Varon D, Martinowitz U. Continuous infusion therapy in haemophilia. Haemophilia 1998; 4:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/73\">",
"      Lubetsky A, Schulman S, Varon D, et al. Safety and efficacy of continuous infusion of a combined factor VIII-von Willebrand factor (vWF) concentrate (Haemate-P) in patients with von Willebrand disease. Thromb Haemost 1999; 81:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/74\">",
"      Fressinaud E, Veyradier A, Sigaud M, et al. Therapeutic monitoring of von Willebrand disease: interest and limits of a platelet function analyser at high shear rates. Br J Haematol 1999; 106:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/75\">",
"      Meskal A, Vertessen F, Van der Planken M, Berneman ZN. The platelet function analyzer (PFA-100) may not be suitable for monitoring the therapeutic efficiency of von willebrand concentrate in type III von willebrand disease. Ann Hematol 1999; 78:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/76\">",
"      Ortel TL, Charles LA, Keller FG, et al. Topical thrombin and acquired coagulation factor inhibitors: clinical spectrum and laboratory diagnosis. Am J Hematol 1994; 45:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/77\">",
"      Alperin JB. Estrogens and surgery in women with von Willebrand's disease. Am J Med 1982; 73:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/78\">",
"      Harrison RL, McKee PA. Estrogen stimulates von Willebrand factor production by cultured endothelial cells. Blood 1984; 63:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/79\">",
"      Bailar J. Hormone-replacement therapy and cardiovascular diseases. N Engl J Med 2003; 349:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/80\">",
"      Ciavarella N, Schiavoni M, Valenzano E, et al. Use of recombinant factor VIIa (NovoSeven) in the treatment of two patients with type III von Willebrand's disease and an inhibitor against von Willebrand factor. Haemostasis 1996; 26 Suppl 1:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/81\">",
"      Grossmann RE, Geisen U, Schwender S, Keller F. Continuous infusion of recombinant factor VIIa (NovoSeven) in the treatment of a patient with type III von Willebrand's disease and alloantibodies against von Willebrand factor. Thromb Haemost 2000; 83:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/82\">",
"      Tengborn L, Petruson B. A patient with Glanzmann thrombasthenia and epistaxis successfully treated with recombinant factor VIIa. Thromb Haemost 1996; 75:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/83\">",
"      Peters M, Heijboer H. Treatment of a patient with Bernard-Soulier syndrome and recurrent nosebleeds with recombinant factor VIIa. Thromb Haemost 1998; 80:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/84\">",
"      Lisman T, Adelmeijer J, Heijnen HF, de Groot PG. Recombinant factor VIIa restores aggregation of alphaIIbbeta3-deficient platelets via tissue factor-independent fibrin generation. Blood 2004; 103:1720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/85\">",
"      Basso IN, Keeling D. Myocardial infarction following recombinant activated factor VII in a patient with type 2A von Willebrand disease. Blood Coagul Fibrinolysis 2004; 15:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/86\">",
"      Veyradier A, Jenkins CS, Fressinaud E, Meyer D. Acquired von Willebrand syndrome: from pathophysiology to management. Thromb Haemost 2000; 84:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/87\">",
"      Federici AB, Rand JH, Bucciarelli P, et al. Acquired von Willebrand syndrome: data from an international registry. Thromb Haemost 2000; 84:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/88\">",
"      Kumar S, Pruthi RK, Nichols WL. Acquired von Willebrand disease. Mayo Clin Proc 2002; 77:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/89\">",
"      Mohri H. Acquired von Willebrand syndrome: features and management. Am J Hematol 2006; 81:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/90\">",
"      Luboshitz J, Lubetsky A, Schliamser L, et al. Pharmacokinetic studies with FVIII/von Willebrand factor concentrate can be a diagnostic tool to distinguish between subgroups of patients with acquired von Willebrand syndrome. Thromb Haemost 2001; 85:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/91\">",
"      Federici AB, Stabile F, Castaman G, et al. Treatment of acquired von Willebrand syndrome in patients with monoclonal gammopathy of uncertain significance: comparison of three different therapeutic approaches. Blood 1998; 92:2707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/92\">",
"      Tefferi A, Hanson CA, Kurtin PJ, et al. Acquired von Willebrand's disease due to aberrant expression of platelet glycoprotein Ib by marginal zone lymphoma cells. Br J Haematol 1997; 96:850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/93\">",
"      Vincentelli A, Susen S, Le Tourneau T, et al. Acquired von Willebrand syndrome in aortic stenosis. N Engl J Med 2003; 349:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/94\">",
"      Tiede A, Rand JH, Budde U, et al. How I treat the acquired von Willebrand syndrome. Blood 2011; 117:6777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/95\">",
"      Mohri H, Motomura S, Kanamori H, et al. Clinical significance of inhibitors in acquired von Willebrand syndrome. Blood 1998; 91:3623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/96\">",
"      van Genderen PJ, Terpstra W, Michiels JJ, et al. High-dose intravenous immunoglobulin delays clearance of von Willebrand factor in acquired von Willebrand disease. Thromb Haemost 1995; 73:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/97\">",
"      Viallard JF, Pellegrin JL, Vergnes C, et al. Three cases of acquired von Willebrand disease associated with systemic lupus erythematosus. Br J Haematol 1999; 105:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/98\">",
"      Sampson B, Anderson DR, Dugal M, et al. Acquired type 2a von Willebrand's disease: response to immunoglobulin infusion. Haemostasis 1997; 27:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/99\">",
"      Friederich PW, Wever PC, Bri&euml;t E, et al. Successful treatment with recombinant factor VIIa of therapy-resistant severe bleeding in a patient with acquired von Willebrand disease. Am J Hematol 2001; 66:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/100\">",
"      Smaradottir A, Bona R. A case of acquired von Willebrand syndrome successfully treated with recombinant Factor VIIa during thyroidectomy. Thromb Haemost 2004; 92:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/101\">",
"      Franchini M, Veneri D, Lippi G. The use of recombinant activated factor VII in congenital and acquired von Willebrand disease. Blood Coagul Fibrinolysis 2006; 17:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/102\">",
"      Petitti DB. Clinical practice. Combination estrogen-progestin oral contraceptives. N Engl J Med 2003; 349:1443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/103\">",
"      Davis A, Godwin A, Lippman J, et al. Triphasic norgestimate-ethinyl estradiol for treating dysfunctional uterine bleeding. Obstet Gynecol 2000; 96:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/104\">",
"      Rubin G, Wortman M, Kouides PA. Endometrial ablation for von Willebrand disease-related menorrhagia--experience with seven cases. Haemophilia 2004; 10:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/105\">",
"      Kaunitz AM, Meredith S, Inki P, et al. Levonorgestrel-releasing intrauterine system and endometrial ablation in heavy menstrual bleeding: a systematic review and meta-analysis. Obstet Gynecol 2009; 113:1104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/106\">",
"      Huq FY, Al-Haderi M, Kadir RA. The outcome of endometrial ablation in women with inherited bleeding disorders. Haemophilia 2012; 18:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/107\">",
"      Conti M, Mari D, Conti E, et al. Pregnancy in women with different types of von Willebrand disease. Obstet Gynecol 1986; 68:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/108\">",
"      Rick ME, Williams SB, Sacher RA, McKeown LP. Thrombocytopenia associated with pregnancy in a patient with type IIB von Willebrand's disease. Blood 1987; 69:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/109\">",
"      Pacheco LD, Costantine MM, Saade GR, et al. von Willebrand disease and pregnancy: a practical approach for the diagnosis and treatment. Am J Obstet Gynecol 2010; 203:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/110\">",
"      Walker ID, Walker JJ, Colvin BT, et al. Investigation and management of haemorrhagic disorders in pregnancy. Haemostasis and Thrombosis Task Force. J Clin Pathol 1994; 47:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/111\">",
"      Ito M, Yoshimura K, Toyoda N, Wada H. Pregnancy and delivery in patients with von Willebrand's disease. J Obstet Gynaecol Res 1997; 23:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/112\">",
"      Kadir RA, Lee CA, Sabin CA, et al. Pregnancy in women with von Willebrand's disease or factor XI deficiency. Br J Obstet Gynaecol 1998; 105:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/113\">",
"      Castaman G, Tosetto A, Rodeghiero F. Pregnancy and delivery in women with von Willebrand's disease and different von Willebrand factor mutations. Haematologica 2010; 95:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/114\">",
"      Depret-Mosser S, Marey A, Parquet-Gernez A, et al. [Willebrand's disease and pregnancy. Fifteen cases]. J Gynecol Obstet Biol Reprod (Paris) 1996; 25:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/22/21866/abstract/115\">",
"      Mullaart RA, Van Dongen P, Gabre&euml;ls FJ, van Oostrom C. Fetal periventricular hemorrhage in von Willebrand's disease: short review and first case presentation. Am J Perinatol 1991; 8:190.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1372 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-217.117.136.88-F836DB8729-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_22_21866=[""].join("\n");
var outline_f21_22_21866=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Type 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Type 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Type 3",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      GENERAL CONSIDERATIONS OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      INHERITED VWD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Desmopressin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Responses according to VWD type",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Replacement therapy with VWF",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18189762\">",
"      - Short-term replacement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18189769\">",
"      - Prophylaxis with VWF",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Preparations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Summary for replacement VWF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Antifibrinolytic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Topical agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Estrogen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Recombinant Factor VIIa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      TREATMENT OF ACQUIRED VWD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      TREATMENT OF EXCESSIVE MENSTRUAL BLEEDING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      TREATMENT IN PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      General concerns",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Trial of DDAVP",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Minor bleeding and minor surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Major bleeding and major surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Acquired VWD",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Pregnancy and childbirth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/1372\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/1372|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/14/5356\" title=\"table 1\">",
"      Classification of VWD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/43/2748\" title=\"table 2\">",
"      Features of bleeding disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/59/14268\" title=\"table 3\">",
"      Treatment of VWD",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/41/17049?source=related_link\">",
"      Biology and normal function of von Willebrand factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/8/44169?source=related_link\">",
"      Classification and pathophysiology of von Willebrand disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/6/20586?source=related_link\">",
"      Clinical and laboratory aspects of platelet transfusion therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21706?source=related_link\">",
"      Clinical features and evaluation of aortic stenosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24794?source=related_link\">",
"      Clinical presentation and diagnosis of von Willebrand disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/36/4682?source=related_link\">",
"      Clinical use of coagulation tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/33/9752?source=related_link\">",
"      Clinical use of plasma components",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/9/29850?source=related_link\">",
"      Congenital and acquired disorders of platelet function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25094?source=related_link\">",
"      Fibrin sealant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=related_link\">",
"      Overview of the causes of venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?5/55/6002?source=related_link\">",
"      Patient information: von Willebrand disease (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?38/32/39425?source=related_link\">",
"      Patient information: von Willebrand disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/59/23482?source=related_link\">",
"      Platelet function testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=related_link\">",
"      Postmenopausal hormone therapy: Benefits and risks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/39/11895?source=related_link\">",
"      Preparation of blood components",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/28/32202?source=related_link\">",
"      Prognosis and treatment of essential thrombocythemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/13/31962?source=related_link\">",
"      Therapeutic uses of recombinant coagulation factor VIIa",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_22_21867="Pregnancy lipoprotein levels";
var content_f21_22_21867=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F59609&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F59609&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Approximate average lipoprotein concentrations in 19 healthy women",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Type of lipoprotein",
"      </td>",
"      <td class=\"subtitle1\">",
"       Nonpregnant*",
"      </td>",
"      <td class=\"subtitle1\">",
"       Early pregnancy*",
"      </td>",
"      <td class=\"subtitle1\">",
"       Late pregnancy*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Total triglycerides",
"      </td>",
"      <td>",
"       60",
"      </td>",
"      <td>",
"       75 to 100",
"      </td>",
"      <td>",
"       210",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Total cholesterol",
"      </td>",
"      <td>",
"       170",
"      </td>",
"      <td>",
"       175 to 200",
"      </td>",
"      <td>",
"       250",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       VLDL cholesterol",
"      </td>",
"      <td>",
"       10",
"      </td>",
"      <td>",
"       10",
"      </td>",
"      <td>",
"       25",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       LDL cholesterol",
"      </td>",
"      <td>",
"       105",
"      </td>",
"      <td>",
"       100 to 125",
"      </td>",
"      <td>",
"       150",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       HDL cholesterol",
"      </td>",
"      <td>",
"       55",
"      </td>",
"      <td>",
"       55 to 75",
"      </td>",
"      <td>",
"       65",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Units are mg/dL; divide cholesterol values by 38.5 and triglycerides by 88.6 to convert to mmol/L.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Fahraeus, L, Larsson-Cohn, U, Wallentin, L. Obstet Gynecol 1985; 66:468.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_22_21867=[""].join("\n");
var outline_f21_22_21867=null;
var title_f21_22_21868="ACC AHA choice imaging CHD diagnosis unable to exercise";
var content_f21_22_21868=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F61603&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F61603&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommendations for cardiac stress imaging as the initial test for diagnosis of coronary heart disease (CHD) in patients with chronic stable angina who are unable to exercise",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Class I",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       1. Adenosine or dipyridamole myocardial perfusion imaging or dobutamine echocardiography in patients with an intermediate pretest probability of CAD.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       2. Adenosine or dipyridamole stress myocardial perfusion imaging or dobutamine echocardiography in patients with prior revascularization (either PTCA or CABG).",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Class IIb",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       1. Adenosine or dipyridamole stress myocardial perfusion imaging or dobutamine echocardiography in patients with a low or high probability of CAD in the absence of electronically paced ventricular rhythm or left bundle-branch block.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2_start\">",
"       2. Adenosine or dipyridamole myocardial perfusion imaging in patients with a low or a high probability of CAD and one of the following baseline ECG abnormalities",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       a. Electronically paced ventricular rhythm",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       b. Left bundle-branch block",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       ACC/AHA classification",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Class I:",
"       </strong>",
"       Conditions for which there is evidence and/or general agreement that a given procedure or treatment is useful and effective.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       <strong>",
"        Class II:",
"       </strong>",
"       Conditions for which there is conflicting evidence and/or a divergence of opinion about the usefulness/efficacy of a procedure or treatment.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       <strong>",
"        Class IIa:",
"       </strong>",
"       Weight of evidence/opinion is in favor of usefulness/efficacy.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       <strong>",
"        Class IIb:",
"       </strong>",
"       Usefulness/efficacy less well established by evidence/opinion.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Class III:",
"       </strong>",
"       Conditions for which there is evidence and/or general agreement that the procedure/treatment is not useful and in some cases may be harmful.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data modified from: Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina). Circulation 2003; 107:149.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_22_21868=[""].join("\n");
var outline_f21_22_21868=null;
var title_f21_22_21869="Uric acid pathways";
var content_f21_22_21869=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F79178&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F79178&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Endogenous production of uric acid",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 221px; height: 251px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Purine catabolism results in the production of hypoxanthine and xanthine, which are metabolized to uric acid via the enzymatic action of xanthine oxidase (XO). This pathway can be blocked by the use of allopurinol, a hypoxanthine analog that competitively inhibits XO. After about two to three days, allopurinol therapy results in increased excretion of both hypoxanthine, which is more soluble than uric acid, and xanthine, which is less soluble than uric acid. A marked increase in xanthine excretion can occur when allopurinol is given for prevention of tumor lysis syndrome and may lead to acute renal failure or xanthine stones. Preformed uric acid is not altered by allopurinol. Urate oxidase (UO), present in most mammals, but not humans, oxidizes preformed uric acid to allantoin, which is 5 to 10 times more soluble than uric acid in acid urine. When exogenous urate oxidase (uricase, rasburicase) is administered, serum and urinary uric acid levels decrease markedly within approximately four hours.",
"    <div class=\"footnotes\">",
"     * Urate oxidase (UO) is not normally present in humans.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_22_21869=[""].join("\n");
var outline_f21_22_21869=null;
var title_f21_22_21870="Pulmonary LAM lung biopsy Low";
var content_f21_22_21870=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F64389&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F64389&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gross features of pulmonary lymphangioleiomyomatosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 206px; height: 242px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADyAM4DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDxTxL/AMjJqv8A19zf+hms3tWn4k48Rar/ANfc3/oZrP6jNakidaQrxTgD2pOgoEIc7aMU4Z9KQgdjQAw98008/SnsMGmjnAx+FACBiucEjPFLBFJPIsdujSSNwFUZJrtfC/hyGOL7ZqyAs33IGPb1Ndnbw2tgUuILOFXA2nAAOKzlPlVy4x5nY8403wbqd4GMy/ZlHTeMmrMvgS+SElbmF5s/LH0yPrXon9ppIMLgY6ioZbwFsL0/UVi60uh0Kgup5DfaXe2CK15btErHaCe9UTXsF7a2epIY75fMX+EHtXDap4Qvobh/7PjNzbgbt3AI9q0hVT3M50XHVHL04Ch1KOyOCrrwVYYIoBHbpWpiKOKfkUzilHNADgeaOh5oGKSmA4Y5pR0pBmlFIBRjvRj2pTilGMd80AIcn3rtvhKP+Kjuf+vRv/Q0rifzrtvhJ/yMdz/16N/6GlDBHN+JR/xUWq/9fcv/AKGazenStPxJn/hIdU/6+5f/AEM1ndu9MQgoozSE+lAAc5puOc0HpyaQdTmgA781s+FbJL3VYw0qKU+YK38R9BWN1p9u8kc8bwMyyg/KV6g0nqhnt9nZWit5l3CRJj5ZGOQT/SsbVJZTciRBwG2kDnir3hTUp7jSVi1c+ZMP4lXr9feq10UWSVosqrdq5G3ezOqnHS5nvMrSH5MPjBfsahM5AxGTvxznvUNxGzMDHkfU0797E4wASe5osa3sSR3YAAdtr9Nuat2l0Tgrk4PWq0dhP5+WjLK3cj+VWIbKWPcBG4Qc9KTSBSHXWn6bqUhkubWEu3LSdCaxtV8IwXt351pcJbxY2mNVzz61uT2tysAcRNs7PtOKhCuoBLgYHQU4tx2YpRjLocZc+D9UiLG28m4jB6q+D+VYNxDLbztHOjJIvVTXpbzFZAeR9Kh1LSrLV4gbjMc4GFmXqv1HcVrGo/tGMqPWJ5wDnjinAZq/rei3WjSgXBSSJvuSxnKt/hWcprZO5g9By8UuewpBS9vpQIcOtLj0pBThmgBCMV23wjH/ABUdz/16N/6GlcXXa/CP/kY7n/r0b/0NKGBzXiMf8VBqn/X3L/6Gazj7Vo+Iz/xUGqf9fc3/AKGazs0xDcUGjOKfbwy3MojgjeWQ9FQZNAER5ppFX5tLv4jiSxuVP/XM1r+GfDkt/db76N4LKPly4wWPoKTaRSTexh6fp91qFwIrKF5HPccAfU133h/wM1vsubmaN505KY+Vfx7mt61urawAjtLYIgGMBcVf/tppAUEcaccDFYupobKiyeFLAWDRRS7JBjJPA/OueureYyssDpMPUGrckKXxYyyAKf8Almg25pYNKfTQJIlYxOcAselYuV3c6EuVWMK5mtoG8q4dTL/EAelTRWzybHt1aVcfKF7Cs++0PT4r/bdamIZJmJw6EAfjUfi2/wBQ8Pada2Vizi3bLG6Tnd7ZFUtdEQ3bVnSJqM9rF5UibcdscirkWsQToEnRzg8gHGa5bwhfTanpDvqJJZX2xyvwWHfr1rUuPIVALacM4PII60pRs7McWnqdvaa0ktrL5ojS2ijydx4ArgtTvre8meaw2NGTghegqfz8QPHMNyMMMh6EVSitURT9ihWOEc4oTBRS1RBHvkblSy9znGKkt7eRm/dyfJ+tSW9q8sbuzqH9AcZrV0+FYlErxkY4J7U2xoz7vRl1Kxa3ulcJ1DqOVPrXnGsaZcaTetBcr7q3Zh617C73D5IkjEQOUC8HHv61T1/R4NY07ZJjK8xyA8qff2ohU5XZ7ETp86utzx9TyfSnA81b1XSrvSrjy7pMKfuyD7rfQ1UHSuq9zltYkRSQTnGKAeKaPenj9aBC44rtvhLx4kuR/wBOjf8AoaVxBz0rt/hIP+Kkuf8Ar0b/ANDShgc14jH/ABUGqf8AX3N/6GazSQBk1qeIB/xUGqf9fc3/AKGag0ywl1G+itocb3Pc44p7IW7GWGnXWoy+XaQtI3cgcD6mvSPD+jJoEAeIo9y4HmykdPYVY03TIdHjNnb5y3Lux61c3wwFi0gZsfhXLUm5aLY6KdO25J/aAkfETs0gqnfXEsmROxXHOMYqa8uovs9uYEVXPXb2NVZrtZD/AKSPMwMZBxis7G60KqTy3DrDaFG3cZPWnQuiuxZxIEO1ip4BpVG5jLApRxxuFQ6jMPsUlpJEjxyfMSvB3fX1qkkLmZ0GhXljFLudAWU8bx0qHUk+zajcXM14ZYJPmRORt9qw9OylsDHJiRRyrDJxVq9ja/spF84xSY69cUtUxtJ6le5k0vX7dre6Z8g/KR1U1p2Fi1lp0VtuN5ar/fUN+hrg49I1C2vYyVkKq2SQeMV01hrAgvHhjuUaZj/qhyAPc03HsJO+6Jb1R5vmGIpGOiEYCj+QqDyVdvMRe3YVuweReMVniKgnDKDkGqfi7w7LO1oNL1KKDHLxyNtJFC1Buxj+XdBVdW2L3Vh1/GpVlZWkjjcPIBhwO3tVyDSZIEEdxI02zrtOc/St6DRYxpX2u0ts3Z6RSNj8TTbsBgaehaeMbF24yM9q6KWSJIAF2ykjlR/Os0W8tshacJG7csqnIWo3d9oji6HuBWctTRIrX9zYW03kvcP9pb7qgfKPqaVLkxQlc5IOTijUNNRmXzYxIqYKsRzVSdXUtgbG7Adx61Ss0DbTJnmju1ZbhUa3HVZFzk+1cF4osrayv1FmjxxSLu2NztNdDrkkyPb4LBAchvenTWlprUEcWoXPl3K/6uRRyfarg+Uwqq5wqnmpRS3ls1peSwPkFGxk96QA10I5mKenau1+En/Ix3PX/j0b/wBDSuK+tdr8JD/xUdz/ANejf+hpTYjnPEJ/4qHVP+vub/0M1J4bYJrEDEd6i8Qf8jDqn/X3N/6GarW87W8qOvUH1pvYE9T2CKO3khH2tvmx68YqCeCNSPK2tERjK9q5S11Zp4kKynpgg1K2vrZhg8qgj8f0rl5Xc61NWNie2ZPmC8dsVBHJCC63ByAfueprJj8a7vlk8mSPP3SpU/nQPFln5u4W0KEdSx3Ucsg9pGxsubi6ixGhSMDoorPzJCrLIPMGflfoVPvVNvGivNHscoEbPC4BHpW3a634avZcXFwYpX5ZX+7+dVytE86ZSN0xBRpd7DuO/wBaLPUJFl8ok/NxuzWpe6Vp9x+80S6hmGOUEgJFUEsTC6mW1fKgjdg5z7VNi0ydEAlI81mX+IE5Kn/CpUgto5d0MMat/FIeprOhgltpgXhkVX65BGasxgTXfBAA6AUho02YQqGDBs8qV/rU6XJuIt0ixAxLhXZeR7VVS1kEjyZfBxhStDwSuSCUjOeVLAGlsXZPcQ3EuS0fyv6+tXLDUZ1RhIODwcmq8k1rHAUmkgjIH3t+TWOutaVYuxM8k7noo6fnRa4cyRp3rma4Pk7iueF7U51kiT5mG7PRR0rHbxfZFuLfaQezVl6r41bc32SNFzx6mhQkL2sVqdVcXBaHcybX6bh3FZMshd2Ykkjoa5Kz8VXcMxZ2ZgTnk5ret/EWn3qgXS4b1XjNVyNE+1UieVkEYiuIt8bHII7H2q5Z2cEMiS+V5jAZBk7VJaXWktBgOwOcjParKzWaqRJOX3DAUfw1LRWjOQ8cWYW7hvl3ATDay+hFc1zXYeNZleztY1cFVOQO9cfit6fwnJUspC5yOa7b4R8+I7n/AK9G/wDQ0riCfSu2+Ef/ACMlz/16N/6GlWzM5zX8f8JBqh/6e5v/AEM1Sxnmrmv/APIwap6fa5v/AEM1VjXI4q0SyOWRwmxWYL1wKr45J7+9X2izxioWtyORSC5WOKbgdqsGE96YY8UDuQ4ppA9KmZKhPXFADo5XhOYneM+qHFaNr4h1e2XEGoTBR/eO6sk9aTNK1xps6kePfEIhCPdRS44DPECRSR+PdaiA2C0Df3vJGT71y2aQ0uVFczL0+sajPctPJezmVjkkORUL3l05O+eRiepLE1W/WlBosguS/aJtu3zHxTCXYZYk/U0nenKaYmxME0Ac06lAoC4zHNOAwcjrS4oP0oEaFjqtxa5AEcg6YkXOKtx67cZyYouOmKxR2p8XB4pOKKUmi3cXEt1MXlbnsvYVHtOMGmg1IpyKdhNiFcV2vwjH/FR3Of8An0b/ANDSuLY8c12nwk/5GS5/69G/9DShiOb17nX9T/6+5v8A0M1Xt+DU+vD/AIqDUz/09zf+hmq8Q71SJZYHXPenEDHSoyCO1PU8DnigkZIB9ahZMDIqZzk8dKY3oKQypJnNQOKuOv51Ay4z1oGVnXA4qJs1ZWJ5GCopZvQCt3T/AA49wimRZCx6BRSvYpK5zKqWbCgsx7AZqza2NxcyFI4yCOu4Yr0rRPDiWRJEC7gOWPLVqxWcKNG7QKGB4qJTsaxptnAW/g6YxCS5kCBumOtVdR8L3FvCZreUTKOoxg16PdIJd3mdBwM1HFs8tlcA4HT1rL2jNXSR43yGIYEMOxpQa7/XtCgvBmJBFKOd4H8xXFahp9xp8gW4QgH7rDoa2jNSMZQcSAU4GmL9aeFzVGYo60U4Lg4qQICKAIR9KkQYJNO8vmnBMUAA5FOXrzQq496cFxQAp6Gu0+En/IyXP/Xo3/oaVxefau0+Ev8AyMdzn/n0b/0NKGBzevEnXdT6/wDH3N/6GarJgetWNbP/ABP9T5/5e5v/AEM1VH6VSEyfOTwadn8aaudoxQxOOKCRshw2RUZozg5NMLcnFAxG74pI4mlcImSx4qzZWVzfSBLaF3JOM44r0Lwz4YjsoTNeYz3JHJ9hUt2KjFyZj+HPC8jjfINo6kk9a6uERW1sUtchxxvPb6VoPcReUIkjKqO3T86l0zSY5i08xZY1BPI6/SueVW7tE7I0lFXkY8c3lIzzuxXrnvUyywy2qPDKrknnnkfWrl3Yr9nEsbfu2ztJXH5is1IIxcSSooDsADtGFP4Vle5skS28aOwM3+rzgnPemahbxLJiHGB0Yc5HvReb/LVEbCt/EKrQgeTvDEjdg00DS3HHT5mAcbSvYk4NVL6xF/atbzpGc+3Ste3j89gVYgejVDc27qxMIO5T81JN3BpWueRappk+n3U0ckb+XG23zNvyn8aqrwete2GRLywkstSto5reXp65HevPPEvhSSxLXGnky23UofvJ/wDWrojU6M4502tUc4BmnL16cVCrlTgjBqRSDWpiSjHHNBAz3pi9al5xQIaMDOKDg0cUEccUDEIrs/hJ/wAjHc/9ejf+hpXG9Oveuz+Ev/Ix3P8A16N/6GlAI5vXDjXdUwP+Xub/ANDNVPerOtj/AInuqdv9Mm/9DNV061S2JZYjH7vNNkH4Cnp9zHAq9pWj3esXHlWiggfeY9FoEZG1pGCopZj0A6muw8O+CLu6ZJ9RRo7fr5Y6t9a7zwr4T07RkE0+2e4HJZuv4V0NxIZlPlARR+uegrCpWjHQ6KVFz1exkWtrYabbBI40LqMKijgfX1qpcXAJ3bcOfXpUtykYLLGzF/0qtKrOT8g4HPaudy5tzuUFDYrGWJ7hSIjvH8RP9Kvy6jKqskLbGb5Q7Hp9KrLDAIzvL7zyCOD9Kt5gEasYyWA/jpOXRDSvuUbaFoZ8zXUtwZOxPAq15IO4NksfTtV/S1knyqRoit9w+lXb60isFSW7cFScADqTUpSb2G5RRi2Vij+YG8x8DKhRyarz6elspLzBQ/OwDkV1ek6lpzSPEXVGxgK/aqevWFrd7XkZYX/vE5Vh71u6TSvc5o1rytY5uSxmvbIw2kwRCfnfv+dOt9Mew05vNuxMynkdyKtwb7eYrEEVOwQ5H4Ul+jEgH5e/1qHKMVobezlJ3ZnQq3mF3OfT2FJcSBC2QMnuKBGzZVSVXtipbmzQ2hZsAr2Pek9XcfKcZ4k02yurWSWKIJdKMgrxu/CuJmt57bBmieMHoWHFevW9vbNHtljBI5Oao31ojqYzGk1vJ/Ceq/StoTtoc9SlfU8vRs85walByK3NX8NNCzSWBLL1MbdawUOCVIwR1BHStlJPY5ZRcdx3407FGO9OamIjauz+Euf+Ekuf+vRv/Q0rjWBxmuz+Epx4kuf+vRv/AENKGBzOtc67qn/X5N/6GarqOean1on+3NUwP+Xyb/0M1BHksM8D1AqlsJliMce1ei/D50TTpPIAMufm9RXnSOFBpbXULmyl82zmeKQd1PWpkrqyCLs9T2u2R93zsc9dx6GrU8gm2Ko2qvH/ANevKbLx9qVuuJo4px3yMGrq/EaYAk6ejE9TvNczoXOmNax6f5KfKR26NVdoS7BVg8xwc8kgV5zH8TbpRg6dCy+7mkn+J+oFCLaygiOOpJNQsPK5o8SrHoN5ptxMhEC+UV5y3ao47S4uXjhnUIc4DZrx6fxjr0t005vnBbqoA2/lTH8W664Ia9bnjPcVoqJP1hHt+oW8NlcW7IkjNGR8wbg1JqV+t/Kck7DyF28g+1fPg1XUgTi/uQTyf3ho/tXUv+f+45/2zWnK+hCqrdnsctmYLsTQgu2cgyDANEzXUx+eUMuc7c8D8K8gGtaiRh7l3x/e5q9a+KLyADekcgHrxSdNvdlqul0PT18yMgkHHqKWS7EjFHXcMfez0rgIvHE8X3YWA7ruyK0bTx3ZvxfWJH+0tZOizWOJXU6kyFU+Xoe1JI7SxkhPujr7VjR+JtDlDYunh3DoVzirQ1jRo4VI1aPn2pODRarRfU0IIAYSDn5uhxUEtq6bWAIAPGarJ4m0AviXVSD7RnAqW48UaDBGGbUI5iORsBJPtilyyXQTqRfUq6k6xsxY7T6+9cb4otoo5oZ41CmUfMR3PrU+o+Jra7vzII5fKDZAI61T1/VYdRaEWyMEQclvX0raEWmrnLUlFqyMwkEU44A5PNRr7Zp+PrWxgIT+tdl8Jcf8JJc4H/Lo3/oaVxhzXZ/CbB8R3P8A16N/6GlAHMaz/wAhvVP+vyb/ANDNQISBU2r/APIb1X1+2Tf+hmoQeKa2Ex/8NRnAFPU/lSsuR60ySrIOeBxUZJqyyntxUbL6UhkWcU0mnMuDTHBHvQAGkDYqNiaYWOaBkpfnFNaQimDLNgVNLZ3CIHMTFT3ApXHYjEhzTt/rURVwMlGGfagMcYoAn7UZpivxjvSqwoAdSjH1NHXpRQAp6+lAAzwKM8805R3oAcqgCpEAz0plSIeOhxTEOA5pSORQKdikBGw9eldn8JRjxHc8f8urf+hpXGNkV2fwlJ/4SK5/69W/9DSgEcrq/wDyHNVz/wA/s3/oZqAdKn1f/kN6qf8Ap9m/9DNQrkfSmtgY9O1PJHamDrmkd/lPf0pkikAnNMbpSFzioi9IYPg+tRNxSlqt2GnzXsihQQp7+tJuw0rlKG1muH2wxs7H0qSXTLqCREuIJIwxxuI4r0XTdFhsYYw7FSev1rpLNIkRfPVZsH5RjIH1rOVSzN40bo85sfCEqPBcSB/JyOq9a7200XToIt7oJMdj2rRnmkkLBmxnsB2qMj5dgIKN19awdRyOiNJRI5oNKWMH7JGV9DwAa53xB4esb6xkMFtEtyf9W6cfn611SW9nHGRPMhyOBjODUsqWJ0uNkl2tG3z4Thh7Uk2tRyin0PD7vQb61Uts3qDg46is4KQdpBDDqDXtlytncEqoxA3Xua5TxT4YS6jWbSSC6D5kbq30raNXuYTo21icGi8UoU0+aGe0fZdQvE3o4xS7xgZFbHOxmMnkYqULgY70qsDTwRTERkGpBx2oIzzS5zQAo55xTienHNNXrTufwpANYV2PwlP/ABUdz/16N/6Glcaa7P4S8eI7n/r0b/0NKBnK6sf+J5qw/wCn2b/0M1XJ71Nq5P8AbmrY6fbZv/QzVZTnOaa2Ex5Y01ifakYjFRsxNMQpfjimZBqxbWVzdf8AHtCz9sjpXV6F4VKBZtQAB6jPQUrjSb2MLS9LMzK0gJzyFrt9KgSxtlJUeYeS237tLMlrazl4FZiB+X4U6K5XDkMxPUKe9YTm+h1U6aW5JcNIZ1kuGDZPH0q5BcyGO4lnhWzt4yNsrPwwqhuLTfvQCGXjnOKI7FdQs5YrtWktXbaVYFay0tqb+hu2moR3UKNazIUPDFRuD/j2rOnu0WZo0BLA8gdqdYWNvpth5VrCyRqeiVVvId9wJYgUVvvjoTUj1Q/eGycHaOvsaV3ZoUG7K/3aWCAy5QghFHan29mGbA3barYV2xLUFwEUNuPYVZl32si42MQeUHNTjSUUiRpWVSOucUxzYwRsGLvJ6571N0x6lW6S1v1ZLmKNkc4w65x9DXKa14JCjzdHl3qefLc/yNdJI5kxsGMe1WrS0l+zm4ikGU52nrWim0ZTppnj9xFLbTNFOhjkXggimbzXq+s6Ra6+gEyLFc9PMAxk15lrOnT6Rfva3I+Zeh7EVvGfMc04crIA3GKeG6VXB454qYHirIJxyMjigmkUHAJ6UvWkIbjvXZ/Cb/kZLn/r0b/0NK4wj8q7P4TY/wCEjuf+vRv/AENKbGjktV/5Dur4/wCf2b/0M1XK45qzqhH9u6v3/wBNm/8AQzUGC+FUEknAA6mhbCZG5rc8PeF77VpkLRSQ2x5MrLjI9q6Hwp4SjguIb3XHXyx8yW4OST2zXW6nqkszeWrCKFOFRegFZzqJOyNYUnLcZaW+n6bYCztog8i9XxUUwjk6h2HvUM2oWtjamSSRHnJwsQPJ9zU+m3cGqJldsTryYw2cj1rnbbOlWjoUjbWmCHBHPJkJpPIsFlUyT7QPTkU7UlLNtRSB9eaxrq3mtgokUFW6E8mnFjehtb7SJmxJCsfVT1J/CrcEgZS8cck6joqNz+Vclbfv7tVYfd7muq00rDOjW8ju4GM9OKrQVm9jD1eHxTcazDPAr2lgSAsWRtC981qXGI5dmS5PG7PArVmjeRWZpCxY8DOayZl8uQjGPQE1HNcuNPl1HLIwjMaqAc5JPU1bifyoTPKwigTlmPRaj09ImuPNu3ARFz1/nVa010Xl9PbQWTNb4++2MH6ik9R9bF26SW7eO6tr6OWwIwEVcEn1zTY7QsMs+e5qEztK+zCrtHAUYUewqxaOwPAkbPoKn0LStuMni8tAyAMvrRauyv5akHP3iavm3ZwwELspHVjgA1Rh0+4D7TLEAP4epqopsmTRMhDOAx8tQepqnrulWl8PJuY/NTblH/iB9jWiNOkZf9YvH8NSoLeygL39xCkaHIJPP0q0nExlZs8tvfB08UuIrlNpP8a9Kx9S0+XTbnyZyH4yHX7pr1uXV9JvGdLe6Q57VzXiKWxOjzgfPJnC5GfxFWpu9jKVONro4VW4wBxSr14qNc/lUgzxWxgKxGa7L4Tj/iorj/r0b/0NK4w+grtPhPx4juP+vRv/AENKGI5HVP8AkO6v/wBfs3/oZpltL5FxFNjdsYNj1pdV/wCQ9q+P+f2b/wBDNQOeMU1sHU9JtfEOj3SDz5ERuDhuCDV3+0dCVC4uos/71eSNzTB+FR7NGntmeo3OreGbpz5xgVzxu5qOLUPC+mSpPFdyllP3YzkGvMzj2pBS9mtg9o9z1oazoN47SLfbcjhXGMU6K2t7xSItShYD7qk5NeRnpzT45HicNG7IR3BoVKKK9vLqeqnQ/KlDx3kLjsK14NN8oAPcQmRhyQcAV5DFrupxEbbuTjpnmrB8Taoxy0+T9KUqdyo17Hsa26RRqDNGfdetVprO2l3k3SAn1615SnirVF6SL+VSJ4rvRG6ypHIzDhjxioVGxbxNz0trXTvKZJ5fMTup71VfUrC2BS1t/lHBwMV5jLr2oyYzOVH+yMVXudTvLhsyTue3BxVeyRLxDPURqduWGyKFSeeW61PJrawph2jjHX5TXjvmMSSWYn3NBZiOWYj0zVKFiHWbPYZdbh+z+dLKTHj726sBvH1va5W2tWmOeWbjNee7327SzbR2zxSYJ7VXKT7Rnc6l8Qri5XENqsfHTOK5DVNRu9TmMl1KzDsoJ2j8Kq4NLtPpT5US5tjY90ZDISrDuKnSWTYcyOfqaj2N6U8IcdKZNx68jrTvpSIpAOQacAcdKAEFdn8J/wDkYrj/AK9G/wDQ0rjCMDtXZfCc/wDFR3OSP+PRv/Q0oYHIar/yH9X/AOv2b/0M1XPWiihbANNM/ioopiDtSdqKKQCN0ooooAD1paKKAHCjFFFAwNB6GiigCEk7hyaZI7A/eP50UUmBE8jjo7fnUbzS5/1r/wDfRoooGQvcTZ/1sn/fRqF7ibn99J/30aKKQETXE3/PWT/vo1G08v8Az1k/76NFFSMYZpf+ej/99GozLJ/ff86KKBjDI/8Afb867/4Ksx8VXWWP/Hk/f/bjoopAf//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Photograph of open lung biopsy from a patient with early lymphangioleiomyomatosis. The main change is the presence of scattered cystic spaces in what is otherwise unremarkable lung tissue.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jeffrey L Myers, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_22_21870=[""].join("\n");
var outline_f21_22_21870=null;
var title_f21_22_21871="Change BMD low dose addback";
var content_f21_22_21871=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F70640&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F70640&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 532px\">",
"   <div class=\"ttl\">",
"    Effects of GnRH agonist alone (solid lines) versus GnRH agonist plus low-dose estrogen-progestin add-back (dotted line) on bone mineral density at the end of 6 months of treatment and then after 6 months of follow up",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 512px; height: 487px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note that the low-dose estrogen plus progestin add-back was associated with continuing bone loss during treatment, but the bone loss was less than that observed in the group treated with the GnRH agonist alone.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Howell, R, Edmonds, D, Dowsett, M. Gonadotropin releasing hormone analogue plus hormone replacement therapy for the treatment of endometriosis: a randomized clinical trial. Fertil Steril 1995; 64:474. Copyright &copy; 1995 American Society for Reproductive Medicine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_22_21871=[""].join("\n");
var outline_f21_22_21871=null;
